8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

ABSTRACT

The invention relates to 8-amino-2-oxo-1,3-diaza-spiro[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.

This application is a continuation of U.S. Nonprovisional patent application Ser. No. 15/405,627, filed Jan. 13, 2017, which claims foreign priority benefit under 35 U.S.C. § 119 of European Patent Application No. 16 151 015.1, filed Jan. 13, 2016, the disclosures of which are incorporated herein by reference.

The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and use in medicine, particularly in various neurological disorders, including but not limited to pain, neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, substance abuse/dependence.

Opioid receptors are a group of Gi/o protein-coupled receptors which are widely distributed in the human body. The opioid receptors are currently subdivided into four major classes, i.e. the three classical opioid receptors mu-opioid (MOP) receptor, kappa-opioid (KOP) receptor, and delta-opioid (DOP) receptor as well as the opioid receptor-like (ORL-1) receptor, which was more recently discovered based on its high homology with said classical opioid receptors. After identification of the endogenous ligand of the ORL-1 receptor, known as nociceptin/orphanin FQ, a highly basic 17 amino acid peptide isolated from tissue extracts in 1995, the ORL-1 receptor was renamed “nociceptin opioid peptide receptor” and abbreviated as “NOP-receptor”.

The classical opioid receptors (MOP, KOP and DOP) as well as the NOP receptor are widely distributed/expressed in the human body, including in the brain, the spinal cord, on peripheral sensory neurons and the intestinal tract, wherein the distribution pattern differs between the different receptor classes.

Nociceptin acts at the molecular and cellular level in very much the same way as opioids. However, its pharmacological effects sometimes differ from, and even oppose those of opioids. NOP-receptor activation translates into a complex pharmacology of pain modulation, which, depending on route of administration, pain model and species involved, leads to either pronociceptive or antinociceptive activity. Furthermore, the NOP receptor system is upregulated under conditions of chronic pain. Systemic administration of selective NOP receptor agonists was found to exert a potent and efficacious analgesia in non-human primate models of acute and inflammatory pain in the absence of side effects. The activation of NOP receptors has been demonstrated to be devoid of reinforcing effects but to inhibit opioid-mediated reward in rodents and non-human primates (Review: Schroeder et al, Br J Pharmacol 2014; 171 (16): 3777-3800, and references therein).

Besides the involvement of the NOP receptor in nociception, results from preclinical experiments suggest that NOP receptor agonists might be useful inter alia in the treatment of neuropsychiatric disorders (Witkin et al, Pharmacology & Therapeutics, 141 (2014) 283-299; Jenck et al., Proc. Natl. Acad. Sci. USA 94, 1997, 14854-14858). Remarkably, the DOP receptor is also implicated to modulate not only pain but also neuropsychiatric disorders (Mabrouk et al, 2014; Pradhan et al., 2011).

Strong opioids acting at the MOP receptor site are widely used to treat moderate to severe acute and chronic pain. However, the therapeutic window of strong opioids is limited by severe side effects such as nausea and vomiting, constipation, dizziness, somnolence, respiratory depression, physical dependence and abuse. Furthermore, it is known that MOP receptor agonists show only reduced effectiveness under conditions of chronic and neuropathic pain.

It is known that some of the above mentioned side-effects of strong opioids are mediated by activation of classic opioid-receptors within the central nervous system. Furthermore, peripheral opioid receptors, when activated, can inhibit transmission of nociceptive signals shown in both, clinical and animal studies (Gupta et al., 2001; Kalso et al., 2002; Stein et al., 2003; Zollner et al., 2008).

Thus, to avoid CNS-mediated adverse effects after systemic administration, one approach has been to provide peripherally restricted opioid receptor ligands that do not easily cross the blood-brain barrier and therefore distribute poorly to the central nervous system (see for instance WO 2015/192039). Such peripherally acting compounds might combine effective analgesia with limited side-effects.

Another approach has been to provide compounds which interact with both the NOP receptor and the MOP receptor. Such compounds have for instance been described in WO 2004/043967, WO 2012/013343 and WO 2009/118168.

A further approach has been to provide multi-opioid receptor analgesics that modulate more than one of the opioid receptor subtypes to provide additive or synergistic analgesia and/or reduced side effects like abuse liability or tolerance.

On the one hand, it would be desirable to provide analgesics that selectively act on the NOP receptor system but less pronounced on the classic opioid receptor system, especially MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity. On the other hand, it would be desirable to provide analgesics that act on the NOP receptor system and also to a balanced degree on the MOP receptor system, whereas it would be desirable to distinguish between central nervous activity and peripheral nervous activity.

There is a need for medicaments which are effective in the treatment of pain and which have advantages compared to the compounds of the prior art. Where possible, such medicaments should contain such a small dose of active ingredient that satisfactory pain therapy can be ensured without the occurrence of intolerable treatment-emergent adverse events.

It is an object of the invention to provide pharmacologically active compounds, preferably analgesics that have advantages compared to the prior art.

This object has been achieved by the subject-matter of the patent claims.

A first aspect of the invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives according to general formula (I)

wherein R¹ and R² independently of one another mean

—H;

C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH₃, —CN and —CO₂CH₃; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH₃, —CN and —CO₂CH₃; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH₃, —CN and —CO₂CH₃; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃₋₆—; —(CH₂)₂—O—(CH₂)₂—; or —(CH₂)₂—NR^(A)—(CH₂)₂—, wherein R^(A) means —H or —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I; preferably with the proviso that R¹ and R² do not simultaneously mean —H; R³ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; R⁴ means

—H;

—C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said —C₁-C₆-alkyl is optionally connected through —C(═O)—, —C(═O)O—, or —S(═O)₂—; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂—; a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6-14-membered aryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂—; or a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5-14-membered heteroaryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂—; R⁵ means

—H;

—C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a moiety according to general formula (X);

R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ independently of one another mean —H, —F, —Cl, —Br, —I, —OH, or —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein “mono- or polysubstituted” means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —R²¹, —C(═O)R²¹, —C(═O)OR²¹, —C(═O)NR²¹R²², —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, ═O, —OR²¹, —OC(═O)R²¹, —OC(═O)OR²¹, —OC(═O)NR²¹R²², —NO₂, —NR²¹R²², —NR²¹—(CH₂)₁₋₆—C(═O)R²², —NR²¹—(CH₂)₁₋₆—C(═O)OR²², —NR²³—(CH₂)₁₋₆—C(═O)NR²¹R²², —NR²¹C(═O)R²², —NR²¹C(═O)—OR²², —NR²³C(═O)NR²¹R²², —NR²¹S(═O)₂R²², —SR²¹, —S(═O)R²¹, —S(═O)₂R²¹, —S(═O)₂₀R²¹, and —S(═O)₂NR²¹R²²; wherein R²¹, R²² and R²³ independently of one another mean

—H;

—C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, and —O—C₁-C₆-alkyl; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; or R²¹ and R²² within —C(═O)NR²¹R²², —OC(═O)NR²¹R²², —NR²¹R²², —NR²³—(CH₂)₁₋₆—C(═O)NR²¹R²², —NR²³C(═O)NR²¹R²², or —S(═O)₂NR²¹R²² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃₋₆—; —(CH₂)₂—O—(CH₂)₂—; or —(CH₂)₂—NR^(B)—(CH₂)₂—, wherein R^(B) means —H or —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I; or a physiologically acceptable salt thereof.

Preferably, aryl includes but is not limited to phenyl and naphthyl. Preferably, heteroaryl includes but is not limited to -1,2-benzodioxole, -pyrazinyl, -pyridazinyl, -pyridinyl, -pyrimidinyl, -thienyl, -imidazolyl, -benzimidazolyl, -thiazolyl, -1,3,4-thiadiazolyl, -benzothiazolyl, -oxazolyl, -benzoxazolyl, -pyrazolyl, -quinolinyl, -isoquinolinyl, -quinazolinyl, -indolyl, -indolinyl, -benzo[c][1,2,5]oxadiazolyl, -imidazo[1,2-a]pyrazinyl, or -1H-pyrrolo[2,3-b]pyridinyl. Preferably, cycloalkyl includes but is not limited to -cyclopropyl, -cyclobutyl, -cyclopentyl and -cyclohexyl. Preferably, heterocycloalkyl includes but is not limited to -aziridinyl, -azetidinyl, -pyrrolidinyl, -piperidinyl, -piperazinyl, -morpholinyl, -sulfamorpholinyl, -oxiridinyl, -oxetanyl, -tetrahydropyranyl, and -pyranyl.

When a moiety is connected through an asymmetric group such as —C(═O)O— or —C(═O)O—CH₂—, said asymmetric group may be arranged in either direction. For example, when R⁴ is connected to the core structure through —C(═O)O—, the arrangement may be either R⁴—C(═O)O-core or core-C(═O)O—R⁴.

In preferred embodiments of the compound according to the invention, R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ independently of one another mean —H, —F, —OH, or —C₁-C₆-alkyl; preferably —H.

In a preferred embodiment of the compound according to the invention, R¹ means —H; and R² means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R¹ means —H and R² means —CH₃.

In another preferred embodiment of the compound according to the invention, R¹ means —CH₃; and R² means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R¹ means —CH₃ and R² means —CH₃.

In still another preferred embodiment of the compound according to the invention, R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃₋₆—. Preferably, R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃—.

In yet another preferred embodiment,

-   -   R¹ means —H or —CH₃; and     -   R² means a 3-12-membered cycloalkyl moiety, saturated or         unsaturated, unsubstituted; wherein said 3-12-membered         cycloalkyl moiety is connected through —CH₂—, unsubstituted;         preferably —CH₂-cycloalkyl, —CH₂-cyclobutyl or —CH₂-cyclopentyl;         or R² means a 3-12-membered heterocycloalkyl moiety, saturated         or unsaturated, unsubstituted; wherein said 3-12-membered         heterocycloalkyl moiety is connected through —CH₂—,         unsubstituted; preferably —CH₂-oxetanyl or         —CH₂-tetrahydrofuranyl.

In a preferred embodiment of the compound according to the invention, R³ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R³ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —OCH₃.

In another preferred embodiment of the compound according to the invention, R³ means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted, optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted. In a preferred embodiment, R³ means -phenyl unsubstituted, mono- or polysubstituted. More preferably, R³ means -phenyl unsubstituted, mono- or disubstituted with —F, —Cl, —CH₃, —CF₃, —OH, —OCH₃, —OCF₃ or —OCH₂OCH₃, preferably —F. In another preferred embodiment, R³ means -benzyl unsubstituted, mono- or polysubstituted. More preferably, R³ means -benzyl unsubstituted, mono- or disubstituted with —F, —Cl, —CH₃, —CF₃, —OH, —OCH₃, —OCF₃ or —OCH₂OCH₃, preferably —F.

In still another preferred embodiment of the compound according to the invention, R³ means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Preferably, R³ means -thienyl or -pyridinyl, in each case unsubstituted, mono- or polysubstituted. More preferably, R³ means -thienyl, -pyridinyl, -imidazolyl or benzimidazolyl, in each case unsubstituted or monosubstituted with —F, —Cl or —CH₃.

In a preferred embodiment of the compound according to the invention, R⁴ means —H.

In another preferred embodiment of the compound according to the invention, R⁴ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R⁴ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with a substituent selected from the group consisting of —F, —Cl, —Br, —I, —CN, —CF₃, —OH, —O—C₁-C₄-alkyl, —OCF₃, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —OC(═O)C₁-C₄-alkyl, —C(═O)C₁-C₄-alkyl, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)_(1\11-12), —C(═O)NHC₁-C₄-alkyl, —C(═O)NHC₁-C₄-alkylene-CN, —C(═O)NHC₁-C₄-alkylene-O—C₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂; —S(═O)C₁-C₄-alkyl, and —S(═O)₂C₁-C₄-alkyl; or with —C(═O)NR²¹R²² wherein R²¹ and R²² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃₋₆—, —(CH₂)₂—O—(CH₂)₂—, or —(CH₂)₂—NR^(B)—(CH₂)₂—, wherein R^(B) means —H or —C₁-C₆-alkyl; or with —C(═O)NH-3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I, —CN, or —OH; or with —C(═O)NH-3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I, —CN, or —OH. More preferably, R⁴ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —O—C₁-C₄-alkyl or —C(═O)N(C₁-C₄-alkyl)₂.

In still another preferred embodiment of the compound according to the invention, R⁴ means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R⁴ means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is connected through —CH₂— or —CH₂CH₂—. More preferably, R⁴ means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said 3-12-membered cycloalkyl moiety is connected through —CH₂— or —CH₂CH₂—.

In a preferred embodiment of the compound according to the invention, R⁴ means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R⁴ means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —CH₂— or —CH₂CH₂—. More preferably, R⁴ means -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said -oxetanyl, -tetrahydrofuranyl or -tetrahydropyranyl is connected through —CH₂— or —CH₂CH₂—.

In yet another preferred embodiment of the compound according to the invention, R⁴ means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R⁴ means -phenyl, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through —CH₂— or —CH₂CH₂—. More preferably, R⁴ means -phenyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said -phenyl is connected through —CH₂— or —CH₂CH₂—.

In a further preferred embodiment of the compound according to the invention, R⁴ means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted. Preferably, R⁴ means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said -phenyl is connected through —CH₂— or —CH₂CH₂— More preferably, R⁴ means -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said -pyridinyl, -pyrimidinyl, -pyrazinyl, or -pyrazolinyl is connected through —CH₂— or —CH₂CH₂—.

In a preferred embodiment of the compound according to the invention, R⁵ means —H.

In another preferred embodiment of the compound according to the invention, R⁵ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl. Preferably, R⁵ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —F, —C₁, —Br, —I, —CN, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl or —S(═O)₂C₁-C₄-alkyl.

More preferably,

-   (i) R⁵ means —C₁-C₆-alkyl, linear or branched, saturated or     unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I,     —CN, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H,     —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —S(═O)C₁-C₄-alkyl or —S(═O)₂C₁-C₄-alkyl; or -   (ii) R⁵ means —C₃-C₆-alkyl, linear or branched, saturated or     unsaturated, monosubstituted with —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, or     —C(═O)N(C₁-C₄-alkyl)₂.

In another preferred embodiment of the compound according to the invention, R⁵ means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C₁-C₄-alkyl-OH, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —NH₂, —NHC₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁C₄-alkyl, —N(C₁-C₄-alkyl)C(═O)C₁-C₄-alkyl, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted.

In a preferred embodiment of the compound according to the invention, R⁵ means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —C₁, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C₁-C₄-alkyl-OH, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —NH₂, —NHC₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁C₄-alkyl, —N(C₁-C₄-alkyl)C(═O)C₁-C₄-alkyl, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted. Preferably, R⁵ means -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidinyl, -piperazinyl, -morpholinyl or -thiomorpholinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidinyl, -piperazinyl, -morpholinyl or -thiomorpholinyl is connected through —CH₂— or —CH₂CH₂—.

In a preferred embodiment of the compound according to the invention, R⁵ means —H;

—C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or tour substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)OC₁-C₄-alkyl, —C(—O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, —NH₂, —NH—C₁-C₄-alkyl, —N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NH—S(═O)₂C₁-C₄-alkyl; or 3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —C₁-C₄-alkyl, —C₁-C₄-alkyl-OH, —NH₂, —NH—C₁-C₄-alkyl, —N(C₁—C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NHS(═O)₂—C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)C₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, -phenyl, —C(═O)-phenyl, —C(═O)-pyridyl, -thiazolyl, —N-methyldiazolyl, -pyridyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —C₁-C₄-alkyl, —C₁-C₄-alkyl-OH, —NH₂, —NH—C₁-C₄-alkyl, —N(C₁-C₄-alkyl)₂, —NBC(═O)—C₁-C₄-alkyl, —NHS(═O)₂—C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, -phenyl, —C(═O)-phenyl, —C(═O)-pyridyl, -thiazolyl, —N-methyldiazolyl, -pyridyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted.

In preferred embodiments, the compound according to the invention has a structure according to any of general formulas (II-A) to (VIII-C):

wherein in each case R¹, R², R³, R⁴, and R⁵ are defined as above, R^(C) means —H, —OH, —F, —CN or —C₁-C₄-alkyl; preferably —H or —OH; R^(D) means —H or —F; or a physiologically acceptable salt thereof.

Preferably, in the compounds according to general formula (I) or any of the compounds according to general formulas (II-A) to (VIII-C), R⁵ is selected from the group consisting of:

In a particularly preferred embodiment of the compound according to the invention

R¹ means —H or —CH₃; R² means —C₁-C₆-alkyl, linear or branched, saturated, unsubstituted; R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH₃, —CH₂CH₃, —CH₂F, —CHF₂, —CF₃, —OCF₃, —OH, —OCH₃, —C(═O)NH₂, C(═O)NHCH₃, —C(═O)N(CH₃)₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHC(═O)CH₃, —CH₂OH, SOCH₃ and SO₂CH₃; or R⁴ means

—H;

—C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, ═O, —S(═O)₂—C₁-C₄-alkyl and —O—C₁-C₄-alkyl; 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C₁-C₆-alkylene; 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl is optionally connected through —C₁-C₆-alkylene-, unsubstituted or substituted with ═O; 6-14-membered aryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl; wherein said 6-14-membered aryl is optionally connected through —C₁-C₆-alkylene- or —S(═O)₂—; R⁵ means

—H;

—C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, —NH—C₁-C₄-alkyl, —N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NH—S(═O)₂C₁-C₄-alkyl; or 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —C₁-C₄-alkyl, —NH₂, —NH—C₁-C₄-alkyl, —N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NHS(═O)₂—C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)C₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, -phenyl, —C(═O)-phenyl, —C(═O)-pyridyl, -pyridyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; and R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ mean —H.

In a particularly preferred embodiment of the compound according to the invention

R¹ means —H or —CH₃; and/or R² means —C₁-C₆-alkyl, linear or branched, saturated, unsubstituted; preferably R² means —CH₃ or —CH₂CH₃; more preferably, R¹ and R² both mean —CH₃; and/or R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH₃, —CH₂CH₃, —CH₂F, —CHF₂, —CF₃, —OCF₃, —OH, —OCH₃, —C(═O)NH₂, C(═O)NHCH₃, —C(═O)N(CH₃)₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHC(═O)CH₃, —CH₂OH, SOCH₃ and SO₂CH₃; preferably, R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with —F; more preferably, R³ means phenyl, unsubstituted; and/or R⁴ means

—H;

—C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl; or 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C₁-C₆-alkylene; preferably, R⁴ means 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through —CH₂— or —CH₂CH₂—; more preferably, R⁴ means -cyclobutyl, unsubstituted or monosubstituted with —OH, wherein said -cyclobutyl is connected through —CH₂—; R⁵ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; preferably, R⁵ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or monosubstituted with —F, —Cl, —Br, —I, —CN, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl or —S(═O)₂C₁-C₄-alkyl; or 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; preferably, R⁵ means -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidinyl, -piperazinyl, -morpholinyl or -thiomorpholinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said -oxetanyl, -tetrahydrofuranyl, -tetrahydropyranyl, -piperidinyl, -piperazinyl, -morpholinyl or -thiomorpholinyl is connected through —CH₂— or —CH₂CH₂—; and R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ mean —H.

Preferred compounds according to the invention are selected from the group consisting of:

SC_4001 CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-butyramide SC_4002 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)- ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-l,3-diazaspiro[4.5]decan-2-one SC_4003 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]- ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4004 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-(2-methoxy- ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4005 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)- ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-l,3-diazaspiro[4.5]decan-2-one SC_4006 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(2-methoxy-ethoxy)-ethyl]-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4007 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-ethyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4008 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-(2-methoxy-ethoxy)- ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4009 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl- 1,3-diazaspiro[4.5]decan-2-one SC_4010 CIS-1-(Cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl- 1,3-diazaspiro[4.5]decan-2-one SC_4011 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methylsulfonyl- ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4012 CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-butyronitrile SC_4013 CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-N-methyl-butyramide SC_4014 CIS-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile SC_4017 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-[2-(2-methoxy- ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4018 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-methyl-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4021 CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-methylsulfonyl- ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4022 CIS-3-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-propionitrile SC_4024 CIS-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-acetonitrile SC_4025 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro- pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one SC_4026 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl- ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4027 CIS-3-(3-Chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4028 CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester SC_4029 CIS-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-propionitrile SC_4030 CIS-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-acetonitrile SC_4031 CIS-3-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4032 CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4033 CIS-1-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4034 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4035 CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-1-(oxetan-3-yl-methyl)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4036 CIS-8-Dimethylamino-1-(3-methoxy-propyl)-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4037 CIS-8-Dimethylamino-8-phenyl-1-(p-tolylsulfonyl)-1,3-diazaspiro[4.5]decan-2-one SC_4038 CIS-8-Dimethylamino-3-[(1,1-dioxo-thian-4-yl)-methyl]-1-[(1-hydroxy- cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4039 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4- yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4040 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-tetrahydro-pyran-4-yl-1,3- diazaspiro[4.5]decan-2-one SC_4041 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)- methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4042 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-tetrahydro- pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one SC_4043 CIS-1-[[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-1-yl]-methyl]-cyclobutane-1-carbonitrile SC_4044 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy- tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4045 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-1,1- dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4046 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(1,1-dioxo-thian-4-yl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4047 CIS-8-Dimethylamino-3-(1,1-dioxo-thian-4-yl)-1-[(1-hydroxy-cyclobutyl)- methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4048 CIS-3-(1-Acetyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4049 CIS-3-(1-Benzoyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4050 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[1-(pyridine-4- carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one SC_4051 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4- yl)-methyl]-8-phcnyl-1,3-diazaspiro[4.5]decan-2-one SC_4052 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(4-hydroxy-tetrahydro-pyran-4- yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4053 CIS-3-[(1-Acetyl-piperidin-4-yl)-methyl]-1-(cyclopropyl-methyl)-8- dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4054 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-piperidin-4-yl-1,3- diazaspiro[4.5]decan-2-one SC_4055 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-hydroxy-2-methyl-propyl)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4056 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyrimidin-5-yl- piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one SC_4057 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-phenyl-piperidin-4- yl)-1,3-diazaspiro[4.5]decan-2-one SC_4058 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(piperidin-4-yl-methyl)-1,3- diazaspiro[4.5]decan-2-one SC_4059 CIS-3-(1-Benzoyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4060 CIS-8-Dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3- diazaspiro[4.5]decan-2-one SC_4061 CIS-3-(1-Acetyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4062 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4- yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4063 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-2-methyl- propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4064 CIS-3-[(1-Amino-cyclopropyl)-methyl]-1-(cyclopropyl-methyl)-8-dimethylamino- 8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4066 CIS-8-Dimethylamino-1,3-bis(2-methylsulfonyl-ethyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4067 CIS-N-[1-[[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-methyl]-cyclopropyl]-acetamide SC_4068 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[(1-pyrimidin-5-yl- piperidin-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one SC_4069 CIS-8-Dimethylamino-8-phenyl-3-[(1-pyrimidin-5-yl-piperidin-4-yl)-methyl]-1,3- diazaspiro[4.5]decan-2-one SC_4070 ClS-8-Dimethylamino-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4071 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(3-hydroxy-oxetan-3-yl)-ethyl]- 8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4072 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-methyl-2-(2-oxo-pyrrolidin-1- yl)-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4073 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[2-(1,1-dioxo-[1,2]thiazolidin-2- yl)-2-methyl-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4074 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(4-hydroxy- tetrahydro-pyran-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4075 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(4-hydroxy-1,1-dioxo-thian-4- yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4076 CIS-3-[(1-Acetyl-piperidin-4-yl)-methyl]-8-dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4077 CIS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-1-(2-oxo-2-pyrrolidin-1-yl- ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4078 TRANS-8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4079 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(4-hydroxy-1,1- dioxo-thian-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4080 CIS-8-Dimethylamino-8-phenyl-3-(1-phenyl-piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4081 CIS-N-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-acetamide SC_4082 CIS-N-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-methanesulfonic acid amide SC_4083 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-(3-hydroxy-oxetan- 3-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4084 CIS-1-[2-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-pyrrolidine-2,5-dione SC_4085 CIS-N-[2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-acetamide SC_4086 CIS-N-[2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl- 1,3-diazaspiro[4.5]decan-3-yl]-1,1-dimethyl-ethyl]-methanesulfonic acid amide SC_4087 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridin-3-yl- piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one SC_4088 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(2- methylsulfonyl-ethyl)-1,3-diazaspiro[4,5]decan-2-one SC_4089 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridin-4-yl- piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one SC_4090 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[2-methyl-2-(2-oxo- pyrrolidin-1-yl)-propyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4091 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-2-methylsulfonyl- propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4092 TRANS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methyl-2-methylsulfonyl- propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4093 CIS-8-Dimethylamino-3-[2-(1,1-dioxo-[1,2]thiazolidin-2-yl)-2-methyl-propyl]-1- [(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4094 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-hydroxy- tetrahydro-pyran-4-yl)-methyl]-1,3-diazaspiro[4.5]decan-2-one SC_4095 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(1- pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one SC_4096 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyridazin-4-yl- piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one SC_4097 CIS-2-[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3- diazaspiro[4,5]decan-1-yl]-N,N-dimethyl-acetamide SC_4098 TRANS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2- methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4099 CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-(l-pyrimidin- 5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one SC_4100 CIS-1-(cyclopropylmethyl)-8-(3-fluorophenyl)-8-(methylamino)-3-(2- (methylsulfonyl)ethyl)-1,3-diazaspiro[4.5]decan-2-one SC_4101 CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-((1-hydroxycyclobutyl)methyl)- 8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4102 CIS-8-(dimethylamino)-8-(3-fluorophenyl)-3-((4-hydroxy-1,1-dioxidotetrahydro- 2H-thiopyran-4-yl)methyl)-1-((1-hydroxycyclobutyl)methyl)-1,3- diazaspiro[4.5]decan-2-one SC_4103 CIS-8-(dimethylamino)-8-(3-fluorophenyl)-1-((1-hydroxycyclobutyl)methyl)-3- ((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one SC_4104 CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-(3-fluorophenyl)-3-((4-hydroxy- 1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one SC_4105 CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(oxetan-3-ylmethyl)-8-phenyl- 1,3-diazaspiro[4.5]decan-2-one SC_4106 CIS-8-(dimethylamino)-8-phenyl-3-((S)-1-(thiophen-3-yl)propan-2-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4107 CIS-8-(dimethylamino)-8-phenyl-1,3-bis((1-(trifluoromethyl)cyclopropyl)methyl)- 1,3-diazaspiro[4.5]decan-2-one SC_4108 CIS-8-(dimethylamino)-1,3-bis((1-fluorocyclopropyl)methyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4109 CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-((3-(hydroxymethyl)oxetan-3- yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4110 CIS-3-((3-aminooxetan-3-yl)methyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4111 CIS-1-((1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl)methyl)cyclobutanecarbonitrile SC_4112 CIS-3-(8-(dimethylamino)-1-((1-fluorocyclopropyl)methyl)-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile SC 5061 CIS-3-[8-(Ethyl-methyl-amino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]- 2,2-dimethyl-propionitrile SC_5062 CIS-3-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2- dimethyl-propionitrile SC_5063 CIS-2,2-Dimethyl-3-(8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3- yl)-propionitrile SC_5065 CIS-3-[8-(Ethyl-methyl-amino)-1-methyl-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile SC_5068 CIS-3-(8-Ethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethyl- propionitrile SC_5075 CIS-3-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4,5]decan-3-yl]-2,2-dimethyl-propionitrile SC_5080 TRANS-3-[1-(Cyclopropyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile and the physiologically acceptable salts thereof.

According to the invention, unless expressly stated otherwise, “—C₁-C₄-alkyl”, “—C₁-C₆-alkyl” and any other alkyl residues can be linear or branched, saturated or unsaturated. Linear saturated alkyl includes methyl, ethyl, n-propyl, n-butyl, n-pentyl and n-hexyl. Examples of branched saturated alkyl include but are not limited to iso-propyl, sec-butyl, and tert-butyl. Examples of linear unsaturated alkyl include but are not limited to vinyl, propenyl, allyl, and propargyl.

According to the invention, unless expressly stated otherwise, “—C₁-C₄-alkyl”, “—C₁-C₆-alkyl” and any other alkyl residues can be unsubstituted, mono- or polysubstituted. Examples of substituted alkyl include but are not limited to —CH₂CH₂OH, —CH₂CH₂OCH₃, —CH₂CH₂CH₂OCH₃, —CH₂CH₂S(═O)₂CH₃, —CH₂C(═O)NH₂, —C(CH₃)₂C(═O)NH₂, —CH₂C(CH₃)₂C(═O)NH₂, and —CH₂CH₂C(═O)N(CH₃)₂—

According to the invention, unless expressly stated otherwise, “—C₁-C₆-alkylene-”, “—C₁-C₄-alkylene” and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of saturated alkylene include but are not limited to —CH₂—, —CH(CH₃)—, —C(CH₃)₂—, —CH₂CH₂—, —CH(CH₃)CH₂—, —CH₂CH(CH₃)—, —CH(CH₃)—CH(CH₃)—, —C(CH₃)₂CH₂—, —CH₂C(CH₃)₂—, —CH(CH₃)C(CH₃)₂—, —C(CH₃)₂CH(CH₃)—, C(CH₃)₂C(CH₃)₂—, —CH₂CH₂CH₂—, and —C(CH₃)₂CH₂CH₂—. Examples of unsaturated alkylene include but are not limited to —CH═CH—, —C≡C—, —C(CH₃)═CH—, —CH═C(CH₃)—, —C(CH₃)═C(CH₃)—, —CH₂CH═CH—, —CH═CHCH₂—, —CH═CH—CH═CH—, and —CH═CH—C≡C—.

According to the invention, unless expressly stated otherwise, “—C₁-C₆-alkylene-”, “—C₁-C₄-alkylene” and any other alkylene residue can be unsubstituted, mono- or polysubstituted. Examples of substituted —C₁-C₆-alkylene- include but are not limited to —CHF—, —CF₂—, —CHOH— and —C(═O)—.

According to the invention, moieties may be connected through —C₁-C₆-alkylene-, i.e. the moieties may not be directly bound to the core structure of compound according to general formula (I), but may be connected to the core structure of compound according to general formula (I) or its periphery through a —C₁-C₆-alkylene-linker.

According to the invention, “3-12-membered cycloalkyl moiety” means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring carbon atoms but no heteroatoms in the ring. Examples of preferred saturated 3-12-membered cycloalkyl moieties according to the invention include but are not limited to cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, hydrindane, and decaline. Examples of preferred unsaturated 3-12-membered cycloalkyl moiety moieties according to the invention include but are not limited to cyclopropene, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, 1,3-cyclohexadiene, and 1,4-cyclohexadiene. The 3-12-membered cycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 3-12-membered heterocycloalkyl moieties include but are not limited to octahydro-1H-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2H-benzo[b][1,4]oxazin, and decahydroquinoxalin, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 6-14-membered aryl moieties include but are not limited to 2,3-dihydro-1H-indene and tetraline, which in each case are connected through the 3-12-membered cycloalkyl moiety. Examples of 3-12-membered cycloalkyl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 3-12-membered cycloalkyl moiety.

According to the invention, the 3-12-membered cycloalkyl moiety may optionally be connected through —C₁-C₆-alkylene-, i.e. the 3-12-membered cycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C₁-C₆-alkylene-linker. Examples include but are not limited to —CH₂-cyclopropyl, —CH₂-cyclobutyl, —CH₂-cyclopentyl, —CH₂-cyclohexyl, —CH₂CH₂-cyclopropyl, —CH₂CH₂-cyclobutyl, —CH₂CH₂-cyclopentyl, and —CH₂CH₂-cyclohexyl.

According to the invention, unless expressly stated otherwise, the 3-12-membered cycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered cycloalkyl moieties include but are not limited to —CH₂-1-hydroxy-cyclobutyl.

According to the invention, “3-12-membered heterocycloalkyl moiety” means a non-aromatic, monocyclic, bicyclic or tricyclic moiety comprising 3 to 12 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas sulfur may be oxidized (S(═O) or (S(═O)₂), whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred saturated 3-12-membered heterocycloalkyl moieties according to the invention include but are not limited to aziridin, azetidine, pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, triazolidine, tetrazolidine, oxiran, oxetane, tetrahydrofurane, tetrahydropyrane, thiirane, thietane, tetrahydrothiophene, diazepane, oxazolidine, isoxazolidine, thiazolidine, isothiazolidine, thiadiazolidine, morpholine, thiomorpholine. Examples of preferred unsaturated 3-12-membered heterocycloalkyl moiety moieties according to the invention include but are not limited to oxazoline, pyrazoline, imidazoline, isoxazoline, thiazoline, isothiazoline, and dihydropyran. The 3-12-membered heterocycloalkyl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 3 to 12 ring atoms of the 3-12-membered heterocycloalkyl moieties. Examples of 3-12-membered heterocycloalkyl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to octahydro-1H-indol, decahydroquinoline, decahydroisoquinoline, octahydro-2H-benzo[b][1,4]oxazin, and decahydroquinoxalin, which in each case are connected through the 3-12-membered heterocycloalkyl moiety. An examples of a 3-12-membered heterocycloalkyl moiety condensed with a 6-14-membered aryl moiety includes but is not limited to 1,2,3,4 tetrahydroquinoline, which is connected through the 3-12-membered heterocycloalkyl moiety. An example of a 3-12-membered heterocycloalkyl moiety condensed with a 5-14-membered heteroaryl moieties includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 3-12-membered heterocycloalkyl moiety.

According to the invention, the 3-12-membered heterocycloalkyl moiety may optionally be connected through —C₁-C₆-alkylene-, i.e. the 3-12-membered heterocycloalkyl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C₁-C₆-alkylene-linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 3-12-membered heterocycloalkyl moiety. Examples include but are not limited to —CH₂-oxetane, —CH₂-pyrrolidine, —CH₂-piperidine, —CH₂-morpholine, —CH₂CH₂-oxetane, —CH₂CH₂-pyrrolidine, —CH₂CH₂-piperidine, and —CH₂CH₂-morpholine.

According to the invention, unless expressly stated otherwise, the 3-12-membered heterocycloalkyl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 3-12-membered heterocycloalkyl moieties include but are not limited to 2-carboxamido-N-pyrrolidinyl-, 3,4-dihydroxy-N-pyrrolidinyl, 3-hydroxy-N-pyrimidinyl, 3,4-dihydroxy-N-pyrimidinyl, 3-oxo-N-piperazinyl, -tetrahydro-2H-thiopyranyl dioxide and thiomorpholinyl dioxide.

According to the invention, “6-14-membered aryl moiety” means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring carbon atoms but no heteroatoms in the ring. Examples of preferred 6-14-membered aryl moieties according to the invention include but are not limited to benzene, naphthalene, anthracen, and phenanthren. The 6-14-membered aryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 6-14-membered aryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 2,3-dihydro-1H-indene and tetraline, which in each case are connected through the 6-14-membered aryl moiety. An example of a 6-14-membered aryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 1,2,3,4-tetrahydroquinoline, which is connected through the 6-14-membered aryl moiety. Examples of 6-14-membered aryl moieties condensed with 5-14-membered heteroaryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 6-14-membered aryl moiety.

According to the invention, the 6-14-membered aryl moiety may optionally be connected through —C₁-C₆-alkylene-, i.e. the 6-14-membered aryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C₁-C₆-alkylene-linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 6-14-membered aryl moiety. Examples include but are not limited to —CH₂—C₆H₅, —CH₂CH₂—C₆H₅ and —CH═CH—C₆H₅.

According to the invention, unless expressly stated otherwise, the 6-14-membered aryl moiety can be unsubstituted, mono- or polysubstituted. Examples of substituted 6-14-membered aryl moieties include but are not limited to 2-fluorophenyl, 3-fluorophenyl, 2-methoxyphenyl and 3-methoxyphenyl.

According to the invention, “5-14-membered heteroaryl moiety” means an aromatic, monocyclic, bicyclic or tricyclic moiety comprising 6 to 14 ring atoms, wherein each cycle comprises independently of one another 1, 2, 3, 4 or more heteroatoms independently of one another selected from the group consisting of nitrogen, oxygen and sulfur, whereas the remaining ring atoms are carbon atoms, and whereas bicyclic or tricyclic systems may share common heteroatom(s). Examples of preferred 5-14-membered heteroaryl moieties according to the invention include but are not limited to pyrrole, pyrazole, imidazole, triazole, tetrazole, furane, thiophene, oxazole, isoxazole, thiazole, isothiazole, pyridine, pyridazine, pyrimidine, pyrazine, indolicine, 9H-chinolicine, 1,8-naphthyridine, purine, imidazo[1,2-a]pyrazine, and pteridine. The 5-14-membered heteroaryl moiety, which is bonded to the compound according to the invention, in its periphery may optionally be condensed with a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; and/or with a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted. Under these circumstances, the ring atoms of the condensed moieties are not included in the 6 to 14 ring carbon atoms of the 6-14-membered heterocycloalkyl moieties. Examples of 5-14-membered heteroaryl moieties condensed with 3-12-membered cycloalkyl moieties include but are not limited to 5,6,7,8-tetrahydroquinoline and 5,6,7,8-tetrahydroquinazoline, which in each case are connected through the 5-14-membered heteroaryl moiety. An examples of a 5-14-membered heteroaryl moiety condensed with a 3-12-membered heterocycloalkyl moiety includes but is not limited to 5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, which is connected through the 5-14-membered heteroaryl moiety. Examples of 5-14-membered heteroaryl moieties condensed with 6-14-membered aryl moieties include but are not limited to quinoline, isoquinoline, phenazine and phenoxacine, which in each case are connected through the 5-14-membered heteroaryl moiety.

According to the invention, the 5-14-membered heteroaryl moiety may optionally be connected through —C₁-C₆-alkylene-, i.e. the 5-14-membered heteroaryl moiety may not be directly bound to the compound according to general formula (I) but may be connected thereto through a —C₁-C₆-alkylene-linker. Said linker may be connected to a carbon ring atom or to a hetero ring atom of the 5-14-membered heteroaryl moiety. Examples include but are not limited to —CH₂-oxazole, —CH₂-isoxazole, —CH₂-imidazole, —CH₂-pyridine, —CH₂-pyrimidine, —CH₂-pyridazine, —CH₂CH₂-oxazole, —CH₂CH₂-isoxazole, —CH₂CH₂— imidazole, —CH₂CH₂-pyridine, —CH₂CH₂-pyrimidine, and —CH₂CH₂-pyridazine.

According to the invention, unless expressly stated otherwise, the 5-14-membered heteroaryl moiety can be unsubstituted, mono- or polysubstituted. Examples of 5-14-membered heteroaryl moieties include but are not limited to 2-methoxy-4-pyridinyl, 2-methoxy-5-pyridinyl, 3-methoxy-4-pyridinyl, 3-methoxy-6-pyridinyl, 4-methoxy-2-pyridinyl, 2-methylsulfonyl-5-pyridinyl, 3-methylsulfonyl-6-pyridinyl, 3-methoxy-6-pyridazinyl, 2-nitrilo-5-pyrimidinyl, 4-hydroxy-2-pyrimidinyl, 4-methoxy-pyrimidinyl, and 2-methoxy-6-pyrazinyl.

Preferably, the compounds according to the invention have a structure according to general formula (I′)

wherein R¹ to R⁵, R¹⁰ to R²⁰ are defined as above, or a physiologically acceptable salt thereof.

In one preferred embodiment, the excess of the cis-isomer so designated is at least 50% de, more preferably at least 75% de, yet more preferably at least 90% de, most preferably at least 95% de and in particular at least 99% de.

Preferably, the compounds according to the invention have a structure according to general formula (IX)

wherein R^(C) means —H or —OH; R³ means -phenyl or -3-fluorophenyl; R⁵ means C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or monosubstituted with —OH, —CN, —NH₂, —NHC(═O)C₁-C₄-alkyl, —NHS(═O)₂—C₁-C₄-alkyl, or —S(═O)₂—C₁-C₄-alkyl; or 3-6-membered heterocycloalkyl, saturated, unsubstituted or substituted with —OH; wherein said 3-6-membered heterocycloalkyl is optionally connected through —CH₂— or —(CH₂)₂—; or a physiologically acceptable salt thereof.

Preferably, the 3-6-membered heterocycloalkyl is selected from the group consisting of oxetanly, tetrahydrofuranyl and tetrahydropyranyl.

In a preferred embodiment, the compounds according to the invention are in the form of the free bases.

In another preferred embodiment, the compounds according to the invention are in the form of the physiologically acceptable salts.

For the purposes of the description, a “salt” is to be understood as being any form of the compound in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution. The term is also to be understood as meaning complexes of the compound with other molecules and ions, in particular complexes which are associated via ionic interactions. Preferred salts are physiologically acceptable, in particular physiologically acceptable salts with anions or acids or also a salt formed with a physiologically acceptable acid.

Physiologically acceptable salts with anions or acids are salts of the particular compound in question with inorganic or organic acids which are physiologically acceptable, in particular when used in humans and/or mammals. Examples of physiologically acceptable salts of particular acids include but are not limited to salts of hydrochloric acid, sulfuric acid, and acetic acid.

The invention also includes isotopic isomers of a compound according to the invention, wherein at least one atom of the compound is replaced by an isotope of the respective atom which is different from the naturally predominantly occurring isotope, as well as any mixtures of isotopic isomers of such a compound. Preferred isotopes are ²H (deuterium), ³H (tritium), ¹³C and ¹⁴C.

Certain compounds according to the invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (mu, delta, kappa, NOP/ORL-1) either centrally or peripherally, or both. The pharmacodynamic response may be attributed to the compound either stimulating (agonizing) or inhibiting (antagonizing) the one or more receptors. Certain compounds according to the invention may antagonize one opioid receptor, while also agonizing one or more other receptors. Compounds according to the invention having agonist activity may be either full agonists or partial agonists.

As used herein, compounds that bind to receptors and mimic the regulatory effects of endogenous ligands are defined as “agonists”. Compounds that bind to a receptor but produce no regulatory effect, but rather block the binding of ligands to the receptor, are defined as “antagonists”.

In certain embodiments, the compounds according to the invention are agonists at the mu opioid (MOP) and/or kappa opioid (KOP) and/or delta opioid (DOP) and/or nociceptin opioid (NOP/ORL-1) receptors.

The compounds according to the invention potently bind to the MOP and/or KOP and/or DOP and/or NOP receptors.

The compounds according to the invention can be modulators at the MOP and/or KOP and/or DOP and/or NOP receptors, and therefore the compounds according to the invention can be used/administered to treat, ameliorate, or prevent pain.

In some embodiments, the compounds according to the invention are agonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are agonists of the MOP and/or KOP and/or DOP and/or NOP receptors.

In some embodiments, the compounds according to the invention are antagonists of one or more opioid receptors. In some embodiments, the compounds according to the invention are antagonists of the MOP and/or KOP and/or DOP and/or NOP receptors.

In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.

In some embodiments, the compounds according to the invention have both, (i) agonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.

In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) agonist activity at one or more of the MOP, KOP, and DOP receptors.

In some embodiments, the compounds according to the invention have both, (i) antagonist activity at the NOP receptor; and (ii) antagonist activity at one or more of the MOP, KOP, and DOP receptors.

In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

-   -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the KOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the DOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the KOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the DOP receptor; or     -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the KOP receptor as well as no significant activity at the         DOP receptor.

In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the MOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

-   -   have agonist activity at the NOP receptor as well as agonist         activity at the MOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the MOP receptor as well as agonist activity at the         KOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the MOP receptor as well as agonist activity at the         DOP receptor;     -   can be regarded as opioid pan agonists, i.e. have agonist         activity at the NOP receptor as well as agonist activity at the         MOP receptor as well as agonist activity at the KOP receptor as         well as agonist activity at the DOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the MOP receptor, but no significant activity at the         KOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the MOP receptor, but no significant activity at the         DOP receptor; or     -   have agonist activity at the NOP receptor as well as agonist         activity at the MOP receptor, but no significant activity at the         KOP receptor as well as no significant activity at the DOP         receptor.

In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

-   -   have agonist activity at the NOP receptor as well as agonist         activity at the KOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the KOP receptor as well as agonist activity at the         MOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the KOP receptor as well as agonist activity at the         DOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the KOP receptor, but no significant activity at the         MOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the KOP receptor, but no significant activity at the         DOP receptor; or     -   have agonist activity at the NOP receptor as well as agonist         activity at the KOP receptor, but no significant activity at the         MOP receptor as well as no significant activity at the DOP         receptor.

In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have balanced agonist activity at the NOP receptor as well as at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

-   -   have agonist activity at the NOP receptor as well as agonist         activity at the DOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the DOP receptor, but no significant activity at the         MOP receptor;     -   have agonist activity at the NOP receptor as well as agonist         activity at the DOP receptor, but no significant activity at the         KOP receptor; or     -   have agonist activity at the NOP receptor as well as agonist         activity at the DOP receptor, but no significant activity at the         MOP receptor as well as no significant activity at the KOP         receptor.

In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have selective agonist activity at the KOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

-   -   have agonist activity at the KOP receptor, but no significant         activity at the MOP receptor;     -   have agonist activity at the KOP receptor, but no significant         activity at the NOP receptor;     -   have agonist activity at the KOP receptor, but no significant         activity at the DOP receptor;     -   have agonist activity at the KOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the NOP receptor;     -   have agonist activity at the KOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the DOP receptor; or     -   have agonist activity at the KOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the NOP receptor as well as no significant activity at the         DOP receptor.

In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention have agonist activity at the MOP receptor, agonist activity at the KOP receptor, and antagonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the peripheral nervous system, the compounds according to the invention

-   -   have agonist activity at the MOP receptor as well as agonist         activity at the KOP receptor as well as antagonist activity at         the DOP receptor;     -   have agonist activity at the MOP receptor as well as agonist         activity at the KOP receptor as well as antagonist activity at         the DOP receptor as well as agonist activity at the NOP         receptor;     -   have agonist activity at the MOP receptor as well as agonist         activity at the KOP receptor as well as antagonist activity at         the DOP receptor as well as antagonist activity at the NOP         receptor; or     -   have agonist activity at the MOP receptor as well as agonist         activity at the KOP receptor as well as antagonist activity at         the DOP receptor, no significant activity at the NOP receptor.

In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective agonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

-   -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the KOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the DOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the KOP receptor;     -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the DOP receptor; or     -   have agonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the KOP receptor as well as no significant activity at the         DOP receptor.

In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have selective antagonist activity at the NOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

-   -   have antagonist activity at the NOP receptor, but no significant         activity at the MOP receptor;     -   have antagonist activity at the NOP receptor, but no significant         activity at the KOP receptor;     -   have antagonist activity at the NOP receptor, but no significant         activity at the DOP receptor;     -   have antagonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the KOP receptor;     -   have antagonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the DOP receptor; or     -   have antagonist activity at the NOP receptor, but no significant         activity at the MOP receptor as well as no significant activity         at the KOP receptor as well as no significant activity at the         DOP receptor.

In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention have antagonist activity at the NOP receptor as well as agonist activity at the DOP receptor. In some embodiments, preferably with respect to receptors of the central nervous system, the compounds according to the invention

-   -   have antagonist activity at the NOP receptor as well as agonist         activity at the DOP receptor;     -   have antagonist activity at the NOP receptor as well as agonist         activity at the DOP receptor, but no significant activity at the         MOP receptor;     -   have antagonist activity at the NOP receptor as well as agonist         activity at the DOP receptor, but no significant activity at the         KOP receptor; or     -   have antagonist activity at the NOP receptor as well as agonist         activity at the DOP receptor, but no significant activity at the         MOP receptor as well as no significant activity at the KOP         receptor.

For the purpose of the specification, “no significant activity” means that the activity (agonist/antagonist) of the given compound at this receptor is lower by a factor of 1000 or more compared to its activity (agonist/antagonist) at one or more of the other opioid receptors.

A further aspect of the invention relates to the compounds according to the invention as medicaments.

A further aspect of the invention relates to the compounds according to the invention for use in the treatment of pain. A further aspect of the invention relates to a method of treating pain comprising the administration of a pain alleviating amount of a compound according to the invention to a subject in need thereof, preferably to a human. The pain is preferably acute or chronic. The pain is preferably nociceptive or neuropathic.

A further aspect of the invention relates to the compounds according to the invention for use in the treatment of neurodegenerative disorders, neuroinflammatory disorders, neuropsychiatric disorders, and substance abuse/dependence. A further aspect of the invention relates to a method of treating any one of the aforementioned disorders, diseases or conditions comprising the administration of a therapeutically effective amount of a compound according to the invention to a subject in need thereof, preferably to a human.

Another aspect of the invention relates to a pharmaceutical composition which contains a physiologically acceptable carrier and at least one compound according to the invention.

Preferably, the composition according to the invention is solid, liquid or pasty; and/or contains the compound according to the invention in an amount of from 0.001 to 99 wt. %, preferably from 1.0 to 70 wt. %, based on the total weight of the composition.

The pharmaceutical composition according to the invention can optionally contain suitable additives and/or auxiliary substances and/or optionally further active ingredients.

Examples of suitable physiologically acceptable carriers, additives and/or auxiliary substances are fillers, solvents, diluents, colorings and/or binders. These substances are known to the person skilled in the art (see H. P. Fiedler, Lexikon der Hilfsstoffe fur Pharmazie. Kosmetik and angrenzende Gebiete, Editio Cantor Aulendoff).

The pharmaceutical composition according to the invention contains the compound according to the invention in an amount of preferably from 0.001 to 99 wt. %, more preferably from 0.1 to 90 wt. %, yet more preferably from 0.5 to 80 wt. %, most preferably from 1.0 to 70 wt. % and in particular from 2.5 to 60 wt. %, based on the total weight of the pharmaceutical composition.

The pharmaceutical composition according to the invention is preferably for systemic, topical or local administration, preferably for oral administration.

Another aspect of the invention relates to a pharmaceutical dosage form which contains the pharmaceutical composition according to the invention.

In one preferred embodiment, the pharmaceutical dosage form according to the invention is produced for administration twice daily, for administration once daily or for administration less frequently than once daily. Administration is preferably systemic, in particular oral.

The pharmaceutical dosage form according to the invention can be administered, for example, as a liquid dosage form in the form of injection solutions, drops or juices, or as a semi-solid dosage form in the form of granules, tablets, pellets, patches, capsules, plasters/spray-on plasters or aerosols. The choice of auxiliary substances etc. and the amounts thereof to be used depend on whether the form of administration is to be administered orally, perorally, parenterally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally, buccally, rectally or locally, for example to the skin, the mucosa or into the eyes.

Pharmaceutical dosage forms in the form of tablets, dragees, capsules, granules, drops, juices and syrups are suitable for oral administration, and solutions, suspensions, readily reconstitutable dry preparations and also sprays are suitable for parenteral, topical and inhalatory administration. Compounds according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of agents promoting penetration through the skin, are suitable percutaneous administration preparations.

The amount of the compounds according to the invention to be administered to the patient varies in dependence on the weight of the patient, on the type of administration, on the indication and on the severity of the disease. Usually, from 0.00005 mg/kg to 50 mg/kg, preferably from 0.001 mg/kg to 10 mg/kg, of at least one compound according to the invention is administered.

Another aspect of the invention relates to a process for the preparation of the compounds according to the invention. Suitable processes for the synthesis of the compounds according to the invention are known in principle to the person skilled in the art.

Preferred synthesis routes are described below:

The compounds according to the invention can be obtained via different synthesis routes. Depending on the synthesis route, different intermediates are prepared and subsequently further reacted.

In a preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIa):

wherein R¹, R² and R³ are defined as above.

In another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIb):

wherein R¹, R² and R³ are defined as above and PG is a protecting group.

Preferably the protecting group is -p-methoxybenzyl. Therefore, in another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of an intermediate according to general formula (IIIc):

wherein R¹, R² and R³ are defined as above.

As already indicated, in general formula (IIIc), the -p-methoxybenzyl moiety represents a protecting group which can be cleaved in the course of the synthesis route.

In yet another preferred embodiment, the synthesis of the compounds according to the invention proceeds via a synthesis route which comprises the preparation of

-   -   an intermediate according to general formula (IIIa) and         according to general formula (IIIb); or     -   an intermediate according to general formula (IIIa) and         according to general formula (IIIc); or     -   an intermediate according to general formula (IIIb) and         according to general formula (IIIc); or     -   an intermediate according to general formula (IIIa), according         to general formula (IIIb) and according to general formula         (IIIc).

The following examples further illustrate the invention but are not to be construed as limiting its scope.

EXAMPLES

“RT” means room temperature (23±7° C.), “M” are indications of concentration in mol/l, “aq.” means aqueous, “sat.” means saturated, “sol.” means solution, “conc.” means concentrated.

Further Abbreviations

-   brine saturated aqueous sodium chloride solution -   CC column chromatography -   cHex cyclohexane -   DCM dichloromethane -   DIPEA N,N-di isopropylethylamine -   DMF N,N-dimethylformamide -   Et Ethyl -   ether diethyl ether -   EE ethyl acetate -   EtOAc ethyl acetate -   EtOH ethanol -   h hour(s) -   H₂O water -   HATU     O-(7-aza-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate -   LDA Lithium-di-isoproyl-amid -   Me Methyl -   m/z mass-to-charge ratio -   MeOH methanol -   MeCN acetonitrile -   min minutes -   MS mass spectrometry -   NBS N-bromo-succinimide -   NEt₃ triethylamine -   PE Petrol Ether (60-80° C.) -   RM reaction mixture -   RT room temperature -   T3P     2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide -   tBME tert-butyl methyl ether -   THF tetrahydrofuran -   v/v volume to volume -   w/w weight to weight

The yields of the compounds prepared were not optimised. All temperatures are uncorrected.

All starting materials, which are not explicitly described, were either commercially available (the details of suppliers such as for example Acros, Aldrich, Bachem, Butt park, Enamine, Fluka, Lancaster, Maybridge, Merck, Sigma, TCI, Oakwood, etc. can be found in the Symyx® Available Chemicals Database of MDL, San Ramon, US or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or the synthesis thereof has already been described precisely in the specialist literature (experimental guidelines can be found in the Reaxys® Database of Elsevier, Amsterdam, NL or the SciFinder® Database of the ACS, Washington D.C., US, respectively, for example) or can be prepared using the conventional methods known to the person skilled in the art.

The mixing ratios of solvents or eluents for chromatography are specified in v/v.

All the intermediate products and exemplary compounds were analytically characterised by mass spectrometry (MS, m/z for [M+H]⁺). In addition ¹H-NMR and ¹³C spectroscopy was carried out for all the exemplary compounds and selected intermediate products.

Remark Regarding Stereochemistry

CIS refers to the relative configuration of compounds described herein, in which both nitrogen atoms are drawn on the same face of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:

TRANS refers to compounds, in which both nitrogen atoms are on opposite faces of the cyclohexane ring as described in the following exemplary structure. Two depictions are possible:

SYNTHESIS OF INTERMEDIATES Synthesis of INT-799: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

NaOH (1.42 g, 35.5 mmol) was added to a solution of CIS-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-794) (3 g, 7.09 mmol) in DMSO (90 mL) under argon atmosphere and the reaction mixture was stirred at 80° C. for 30 min. ((1-(Bromomethyl)cyclobutoxy)methyl)benzene (5.4 g, 21.3 mmol) was added and stirring was continued for 2 days at 80° C. The reaction completion was monitored by TLC. The reaction mixture was diluted with water (500 mL) and extracted with diethyl ether (4×300 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (230-400 mesh silica gel; 65-70% EtOAc in petroleum ether as eluent) to afford 2.5 g (59%) of CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-di azaspiro[4.5]decan-2-one (TLC system: 10% MeOH in DCM; Rf: 0.8).

Step 2: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

TFA (12 mL) was added to CIS-1-((1-(benzyloxy)cyclobutyl)methyl)-3-(3,4-dimethoxybenzyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.5 g, 4.18 mmol) at 0° C. and the resulting mixture was stirred at 70° C. for 6 h. The reaction completion was monitored by LCMS. The reaction mixture was concentrated under reduced pressure. To the residue sat. aq. NaHCO₃ was added (until pH 10) and the organic product was extracted with DCM (3×150 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (230-400 mesh silica gel; 5% MeOH in DCM as eluent) to afford 500 mg (33%) of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-799) (TLC system: 10% MeOH in DCM; Rf: 0.5). [M+H]⁺ 358.2

Synthesis of INT-951: CIS-1-[(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile

Step 1: 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile

NaH (50% in mineral oil) (2.44 g, 50.89 mmol) was added to a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (5 g, 12.72 mmol) in DMF (100 mL) at 0° C. portionwise over 10 min. 1-(Bromomethyl)cyclobutanecarbonitrile (4.4 g, 25.44 mmol) was added dropwise over 10 minutes at 0° C. The reaction mixture was allowed to stir at RT for 3 h, then quenched with water and the organic product was extracted with ethyl acetate (3×200 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 5 g (crude) of 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane-carbonitrile as gummy brown liquid. The material was used for the next step without further purification.

Step 2: 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide

TFA (100 mL) was added to 1-((CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarbonitrile (5 g, 10.28 mmol) at 0° C. and the reaction mixture at mixture was stirred at RT for 2 days. The reaction mixture was concentrated in vacuo. To the residue sat. aq. NaHCO₃ was added (until pH 10) and the organic product was extracted with dichloromethane (3×150 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 3.5 g (crude) of 1-((CIS-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl) cyclobutanecarboxamide. The material was used for the next step without further purification.

Step 3: 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutane carbonitrile

Thionyl chloride (35 mL) was added to 1-((cis-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)methyl)cyclobutanecarboxamide (3.5 g, 9.11 mmol) at RT and the resulting mixture was stirred at reflux for 2 h. The reaction mixture was concentrated in vacuo. To the residue sat. aq. NaHCO₃ was added (until pH 10) and the organic product was extracted with dichloromethane (3×150 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography to afford 1.3 g (34% after three steps) of CIS-1-[(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-methyl]-cyclobutane-1-carbonitrile (INT-951). [M+H]⁺ 367.2.

Synthesis of INT-952: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

To a solution of CIS-8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (10 g, 25 mmol) in THF (500 mL) was added KOtBu (7.1 g, 63 mmol) at 50° C. The reaction mixture was heated up to reflux, cyclobutylmethylbromide (11.3 g, 76 mmol) was added in one portion, and stirring was continued at reflux for 12 h. KOtBu (7.1 g) and cyclobutylmethylbromide (11.3 g) were added again. The reaction mixture was allowed to stir another 2 h at reflux, then cooled to RT, diluted with water (150 mL) and the layers partitioned. The aqueous layer was extracted with EtOAc (3×300 mL). The combined organic layers were dried over Na₂SO₄ and then concentrated in vacuo. The residue was filtered through a plug of silica gel using a DCM/MeOH (19/1 v/v) mixture. The filtrate was concentrated in vacuo and the resulting solid was recrystallized from hot ethanol to yield 7.8 g of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-952). [M+H]⁺ 461.3.

Synthesis of INT-953: CIS-1-(Cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: 1-Cyclobutylmethyl-3-(4-meth oxy-benzyl)-9,12-dioxa-1,3-diaza-dispiro[4.2.4.2]tetradecan-2-one

To a stirred solution of 3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diaza-dispiro[4.2.4.2]tetradecan-2-one (4 g, 12.04 mmol) in anhydrous DMF (60 ml) was added NaH (1.38 g, 60% dispersion in oil, 36.14 mmol) at RT. The reaction mixture was stirred for 10 min, bromomethylcyclobutane (3 ml, 26.5 mmol) was added dropwise and stirring was continued for 50 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NH₄Cl (50 ml) and extracted with EtOAc (3×200 ml). The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified column chromatography (neutral aluminum oxide, EtOAc petroleum ether (2:8)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diaza-dispiro[4.2.4.2]tetradecan-2-one (2.4 g, 50%, white solid). TLC system: EtOAc pet ether (6:1); R_(f)=0.18.

Step 2: 1-Cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione

To a stirred solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-9,12-dioxa-1,3-diaza-dispiro[4.2.4.2]tetradecan-2-one (1 g, 2.5 mmol) in MeOH (7 ml) was added 10% aq. HCl (8 ml) at 0° C. The reaction mixture was warmed up to RT and stirred for 16 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was quenched with sat. aq. NaHCO₃ (30 ml) and extracted with EtOAc (3×50 ml). The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel, 230-400 mesh, EtOAc pet ether (1:3)-43:7)) to give 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione (650 mg, 73%, colorless viscous oil). TLC system: EtOAc pet ether (6:4); R_(J)=0.40.

Step 3: 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile

To a stirred solution of N-isobutyl-N-methylamine (1.34 ml, 11.23 mmol) and MeOH/H₂O (8 ml, 1:1, v/v) was added 4N aq. HCl (1.5 ml) and the reaction mixture was stirred for 10 min at 0° C. (ice bath). A solution of 1-cyclobutylmethyl-3-(4-methoxy-benzyl)-1,3-diaza-spiro[4.5]decane-2,8-dione (1 g, 2.80 mmol) in MeOH (7 ml) and KCN (548 mg, 8.42 mmol) were added and the reaction mixture was stirred at 45° C. for 20 h. TLC analysis showed complete consumption of the starting material. The reaction mixture was diluted with water (30 ml), extracted with EtOAc (3×30 ml), the combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to give 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, viscous yellow oil). TLC system: EtOAc pet ether (1:1); R_(f)=0.45. The product was used for the next step without additional purification.

Step 4: CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A round bottom flask containing 1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (1.3 g, 2.81 mmol) was cooled in an ice bath (˜0° C.) and a solution of phenylmagnesium bromide (26 ml, 2M in THF) was added slowly at 0° C.-5° C. The ice bath was removed and the reaction mixture was stirred for 30 min, then diluted with sat. aq. NH₄Cl (25 ml) and extracted with EtOAc (4×30 ml). The combined organic phase was dried over Na₂SO₄ and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified by column chromatography (silica gel, 230-400 mesh, eluent: EtOAc pet ether (15:85)>(2:4)) to give CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (135 mg, 10%, white solid). TLC system: EtOAc pet ether (1:1); R_(f)=0.6

Step 5: CIS-1-(Cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A round bottom flask containing CIS-1-(cyclobutylmethyl)-8-(isobutyl(methyl)amino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (130 mg, 0.25 mmol) was cooled in an ice bath and a mixture of TFA/CH₂Cl₂ (2.6 ml, 1:1, v/v) was added slowly at 0° C.-5° C. The reaction mixture was warmed to RT and stirred for 20 h, then quenched with methanolic NH₃ (10 ml, 10% in MeOH) and concentrated under reduced pressure to give pale yellow viscous oil. This residue was purified twice by column chromatography (silica gel, 230-400 mesh, eluent: MeOH—CHCl₃ (1:99)→(2:98)) to give CIS-1-(cyclobutyl-methyl)-8-(methyl-(2-methyl-propyl)-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-953) (65 mg, 66%, white solid). TLC system: MeOH—CHCl₃ (5:95); R_(f)=0.25; [M+H]⁺ 384.3

Synthesis of INT-958: 4-Oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile

Step 1: Ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate

KOtBu (57.0 g, 508.4 mmol) was added to the solution of 2-(pyridin-2-yl)acetonitrile (50.0 g, 423.7 mmol) and ethyl acrylate (89.0 g, 889.8 mmol) in THF (500 mL) at 0° C. and stirred for 16 h at RT. The reaction mixture was quenched with sat. aq. NH₄Cl and extracted with EtOAc (2×500 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 68.0 g (60%; crude) of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate as a brown liquid (TLC system: 50% ethyl acetate in petroleum ether; Rf: 0.65).

Step 2: 4-Oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile

A solution of ethyl 5-cyano-2-oxo-5-(pyridin-2-yl)cyclohexanecarboxylate (68.0 g, 250.0 mmol) was added to a mixture of conc. aq. HCl and glacial acetic acid (170 mL/510 mL) at 0° C. The reaction mixture was heated to 100° C. for 16 h. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO₃ and extracted with ethyl acetate (3×300 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 44.0 g (88%) of 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile INT-958 as a brown solid (TLC system: 50% ethyl acetate in pet ether; Rf: 0.45). [M+H]⁺ 201.1

Synthesis of INT-961: 4-Dimethylamino-4-pyridin-2-yl-cyclohexan-1-one

Step 1: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile

A solution of 4-oxo-1-pyridin-2-yl-cyclohexane-1-carbonitrile (INT-958) (44.0 g, 220.0 mmol), ethylene glycol (27.0 g, 440.0 mmol) and PTSA (4.2 g, 22.0 mmol) in toluene (450 mL) was heated to 120° C. for 16 h using Dean Stark apparatus. All volatiles were evaporated under reduced pressure. The residue was diluted with sat. aq. NaHCO₃ and extracted with ethyl acetate (3×300 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 45.0 g (85%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile as a light brown solid (TLC system: 50% ethyl acetate in petroleum ether; Rf: 0.55).

Step 2: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide

Potassium carbonate (50.0 g, 368.84 mmol) and 30% aq. H₂O₂ (210.0 mL, 1844.2 mmol) were added to the solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carbonitrile (45.0 g, 184.42 mmol) in DMSO (450 mL) at 0° C. and the resulting mixture was stirred at RT for 14 h. The reaction mixture was diluted with water (1.5 L) and stirred for 1 h. The precipitated solid was separated by filtration, washed with water, petroleum ether and dried under reduced pressure to get 32.0 g (66%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide as a white solid. (TLC system: 10% MeOH in DCM Rf: 0.35).

Step 3: methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate

A mixture of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decane-8-carboxamide (25.0 g, 95.41 mmol), sodium hypochlorite (5 wt % aq. solution, 700 mL, 477.09 mmol) and KF—Al₂O₃ (125.0 g) in methanol (500 mL) was heated to 80° C. for 16 h. The reaction mixture was filtered through celite and the solid residue was washed with methanol. The combined filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (3×500 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 18.0 g (66%) of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate as a light brown solid. (TLC system: 5% MeOH in DCM Rf: 0.52.)

Step 4: 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine

A suspension of methyl 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-ylcarbamate (18.0 g, 61.64 mmol) in 10 wt % aq. NaOH (200 mL) was heated to 100° C. for 24 h. The reaction mixture was filtered through celite pad, the solid residue was washed with water and the combined filtrate was extracted with EtOAc (4×200 mL). The combined organic layer washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 12.5 g (88%) of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine as a light brown semi-solid. (TLC system: 5% MeOH in DCM R_(f): 0.22.).

Step 5: 4-Dimethylamino-4-pyridin-2-yl-cyclohexan-1-one

Sodium cyanoborohydride (13.7 g, 0.213 mol) was added portionwise to a solution of 8-(pyridin-2-yl)-1,4-dioxaspiro[4.5]decan-8-amine (12.5 g, 53.418 mmol) and 35 wt % aq. formaldehyde (45 mL, 0.534 mol) in acetonitrile (130 mL) at 0° C. The reaction mixture was warmed up to room temperature and stirred for 16 h. The reaction mixture was quenched with sat. aq. NH₄Cl and concentrated under reduced pressure. The residue was dissolved in water and extracted with EtOAc (3×200 mL). The combined organic layer was washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure to afford 10.5 g (72%) of 4-dimethylamino-4-pyridin-2-yl-cyclohexan-1-one (INT-961) as a light brown solid. (TLC system: 5% MeOH in DCM Rf: 0.32.). [M+H]⁺ 219.1

Synthesis of INT-965: 4-Dimethylamino-4-phenyl-cyclohexan-1-one

Step 1: 8-(Dimethylamino)-1,4-dioxaspiro 4.5]decane-8-carbonitrile

Dimethylamine hydrochloride (52 g, 0.645 mol) was added to the solution of 1,4-dioxaspiro-[4.5]-decan-8-one (35 g, 0.224 mmol) in MeOH (35 mL) at RT under argon atmosphere. The solution was stirred for 10 min and 40 wt % aq. dimethylamine (280 mL, 2.5 mol) and KCN (32 g, 0.492 mol) were sequentially added. The reaction mixture was stirred for 48 h at RT, then diluted with water (100 mL) and extracted with EtOAc (2×200 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 44 g of 8-(dimethylamino)-1,4-dioxaspiro-[4.5]-decane-8-carbonitrile (93%) as a white solid.

Step 2: N,N-dimethyl-8-phenyl-1,4-dioxaspiro [4.5]decan-8-amine

8-(Dimethylamino)-1,4-dioxaspiro[4.5]decane-8-carbonitrile (35 g, 0.167 mol) in THF (350 mL) was added to the solution of 3M phenylmagnesium bromide in diethyl ether (556 mL, 1.67 mol) dropwise at −10° C. under argon atmosphere. The reaction mixture was stirred for 4 h at −10° C. to 0° C. and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., diluted with sat. aq. NH₄Cl (1 L) and extracted with EtOAc (2×600 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 60 g of, N N-dimethyl-8-phenyl-1,4-dioxaspiro-[4.5]-decan-8-amine as a liquid.

Step 3: 4-(dimethylamino)-4-phenylcyclohexanone

A solution of N,N-dimethyl-8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine (32 g, 0.123 mol) in 6N aq. HCl (320 mL) was stirred at 0° C. for 2 h and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was extracted with DCM (2×150 mL). The aqueous layer was basified to pH 10 with solid NaOH and extracted with ethyl acetate (2×200 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The solid residue was washed with hexane and dried in vacuo to afford 7 g of 4-dimethylamino-4-phenyl-cyclohexan-1-one (INT-965) (25% over 2 steps) as a brown solid. [M+H]⁺ 218.1

Synthesis of INT-966: 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione

Step 1: 9,12-Dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}]tetradecane-1,3-dione

KCN (93.8 g, 1441.6 mmol) and (NH₄)₂CO₃ (271.8 g, 1729.9 mmol) were added to the solution of 1,4-dioxaspiro[4.5]decan-8-one (150 g, 961 mmol) in MeOH:H₂O (1:1 v/v) (1.92 L) at RT under argon atmosphere. The reaction mixture was stirred at 60° C. for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., the precipitated solid was filtered off and dried in vacuo to afford 120 g (55%) of 9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}0.2{S}]tetradecane-1,3-dione. The filtrate was extracted with DCM (2×1.5 L). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford additional 30 g (14%) of 9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}]tetradecane-1,3-dione (TLC system: 10% Methanol in DCM; Rf: 0.4).

Step 2: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}] tetradecane-1,3-dione

Cs₂CO₃ (258.7 g, 796.1 mmol) was added to the solution of 73a (150 g, 663.4 mmol) in MeCN (1.5 L) under argon atmosphere and the reaction mixture was stirred for 30 min. A solution of p-methoxybenzyl bromide (96 mL, 663.4 mmol) was added. The reaction mixture was stirred at RT for 48 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH₄Cl (1.0 L) and the organic product was extracted with EtOAc (2×1.5 L). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was washed with diethyl ether and pentane and dried under reduced pressure to afford 151 g (65%) of 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}]tetradecane-1,3-dione as an off white solid (TLC system: 10% MeOH in DCM; Rf: 0.6).

Step 3: 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}] tetradecan-3-one

AlCl₃ (144.3 g, 1082.6 mmol) was added to a solution of LiAlH₄ (2M in THF) (433 mL, 866.10 mmol) in THF (4.5 L) at 0° C. under argon atmosphere and the resulting mixture was stirred at RT for 1 h. 2-[(4-Methoxyphenyl)-methyl]-9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}]tetradecane-1,3-dione (150 g, 433.05 mmol) was added at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with sat. aq. NaHCO₃ (500 mL) and filtered through celite pad. The filtrate was extracted with EtOAc (2×2.0 L). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuo to afford 120 g (84%) of 2-[(4-methoxyphenyl)-methyl]-9,12-dioxa-2,4-di azadispiro[4.2.4̂{8}.2̂{5}]tetradecan-3-one as an off-white solid. (TLC system: 10% MeOH in DCM, Rf: 0.5).

Step 4: 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione

A solution of 2-[(4-methoxyphenyl)-methyl]-9,12-di oxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}] tetradecan-3-one (120 g, 361.03 mmol) in 6N aq. HCl (2.4 L) was stirred at 0° C. for 2 h and then at RT for 18 h. The reaction completion was monitored by TLC. The reaction mixture was extracted with DCM (2×2.0 L). The aqueous layer was basified to pH 10 with 50% aq. NaOH and then extracted with DCM (2×2.0 L). Combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The solid residue was washed with hexane and dried in vacuo to afford 90 g of 3-[(4-Methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-dione (INT-966) as an off-white solid (TLC system: 10% MeOH in DCM; Rf: 0.4) [M+H]⁺ 289.11.

Synthesis of INT-971: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-951 step 1 CIS-8-Dimethylamino-8-[3-(methoxymethyloxy)-phenyl]-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-968) was converted into CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-(methoxymethoxy)phenyl)-1,3-diazaspiro[4.5]decan-2-one.

Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

TFA (0.2 mL) was added to the solution of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(4-methoxybenzyl)-8-(3-methoxyphenyl)-1,3-diazaspiro[4.5]decan-2-one (300 mg, 0.57 mmol) in DCM (1.5 mL) at 0° C. The reaction mixture was stirred at 0° C. for 3 h. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NaHCO₃ and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. Purification of the residue by preparative TLC (3% MeOH in DCM as mobile phase) yielded 50 mg (18%) of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-hydroxyphenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-971) as an off white solid. (TLC system: 10% MeOH in DCM; Rf: 0.20) [M+H]⁺ 478.3

Synthesis of INT-974: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

Step 1: 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile

Dimethylamine hydrochloride (76.4 g, 936.4 mmol) was added to a solution of 3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decane-2,8-di one (INT-966) (90 g, 312.13 mmol) in MeOH (180 mL) at RT under argon atmosphere. The solution was stirred for 15 min and 40 wt % aq. dimethylamine (780 mL) and KCN (48.76 g, 749.11 mmol) were sequentially added. The reaction mixture was stirred for 48 h and the completion of the reaction was monitored by NMR. The reaction mixture was diluted with water (1.0 L) and the organic product was extracted with ethyl acetate (2×2.0 L). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 90 g (85%) of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile as an off white solid (TLC system: TLC system: 10% MeOH in DCM; Rf: 0.35, 0.30).

Step 2: CIS-8-Dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

3-Fluorophenylmagnesium bromide (1M in THF) (220 mL, 219.17 mmol) was added dropwise to a solution of 8-(dimethylamino)-3-(4-methoxybenzyl)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (15 g, 43.83 mmol) in THF (300 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred for 16 h at RT. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with sat. aq. NH₄Cl (200 mL) and the organic product was extracted with EtOAc (2×200 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The reaction was carried out in 4 batches (15 g×2 and 5 g×2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (230-400 mesh) (2 times) (0-20% methanol in DCM) eluent and subsequently by washing with pentane yielded 5.6 g (11%) of CIS-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-974) as an off-white solid. (TLC system: 5% MeOH in DCM in presence of ammonia; Rf: 0.1). [M+H]⁺ 412.2

Synthesis of INT-975: CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

KOtBu (1M in THF) (29.30 mL, 29.30 mmol) was added to the solution of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one INT-976 (8.0 g, 29.30 mmol) in THF (160 mL) under argon atmosphere and the reaction mixture was stirred for 30 min. 4-Methoxybenzyl bromide (4.23 mL, 29.30 mmol) was added and stirring was continued at RT for 4 h. The reaction completion was monitored by TLC. The reaction mixture was diluted with sat. aq. NH₄Cl (150 mL) and the organic product was extracted with EtOAc (2×150 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The reaction was carried out in 2 batches (8 g×2) and the batches were combined for purification. Purification of the crude product by flash column chromatography on silica gel (0-10% methanol in DCM) and subsequently by washing with pentane yielded 11 g (47%) of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) as a white solid. [M+H]⁺ 394.2

Synthesis of INT-976: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione

In a sealed tube 4-dimethylamino-4-phenyl-cyclohexan-1-one (INT-965) (2 g, 9.22 mmol) was suspended in 40 mL EtOH/H₂O (1:1 v/v) at RT under argon atmosphere. (NH₄)₂CO₃ (3.62 g, 23.04 mmol) and KCN (0.6 g, 9.22 mmol) were added. The reaction mixture was stirred at 60° C. for 18 h. The reaction mixture was cooled to 0° C. and diluted with ice-water and filtered through a glass filter. The solid residue was dried under reduced pressure to afford 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decane-2,4-dione (1.8 g, 86%) as an off white crystalline solid (TLC: 80% EtOAc in hexane; Rf: 0.25).

Step 2: 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2-one

LiAlH₄ (2M in THF) (70 mL, 139.4 mmol) was added to the solution of 8-(dimethylamino)-8-phenyl-1,3-di azaspiro[4,5]decane-2,4-dione (10 g, 34.8 mmol) in THF/Et₂O (2:1 v/v) (400 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred for 4 h at 60° C. The reaction completion was monitored by TLC. The reaction mixture was cooled to 0° C., quenched with saturated Na₂SO₄ solution (100 mL) and filtered through Celite pad. The filtrate was dried over anhydrous Na₂SO₄ and concentrated in vacuo to afford 5.7 g (59%) of 8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2-one as an off white solid. (TLC system: 10% MeOH in DCM, Rf: 0.3).

Step 3: CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A mixture of CIS- and TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4,5]decan-2-one (8 g, 29.30 mmol) was purified by preparative chiral SFC (column: Chiralcel AS-H, 60% CO₂, 40% (0.5% DEA in MeOH)) to get 5 g of CIS-8-Dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) as a white solid. [M+H]⁺ 274.2.

Synthesis of INT-977: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid; 2,2,2-trifluoro-acetic acid salt

Step 1: CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester

A solution of CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (5.0 g, 12.7 mmol) in THF (18 mL) was cooled to 0° C. and treated with LDA solution (2M in THF/heptane/ether, 25.4 mL, 50.8 mmol). The resulting mixture was allowed to warm up to RT over 30 min. The solution was then cooled to 0° C. again and tert-butyl-bromoacetate (5.63 mL, 38.1 mmol) was added. The reaction mixture was stirred at RT for 16 h, quenched with water and extracted with DCM (3×). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-2-[8-dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester (4.4 g).

Step 2: cis-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid trifluoroacetic acid salt

CIS-2-[8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-acetic acid tert-butyl ester (200 mg, 0.4 mmol) was dissolved in TFA (5 mL) and heated to reflux overnight. After cooling to RT all volatiles are removed in vacuo. The residue was taken up in THF (1 mL) and added dropwise to diethyl ether (20 mL). The resulting precipitate was filtered off and dried under reduced pressure to give CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid; 2,2,2-trifluoro-acetic acid salt (INT-977) (119 mg) as a white solid. [M+H]⁺ 332.2

Synthesis of INT-978: CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide

CIS-2-(8-Dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-acetic acid (INT-977) trifluoroacetic acid salt (119 mg, 0.35 mmol) was dissolved in DCM (5 mL). Triethylamine (0.21 mL, 1.6 mmol), dimethylamine (0.54 mL, 1.1 mmol) and T3P (0.63 mL, 1.1 mmol) were sequentially added. The reaction mixture was stirred at RT overnight, then diluted with 1 M aq. Na₂CO₃ (5 mL). The aqueous layer was extracted with DCM (3×5 mL), the combined organic layers were dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to yield CIS-2-(8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl)-N,N-dimethyl-acetamide (INT-978) (39 mg) as a white solid. [M+H]⁺ 359.2

Synthesis of INT-982: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

A solution of NaOH (2.85 g, 71.2 mmol) in DMSO (25 mL) was stirred at RT for 10 min. CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5] decan-2-one (INT-975) (7.00 g, 17.8 mmol) was added and stirring was continued for 15 min. 1-(Bromo-methyl)-1-methyl-cyclobutane (8.7 g, 53.4 mmol) was added at 0° C. The reaction mixture was heated to 60° C. for 16 h. After cooling down to RT, water (100 mL) was added and the mixture was extracted with DCM (3×150 mL). The combined organic layers were washed with water (70 mL), brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure. Purification of the residue by column chromatography on silica gel provided CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-1-((1-methylcyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (6.5 g) as a light yellow solid.

Step 2: CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To the solution of CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (6.66 g, 14.0 mmol) in DCM (65 mL) was added TFA (65 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was concentrated under reduced pressure. The residue was taken up in DCM (100 mL) and water (60 mL) and basified with 2M aq. NaOH to pH 10. The organic layer was separated and washed with brine (40 mL), dried over MgSO₄, filtered and concentrated under reduced pressure. Crystallization of the residue from EtOAc provided CIS-8-Dimethylamino-1-[(1-methyl-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-982) (3.41 g) as an off-white solid. [M+H]⁺ 356.3

Synthesis of INT-984: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-951 step 1 CIS-8-Dimethylamino-3-[(4-methoxyphenyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) was converted into CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one.

Step 2: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-982 step 2 CIS-8-(dimethylamino)-1-isobutyl-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-984).

Synthesis of INT-986: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

N-Iodosuccinimide (3.11 g, 13.92 mmol) was added to the solution of CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[phenyl-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-950) (4 g, 9.28 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 80 mL) and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH-10 and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was stirred vigorously with a mixture of 10 wt % aq. citric acid (5 mL) and DCM (10 mL) at RT for 10 min. The reaction mixture was basified with 5N aq. NaOH to pH-10 and extracted with DCM (3×10 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuo to give 3.5 g (crude) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as semi solid (TLC system: 10% MeOH in DCM; Rf: 0.60.).

Step 2: CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Sodium cyanoborohydride (1.56 g, 25.17 mmol, 3 equiv.) was added to the solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(methylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (3.5 g, 8.39 mmol), acetaldehyde (738 mg, 16.78 mmol, 2 equiv.) and acetic acid (0.5 mL) in methanol (20 mL). The reaction mixture was stirred at RT for 3 h, then quenched with sat. aq. NaHCO₃ and the organic product was extracted with DCM (3×50 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated in vacuo. Purification of the residue by flash column chromatography on silica gel (230-400 mesh) (20-25% ethyl acetate in petroleum ether) yielded 2.3 g (62%) of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as a solid. (TLC system: 50% EtOAc in Pet. Ether; Rf: 0.65).

Step 3: CIS-1-(Cyclobutyl-methyl)-8-(ethyl-methyl-amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986)

Sodium metal (1.18 g, 51.68 mmol, 10 equiv.) was added to liquid ammonia (˜25 mL) at −78° C. The resulting mixture was stirred for 10 min at −78° C. A solution of CIS-3-benzyl-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (2.3 g, 5.16 mmol) in THF (25 mL) was added at −78° C. The reaction mixture was stirred for 15 min, then quenched with sat. aq. NH₄C₁, warmed to RT and stirred for 1 h. The organic product was extracted with DCM (3×50 mL). The combined organic layer was washed with water, brine and concentrated under reduced pressure to afford 1.30 g (72%) of CIS-1-(cyclobutylmethyl)-8-(ethyl(methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-986) as an off-white solid. (TLC system: 10% MeOH in DCM Rf: 0.15.). [M+H]⁺ 356.3

Synthesis of INT-987: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method as described for INT-982 step 2 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-952) was converted into CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-di azaspiro[4.5]decan-2-one (INT-987).

Synthesis of INT-988: CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Sodium hydroxide (78.06 mg, 4.0 equiv.) was suspended in DMSO (3.5 mL), stirred for 10 minutes, 8-(dimethylamino)-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (192.0 mg, 1.0 equiv.) was added, the reaction mixture was stirred for 5 min followed by addition of 2-(1-methoxycyclobutyl)ethyl 4-methylbenzenesulfonate (416.2 mg, 3.0 equiv.) in DMSO (1.5 mL). The resulting mixture was stirred overnight at 50° C. The reaction mixture was quenched with water and extracted with DCM (3×20 mL). The combined organic phases were washed with brine, dried over Na₂SO₄ and concentrated under reduced pressure. The residue (283 mg yellow oil) was purified by column chromatography on silica gel (eluent DCM/EtOH 98/2 to 96/4) to give 8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one 163 mg (66%).

Step 2: CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-988)

In analogy to the method described for INT-982 step 2 CIS-8-(dimethylamino)-1-[2-(1-methoxycyclobutyl)ethyl]-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one was converted into CIS-8-(dimethylamino)-1-(2-(1-methoxycyclobutyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-988). Mass: m/z 386.3 (M+H)⁺.

Synthesis of INT-1008: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one

Step 1 and step 2: ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride (INT-1004)

A mixture of 1,4-dioxa-spiro[4.5]decan-8-one (25.0 g, 160.25 mmol, 1.0 eq.) and 2M solution of EtNH₂ in THF (200 ml, 2.5 eq. 400.64 mmol) in EtOH (30 ml) was stirred at RT for 48 h. The reaction mixture was concentrated under argon atmosphere and the residue was diluted with ether (60 ml), and a freshly prepared PhLi solution was added [prepared by addition of 2.5M n-BuLi in THF (70.5 ml, 1.1 eq. 176.27 mmol) to a solution of bromobenzene (27.675 g, 1.1 eq. 176.275 mmol) in ether (100 ml) at −30° C. and stirred at RT for 1 h). The reaction mixture was stirred at RT for 1.5 h, quenched with saturated NH₄Cl solution (100 ml) at 0° C. and extracted with ethyl acetate (2×750 ml). The combined organic layer was washed with water (3×350 ml), brine (300 ml), dried over Na₂SO₄ and concentrated under reduced pressure. The resulting residue was dissolved in ethyl methyl ketone (100 ml) and trimethylsilyl chloride (37.5 ml) was added at 0° C. The resulting mixture was stirred at RT for 16 h. The precipitated solid was filtered off and washed with acetone followed by THF to get ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride as an off white solid. This reaction was done in 2 batches of 25 g scale and the yield is given for 2 combined batches. Yield: 18% (17.1 g, 57.575 mmol). LCMS: m/z 262.2 (M+H)⁺.

Step 3: 4-ethylamino-4-phenyl-cyclohexanone (INT-1005)

To a solution of ethyl-(8-phenyl-1,4-dioxa-spiro[4.5]dec-8-yl)-amine hydrochloride (10.1 g, 34.0 mmol, 1 eq.) in water (37.5 ml) was added conc. aq. HCl (62.5 ml) at 0° C. and the resulting mixture was stirred at RT for 16 h. The reaction mixture was basified with aq. NaOH (pH 14) at 0° C. and extracted with DCM (2×750 ml). Organic layer was washed with water (400 ml), brine (400 ml), dried over Na₂SO₄ and concentrated under reduced pressure to yield 4-ethylamino-4-phenyl-cyclohexanone which was used in the next step without further purification. This reaction was carried out in another batch of 15.1 g scale and the yield is given for 2 combined batches. Yield: 92% (17.0 g, 78.34 mmol).

Step 4: cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006 and INT-1007)

To a solution of 4-ethylamino-4-phenyl-cyclohexanone (17 g, 78.341 mmol, 1.0 eq.) in EtOH (250 ml) and water (200 ml) was added (NH₄)₂CO₃ (18.8 g, 195.85 mmol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (5.09 g, 78.341 mmol, 1.0 eq.) was added and stirring was continued at 60° C. for 18 h. The reaction mixture was cooled down to RT. The precipitated solid was filtered off, washed with water (250 ml), EtOH (300 ml), hexane (200 ml) and dried under reduced pressure to yield cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (13.0 g, 45.29 mmol, 58%) as a white solid. Yield: 58% (13 g, 45.296 mmol). LC-MS: m/z [M+1]⁺=288.2.

Step 5: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (INT-1006)

To a solution of cis and trans mixture of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (12 g) in MeOH-DCM (1:1, 960 ml) was added a solution of L-tartaric acid in MeOH (25 ml) and the resulting mixture stirred at RT for 2 h and then kept in refrigerator for 16 h. The precipitated solid was filtered off and washed with MeOH-DCM (1:5, 50 ml) to get tartrate salt of 8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (7.5 g) as a white solid. To this solid sat. aq. NaHCO₃ was added (pH-8) and the resulting mixture was extracted with 25% MeOH-DCM (2×800 ml). Combined organic layer was washed with water (300 ml), brine (300 ml), dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was triturated with 20% DCM-hexane and the resulting solid was dried under reduced pressure to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione as white solid. This step was done in 2 batches (12 g & 2.4 g) and the yield is given for 2 combined batches. Yield: 31.2% (5.0 g, 17.421 mmol). LC-MS: m/z [M+1]⁺=288.0.

Step 6: CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008)

To a slurry of LiAlH₄ (793 mg, 20.91 mmol, 3.0 eq.) in THF (15 ml) was added a suspension of CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (2.0 g, 6.97 mmol, 1.0 eq.) in THF (60 ml) at 0° C. and the reaction mixture was heated to 65° C. for 16 h. The reaction mixture was cooled to 0° C., quenched with sat. aq. Na₂SO₄ (20 ml), stirred at RT for 1 h and filtered through celite pad. The residue was washed with 15% MeOH-DCM (500 ml). The combined filtrate was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give crude product which was triturated with 15% DCM-Hexane to afford CIS-8-ethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1008) (1.6 g, 5.86 mmol, 84%) as a white solid. Yield: 84% (1.6 g, 5.86 mmol). LC-MS: m/z [M+1]⁺=274.2.

Synthesis of INT-1026: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfinamide

Titanium ethoxide (58.45 g, 256.4 mmol) was added to a solution of 1,4-dioxaspiro[4.5]decan-8-one (20 g, 128.20 mmol) and 2-methylpropane-2-sulfinamide (15.51 g, 128.20 mmol) in THF (200 mL) at RT and the reaction mixture was stirred at RT for 18 h. The reaction mixture was cooled to 0° C. and quenched by dropwise addition of sat. aq. NaHCO₃ (500 mL) over a period of 30 min. The organic product was extracted with EtOAc (3×100 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated in vacuo to afford 10 g (crude) of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfinamide as a white solid (TLC system: 30% Ethyl acetate in hexane; Rf: 0.30).

Step 2: 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide

Phenylmagnesium bromide (1M in THF, 116 mL, 116 mmol) was added dropwise to a solution of 2-methyl-N-(1,4-dioxaspiro[4.5]decan-8-ylidene)propane-2-sulfinamide (10 g, 38.61 mmol) in THF (500 mL) at −10° C. under argon atmosphere. The reaction mixture was stirred for 2 h at −10° C. to 0° C. The reaction completion was monitored by TLC. The reaction mixture was quenched with sat. aq. NH₄Cl (50 mL) at 0° C. and the organic product was extracted with EtOAc (3×100 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography (silica gel 230-400 mesh; 40-60% ethyl acetate in hexane) to yield 6.0 g (46%) of 2-methyl-N-(8-phenyl-1,4-dioxaspiro[4.5]decan-8-yl)propane-2-sulfinamide as a liquid (TLC system: 70% Ethyl acetate in hexane; Rf: 0.30).

Step 3: 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride

2N solution of HCl in diethyl ether (17.80 mL, 35.60 mmol) was added to a solution of 2-methyl-N-(8-phenyl-1,4-di oxaspiro[4.5]decan-8-yl)propane-2-sulfinamide (6.0 g, 17.80 mmol) in DCM (60 mL) at 0° C. The reaction mixture was stirred at RT for 2 h. The reaction mixture was concentrated in vacuo. The residue was washed with diethyl ether to yield 3 g (crude) of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride as a brown solid (TLC system: 5% MeOH in DCM; Rf: 0.10).

Step 4: 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine

Sodium cyanoborohydride (2.17 g, 33.45 mmol) was added to a solution of 8-phenyl-1,4-dioxaspiro[4.5]decan-8-amine hydrochloride (3.0 g, 11.15 mmol) and tetrahydrofuran-3-carbaldehyde (4.46 mL, 22.30 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated in vacuo at 30° C. and to the residue sat. aq. NaHCO₃ was added. The organic product was extracted with DCM (3×30 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and solvent was concentrated under reduced pressure to get 3 g (crude) of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi-solid (TLC system: 10% MeOH in DCM; Rf: 0.22).

Step 5: N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine)

Sodium cyanoborohydride (1.76 g, 28.39 mmol) was added to a solution of 8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (3.0 g, 9.46 mmol), 37% formaldehyde in water (7.70 mL, 94.60 mmol) and acetic acid (0.05 mL) in methanol (30 mL) at 0° C. The reaction mixture was stirred at RT for 16 h. The reaction mixture was concentrated in vacuo and to the residue sat. aq. NaHCO₃ was added. The organic product was extracted with DCM (3×30 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and solvent was concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 2.50 g (83%) of N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine as a semi solid (TLC system: 10% MeOH in DCM; Rf: 0.25).

Step 6: 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone

5% sulfuric acid in water (25 mL) was added to N-methyl-8-phenyl-N-((tetrahydrofuran-3-yl)methyl)-1,4-dioxaspiro[4.5]decan-8-amine (2.50 g, 7.55 mmol) at 0° C. and the resulting mixture was stirred at RT for 24 h. The reaction mixture was quenched with sat. aq. NaHCO₃ and the organic product was extracted with DCM (2×50 mL). The combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in vacuo to afford 2.0 g (crude) of 4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone as a thick liquid (TLC system: 10% MeOH in DCM, Rf: 0.20).

Step 7: 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-d lone

4-(methyl((tetrahydrofuran-3-yl)methyl)amino)-4-phenylcyclohexanone (1.50 g, 5.22 mmol) was suspended in 30 mL of EtOH:H₂O (1:1 v/v) at RT under argon atmosphere. (NH₄)₂CO₃ (1.9 g, 13.05 mmol) and KCN (0.34 g, 5.22 mmol) were added. The reaction mixture was heated to 70° C. for 16 h. The reaction mixture was diluted with ice-water and the organic product was extracted with DCM (2×50 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuo to give 1.0 g (crude) of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione as a solid (TLC system: 70% Ethyl acetate in hexane; Rf: 0.18).

Step 8: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione

Diastereomeric mixture of 8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (1.0 g) was separated by reverse phase preparative HPLC to afford 400 mg of isomer 1 (CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione) and 60 mg of isomer 2 (TRANS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione) and 300 mg of mixture of both isomers. Reverse phase preparative HPLC conditions: mobile phase: 10 mM ammonium bicarbonate in H₂O/acetonitrile, column: X-BRIDGE-C₁₈ (150*30), 5 μm, gradient (T/B %): 0/35, 8/55, 8.1/98, 10/98, 10.1/35, 13/35, flow rate: 25 ml/min, diluent: mobile phase+ THF.

Step 9: CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026)

LiAlH₄ (1M in THF) (4.48 mL, 4.48 mmol) was added to a solution of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (isomer-1) (0.4 g, 1.12 mmol) in THF:Et₂O (2:1 v/v, 15 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred at 65° C. for 16 h. The mixture was cooled to 0° C., quenched with sat. aq. Na₂SO₄ (1000 mL) and filtered through celite pad. The filtrate was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by column chromatography (silica gel 230-400 mesh; 5-6% MeOH in DCM) to yield 0.3 g (78%) of CIS-8-(methyl((tetrahydrofuran-3-yl)methyl)amino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1026) as an off white solid. (TLC system: 10% MeOH in DCM, Rf: 0.2). LC-MS: m/z [M+1]⁺=344.2.

Synthesis of INT-1031: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-952 CIS-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one (INT-974) was converted into CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one.

Step 2: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for INT-982 step 2 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-3-[(4-methoxyphenyl)-methyl]-1,3-diazaspiro[4.5]decan-2-one was converted into 1-(cyclobutyl-methyl)-8-dimethylamino-8-(3-fluorophenyl)-1,3-di azaspiro[4.5]decan-2-one (INT-1031).

Synthesis of INT-1037: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile

Step 1: 9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}]tetradecan-3-one

Lithiumaluminiumhydride (2.2 equiv., 292 mmol) was suspended in THF (400 mL) and the suspension was cooled to 0° C. 8-(Dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (B, 75 mg, 0,261 mmol) (step 1 of INT-965) was added portionwise at 0° C. The reaction mixture was stirred 1.5 h at 0° C., then overnight at RT and then 2 h at 40° C. The reaction mixture was cooled down to 0° C., quenched carefully with sat. aq. Na₂SO₄, EtOAc (400 mL) was added and the resulting mixture was stirred for 2 h and then left without stirring for 2 h at RT. The precipitate was filtered off and washed with EtOAc and MeOH. The resulting solid residue was suspended in methanol and stirred at RT overnight. The precipitate was filtered off and disposed. The filtrate was concentrated under reduced pressure, the residue was suspended thoroughly in water (50 mL) at 40° C., the precipitate was filtered off and dried under reduced pressure to yield 9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}]tetradecan-3-one (11.4 g, 41%). Mass: m/z 213.2 (M+H)⁺.

Step 2: 1,3-diazaspiro[4.5]decane-2,8-dione

In analogy to the method described for INT-1003 step 3 9,12-dioxa-2,4-diazadispiro[4.2.4̂{8}.2̂{5}]tetradecan-3-one was treated with conc. aq. HCl to be converted into 1,3-diazaspiro[4.5]decane-2,8-dione. Mass: m/z 169.1 (M+H)⁺.

Step 3: 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037)

In analogy to the method described for INT-965 step 1 1,3-diazaspiro[4.5]decane-2,8-dione was treated with dimethyl amine and potassium cyanide to be converted into 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (INT-1037). Mass: m/z 223.2 (M+H)⁺.

Synthesis of INT-1038: CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one

To the suspension of 8-(dimethylamino)-2-oxo-1,3-diazaspiro[4.5]decane-8-carbonitrile (200 mg, 0.90 mmol) in THF (4 mL) at RT was added dropwise 1M bromo(m-tolyl)magnesium in THF (4 equiv., 3.6 mmol, 3.6 mL) and the reaction mixture was stirred for 1 h at RT. Additional portion of 1M bromo(m-tolyl)magnesium in THF (1 equiv., 0.8 mL) was added. The reaction mixture was stirred at RT overnight, then quenched with methanol/water. Solid NH₄Cl and DCM were added to the resulting mixture and the precipitate was filtered off. The organic phase of the filtrate was separated and the aqueous phase was extracted with DCM (3×). The combined organic phases were dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (DCM/MeOH, 100/0 to 65/35) to yield CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one (INT-1038) (81 mg, 31%). Mass: m/z 288.2 (M+H)⁺.

Synthesis of INT-1052: CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile

NaH (60% in mineral oil) (1.76 g, 44.04 mmol) was added to the solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-983) (3.6 g, 11.01 mmol) in DMSO (150 mL) at RT under argon atmosphere. 2-Cyano-2-methylpropyl 4-methylbenzenesulfonate (113 mg, 0.45 mmol) was added to the reaction mixture in one portion. The reaction mixture was heated at 70° C. for 16 h. The reaction mixture was cooled to 0° C. and quenched with water (20 mL). The organic product was extracted with EtOAc (2×200 mL). The combined organic extracts were dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 100-200 mesh, 0-10% MeOH in DCM) to get 2.1 g, 46% of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile as an off-white solid (TLC system: 5% MeOH in DCM; Rf: 0.60).

Step 2: CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanamide

H₂O₂ (30% in water) (8 mL) was added to a solution of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (2.0 g, 4.90 mmol) in DMSO (50 mL) at RT under argon atmosphere. A solution of KOH (1.1 g, 19.6 mmol) in water (10 mL) was added dropwise to the reaction mixture. The reaction mixture was stirred at RT for 16 h. The reaction mixture was diluted with water (300 mL) and the organic product was extracted with EtOAc (2×100 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 100-200 mesh, 0-5% MeOH in DCM) to get 0.44 g (21%) of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanamide as a gummy solid (TLC system: 5% MeOH in DCM; Rf: 0.30) and 1.1 g of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile was also reisolated (TLC system: 5% MeOH in DCM; Rf: 0.30).

Step 3: CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1052)

PhI(OCOCF₃)₂ (703.5 mg, 1.636 mmol) was added to a solution of CIS-3-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanamide (410 mg, 0.962 mmol) in mixture of acetonitrile (15 mL) and water (15 mL) at RT under argon atmosphere. The reaction mixture was stirred for 18 h at RT. The reaction mixture was diluted with water (15 mL) and the aqueous layer was washed with EtOAc (2×20 mL). The water layer was basified with solid NaHCO₃ and the organic product was extracted with EtOAc (2×30 mL). The organic layer was dried over anhydr. Na₂SO₄ and solvent was concentrated under reduced pressure to afford 350 mg, 91% of CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as gummy solid (TLC system: 5% MeOH in DCM; Rf: 0.15). Mass: m/z 399.3 (M+H)⁺.

Synthesis of INT-1054: CIS-8-(dimethylamino)-8-(m-tolyl)-1,3-diazaspiro[4.5]decan-2-one

To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (50 g, 230.1 mmol) in MeOH (400 mL) was added NH₄Cl (24.6 g, 460.8 mmol) followed by NH₄OH (400 mL) at RT and stirred for 15 min. NaCN (22.5 g, 460.83 mmol) was added to the reaction mixture and stirred for 16 h at RT. The reaction mixture was extracted with DCM (3×750 ml). Organic layer was washed with water (750 ml), brine (750 ml) and dried over Na₂SO₄. The solvent was evaporated under reduced pressure. The residue was triturated with DCM/hexane to get crude 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (50 g, 90%) as off white solid which was used in next step without purification. Yield: 78% (44 g, 181 mmol). Mass: m/z 244.2 (M+H)⁺.

Synthesis of INT-1055 and INT-1056: CIS- and TRANS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: N-(1-cyano-4-(dimethylamino)-4-phenylcyclohexyl)cyclobutanecarboxamide (CIS-/TRANS mixture)

To a solution of 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (INT-1054) (5.0 g, 20.57 mmol, 1.0 eq.) in THF (100 mL) were added cyclobutanecarboxylic acid (2.50 g, 24.69 mmol, 1.2 eq), DIPEA (10.5 mL, 61.71 mmol, 3.0 eq) and T3P (18.38 mL, 30.85 mmol, 1.5 eq). The reaction mixture was stirred at RT for 16 h, diluted with water (100 mL) and extracted with EtOAc (2×200 ml). Combined organic layer was washed with brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude cyclobutanecarboxylic acid (1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-amide as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 326.3 (M+H)⁺.

Step 2: 1-(aminomethyl)-N¹-(cyclobutylmethyl)-N⁴,N⁴-dimethyl-4-phenylcyclohexane-1,4-diamine (CIS/TRANS-mixture)

To suspension of LiAlH₄ (2.81 g, 73.84 mmol, 6.0 eq.) in dry THF (25 mL) was added a solution cyclobutanecarboxylic acid (1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-amide (4.0 g, 12.3 mmol, 1.0 eq.) in dry THF (35 mL) dropwise at 0° C. The reaction mixture was stirred at RT for 16 h, then quenched with sat. aq. Na₂SO₄ at 0° C., excess THF was added and the resulting mixture stirred at RT for 2 h. The reaction mixture was filtered through celite and washed with THF (100 mL). Filtrate was concentrated under reduced pressure to get crude 1-aminomethyl-N-cyclobutylmethyl-N′,N′-dimethyl-4-phenyl-cyclohexane-1,4-diamine (3.0 g) as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 316.4 (M+H)⁺.

Step 3: N-((1-((cyclobutylmethyl)amino)-4-(dimethylamino)-4-phenylcyclohexyl)methyl)-2-methyl-2-(methylthio)propanamide (CIS/TRANS-mixture)

To a solution of crude 1-aminomethyl-N-cyclobutylmethyl-N′,N′-dimethyl-4-phenyl-cyclohexane-1,4-diamine (3.0 g, 9.23 mmol, 1.0 eq.) in THF (50 mL) were added 2-methyl-2-methylsulfanyl-propionic acid (1.23 g, 9.23 mmol, 1.0 eq), DIPEA (4.81 mL, 27.69 mmol, 3.0 eq) and T3P (8.3 mL, 13.84 mmol, 1.5 eq, 50% solution in EtOAc) at 0° C. and the resulting mixture was stirred at RT for 16 h. The reaction mixture was diluted with DCM (300 mL), washed with water (100 mL) and brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude N-[1-(cyclobutylmethyl-amino)-4-dimethylamino-4-phenyl-cyclohexylmethyl]-2-methyl-2-methylsulfanyl-propionamide as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 432.1 (M+H)⁺.

Step 4: N¹-(cyclobutylmethyl)-N⁴,N⁴-dimethyl-1-(((2-methyl-2-(methylthio)propyl)amino)methyl)-4-phenylcyclohexane-1,4-diamine (CIS/TRANS-Mixture)

To a solution of crude N-[1-(cyclobutylmethyl-amino)-4-dimethylamino-4-phenyl-cyclohexylmethyl]-2-methyl-2-methylsulfanyl-propionamide (2.5 g, 5.8 mmol, 1.0 eq.) in THF (60 mL) was added BH₃×Me₂S (2.75 ml, 29.0 mmol, 5.0 eq.). The reaction mixture was stirred at RT for 16 h, then quenched with MeOH (10 mL) and 2N HCl (10 mL) at 0° C. and stirred at RT for 30 min. The resulting mixture was concentrated under reduced pressure, diluted with water (50 mL), basified with sat. aq. NaHCO₃ and extracted with DCM (2×250 mL). Combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure to get crude N-cyclobutylmethyl-N′,N′-dimethyl-1-[(2-methyl-2-methylsulfanyl-propylamino)-methyl]-4-phenyl-cyclohexane-1,4-diamine as a light yellow sticky material which was used in the next step without further purification. Mass: m/z 418.4 (M+H)⁺.

Step 5: CIS- and TRANS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1055 and INT-1056)

To a solution of crude N-cyclobutylmethyl-N′,N′-dimethyl-1-[(2-methyl-2-methylsulfanyl-propylamino)-methyl]-4-phenyl-cyclohexane-1,4-diamine (2.0 g, 4.79 mmol, 1.0 eq.) in toluene (30 ml) was added KOH (1.61 g, 28.77 mmol, 6.0 eq) in water (60 mL) at 0° C. followed by addition of COCl₂ (5.84 L 16.76 mmol, 3.5 eq., 20% in toluene). The reaction mixture was stirred at RT for 16 h, then basified with sat. aq. NaHCO₃ and extracted with DCM (2×200 mL). Combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by prep HPLC to get CIS-1-cyclobutylmethyl-8-dimethylamino-3-(2-methyl-2-methylsulfanyl-propyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1055) as peak 2 (45 mg) and TRANS-1-cyclobutylmethyl-8-dimethylamino-3-(2-methyl-2-methylsulfanyl-propyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-1056) as peak 1 (300 mg). Mass: m/z 444.1 (M+H)⁺ (trans), m/z 444.0 (M+H)⁺ (cis).

Synthesis of INT-1059: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione

To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (250.0 g, 1.15 mol, 1.0 eq.) in EtOH (2.5 L) and water (2.1 L) was added (NH₄)₂CO₃ (276.2 g, 2.87 mol, 2.5 eq.) and the reaction mixture was stirred at RT for 15 min. KCN (74.92 g, 1.15 mol, 1.0 eq.) was added. The reaction mixture was stirred at 60° C. for 18 h and then filtered in hot condition to get white solid which was washed with water (2.5 L), ethanol (1 L) and hexane (2.5 L). The resulting solid was dried under reduced pressure to get CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (223 g, 0.776 mol, 65%) as a white solid. The filtrate was collected from multiple batches (˜450 g) which contained a mixture of cis and trans isomers. The filtrate was concentrated under reduced pressure and solid obtained was filtered and washed with water (1 L) and hexane (1 L). Solid material was dried under reduced pressure to get 100 g of a mixture of cis and trans (major) isomers. Crude material was partially dissolved in hot MeOH (600 mL) and cooled to RT, filtered through sintered funnel, washed with MeOH (200 mL) followed by ether (150 mL) and dried to get TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (50 g, 0.174 mmol, 9-10%).

Step 2: TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059)

In analogy to the method described for INT-976 step 2 TRANS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione was treated with LiAlH₄ to be converted into TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1059). Mass: m/z 274.2 (M+H)⁺.

Synthesis of INT-1068 and INT-1069: CIS- and TRANS-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-1,3-diazaspiro[4.5]decan-2-one

Step 1: 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile

To a stirred solution of 4-dimethylamino-4-phenyl-cyclohexanone (50 g, 230.096 mmol) in MeOH (400 mL) was added NH₄Cl (24.6 g, 460.8 mmol) followed by NH₄OH (400 mL) at RT and the reaction mixture was stirred for 15 min. NaCN (22.5 g, 460.83 mmol) was added and the resulting mixture was stirred for 16 h at RT. The reaction mixture was extracted with DCM (3×750 mL). Combined organic layer was washed with water (750 mL), brine (750 mL), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was triturated with DCM/hexane to get crude 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (50 g, 90%) as an off white solid which was used in next step without further purification. LC-MS: m/z [M+H]⁺=244.2 (MW calc. 244.09).

Step 2: N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide

To a solution of 1-amino-4-dimethylamino-4-phenyl-cyclohexanecarbonitrile (5.0 g, 20.57 mmol, 1.0 eq.) in THF (100 ml) were added DIPEA (10.72 ml, 61.71 mmol, 3.0 eq), trifluoroacetic acid (1.89 ml, 24.69 mmol, 1.2 eq) and T3P (18.2 ml, 30.85 mmol, 1.5 eq) at 0° C. The reaction mixture was stirred at RT for 16 h, then diluted with water (100 ml) and extracted with 10% MeOH in DCM (2×250 mL). Combined organic layer was washed with brine (100 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoroacetamide as a light yellow sticky material which was used in the next step without further purification. LC-MS: m/z [M+1]+=339.9 (MW calc. 339.36).

Step 3: 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoroethyl)cyclohexane-1,4-diamine

To suspension of LiAlH₄ (4.03 g, 106.19 mmol, 6.0 eq.) in dry THF (40 mL) was added N-(1-cyano-4-dimethylamino-4-phenyl-cyclohexyl)-2,2,2-trifluoro-acetamide (6.0 g, 17.69 mmol, 1.0 eq.) in dry THF (100 mL) dropwise at 0° C. The reaction mixture was stirred at RT for 16 h, then quenched with sat. aq. Na₂SO₄ at 0° C., excess THF was added and the resulting mixture was stirred at RT for 2 h. The resulting suspension was filtered through celite and the filter cake was washed with 10% MeOH in DCM (150 mL). Combined filtrate was concentrated under reduced pressure to yield crude 1-aminomethyl-N,N-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, crude) as a light yellow sticky material which was directly used in the next step without further purification. LC-MS: m/z [M+1]⁺=330.0 (MW calc. 329.40).

Step 4: CIS- and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1068 and INT-1069)

To a solution of 1-aminomethyl-N′,N′-dimethyl-4-phenyl-N-(2,2,2-trifluoro-ethyl)-cyclohexane-1,4-diamine (4.2 g, 12.76 mmol, 1.0 eq.) in toluene (60 ml) was added KOH (4.29 g, 76.56 mmol, 6.0 eq.) in water (120 ml) at 0° C. followed by addition of COCl₂ (15.6 ml, 44.66 mmol, 3.5 eq., 20% in toluene) at 0° C. and stirred at RT for 16 h. Reaction mixture was basified with sat NaHCO₃ solution and extracted with DCM (2×200 ml). Combined organic layer was dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by prep HPLC to get CIS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1068) (1.5 g) (major isomer, polar spot on TLC) and TRANS-8-dimethylamino-8-phenyl-1-(2,2,2-trifluoro-ethyl)-1,3-diaza-spiro[4.5]decan-2-one (INT-1069) as minor isomer (non-polar spot on TLC) (120 mg, 92.93% by HPLC) as off-white solids. CIS-isomer: LC-MS: m/z [M+1]⁺=356.2 (MW calc.=355.40). HPLC: 98.53%, Column: Xbridge C-18 (100×4.6), 5μ, Diluent: MeOH, Mobile phase: A) 0.05% TFA in water; B) ACN flow rate: 1 ml/min, =5.17 min. ¹HNMR (DMSO-d₆, 400 MHz), δ (ppm)=7.43-7.27 (m, 5H), 6.84 (s, 1H), 3.30-3.25 (m, 4H), 2.66-2.63 (d, 2H, J=12.72 Hz), 1.89 (s, 6H), 1.58-1.51 (m, 2H), 1.46-1.43 (m, 2H), 1.33-1.23 (m, 2H).

Synthesis of INT-1071: CIS-8-(dimethylamino)-8-phenyl-1-(2,2,2-trifluoroethyl)-1,3-diazaspiro[4.5]decan-2-one

Step 1: tert-butyl CIS-2-(8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate

To a solution of CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-976) (10.0 g, 36.63 mmol, 1.0 eq.) in dry THF (1.5 L) was added potassium tert-butoxide (7.14 mg, 36.63 mmol, 1.1 eq.) at RT. The reaction mixture was stirred for 30 min followed by addition of tert-butyl bromo acetate (4.51 g, 40.293 mmol, 1.1 eq.). The reaction mixture was stirred at RT for 4 h, poured into ice-water and extracted with EtOAc (2×700 mL). The organic layer was washed with water (400 mL), brine (400 mL) and dried over Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (neutral alumina; 1% MeOH/Hexane) to yield CIS-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (7 g, 18.06 mmol, 49%) as a white solid. LC-MS: m/z [M+1]⁺=387.9 (MW calc.=387.52).

Step 2: Mixture of CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic Acid Cyclopropylmethyl Ester and CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic Acid Tert-Butyl Ester

To a solution of CIS-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (2.0 g, 5.16 mmol, 1.0 eq.) in dry DMF (40 mL) was added 60 wt % NaH (413 mg, 10.33 mmol, 2 eq.) at RT. The reaction mixture was stirred for 30 min followed by addition of bromomethylcyclopropane (1.74 g, 12.91 mmol, 2.5 eq.). The reaction mixture was stirred at RT for 20 h, poured slowly into ice-water and extracted with EtOAc (2×400 mL). The organic layer was washed with water (2×200 mL), brine (200 mL) and dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 30% EA/Hexane) to yield a mixture of CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid cyclopropylmethyl ester and CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (3:2) (1.1 g, 2.505 mmol, 48%) as a light brown sticky liquid. LC-MS: m/z [M+1]⁺=440.0, 442.0 (MW calc.=439.59, 441.61).

Step 3: CIS-2-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetamide

To a mixture of CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid cyclopropylmethyl ester and CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetic acid tert-butyl ester (2.0 g, 4.55 mmol, 1.0 eq.) in dry MeOH (5 mL) was added 7M NH₃ in MeOH (15 mL) and the reaction mixture was stirred in a sealed tube at 95° C. for 48 h. Solvent was evaporated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 2% MeOH/DCM) to yield CIS-2-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetamide (1.2 g, 3.15 mmol, 68%) as an off-white solid. LC-MS (Method 1): m/z [M+H]⁺=385.2 (MW calc.=384.52).

Step 4: CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl) Acetonitrile (INT-1071)

To a solution of CIS-2-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetamide (1.7 g, 4.42 mmol, 1.0 eq.) in dry DMF (40 mL) was added cyanuric chloride (2.4 g, 13.28 mmol, 3 eq.) at RT. The reaction mixture was stirred at RT for 1.5 h, basified (pH-9) with sat. aq. NaHCO₃ and extracted with EtOAc (2×400 mL). The combined organic layer was washed with water (2×300 mL), brine (300 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 80% DCM/Hexane) to yield CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl) acetonitrile (1.1 g, 3.00 mmol, 68%) as an off-white solid. LC-MS: m/z [M+1]⁺=367.3 (MW calc.=366.50).

For further intermediates the synthesis in analogy to previously described methods is given in the following table. The syntheses of the building blocks and intermediates have either been described previously within this application or can be performed in analogy to the herein described methods or by methods known to the person, skilled in the art. Such a person will also know which building blocks and intermediates need to be chosen for synthesis of each exemplary compound.

Inter- in analogy m/z mediate Chemical Name Chemical Structure to method [M + H]⁺ INT- 794 CIS-3-(3,4-dimethoxybenzyl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-975 424.3 INT- 796 CIS-8-Dimethylamino-3-[(4- methoxyphenyl)-methyl]-8- (3-methoxy- propyl)-1,3-diazaspiro[4.5] decan-2-one

INT-974 390.3 INT- 797 CIS-8-(Ethyl-methyl-amino)-8- phenyl-1,3-diazaspiro[4.5]decan- 2-one

INT-976 288.2 INT- 949 CIS-8-Dimethylamino-1-ethyl- 8-phenyl-1,3-diazaspiro[4.5] decan-2-one

INT-984 302.2 INT- 950 CIS-1-(Cyclobutyl-methyl)-8- dimethylamino-8-phenyl-3- [phenyl-methyl]-1,3- diazaspiro[4.5]decan-2-one

INT-952 432.3 INT- 954 4-Dimethylamino-4-(5-methyl- thiophen-2-yl)-cyclohexan-1-one

INT-965 238.1 INT- 955 4-Dimethylamino-4-thiophen-2- yl-cylcohexan-1-one

INT-965 224.1 INT- 956 1-(1-Methyl-1H-pyrazol-3-yl)-4- oxo-cyclohexane-1-carbonitrile

INT-958 204.1 INT- 957 4-Oxo-1-pyrazin-2-yl- cyclohexane-1-carbonitrile

INT-958 202.1 INT- 959 4-Dimethylamino-4-(1-methyl- 1H-pyrazol-3-yl)-cyclohexan- 1-one

INT-961 222.2 INT- 960 4-Dimethylamino-4-pyrazin-2- yl-cyclohexan-1-one

INT-961 220.1 INT- 962 4-Dimethylamino-4-(3- methoxyphenyl)-cylcohexan-1- one

INT-965 248.2 INT- 963 CIS-3-Benzyl-8- dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-975 364.2 INT- 964 4-(Ethyl-methyl-amino)-4- phenyl-cyclohexan-1-one

INT-965 232.2 INT- 967 CIS-8-Dimethylamino-8- [4-(methoxymethyloxy)-phenyl]- 3-[(4-methoxyphenyl)-methyl]- 1,3-diazaspiro[4.5]decan-2-one

INT-974 454.3 INT- 968 CIS-8-Dimethylamino-8-[3- (methoxymethyloxy)-phenyl]-3- [(4-methoxyphenyl)-methyl)- 1,3-diazazpiro[4.5]decan-2-one

INT-974 454.3 INT- 969 CIS-1-(Cyclobutyl-methyl)-8- dimethylamino-8-(4- hydroxyphenyl)-3-[(4- methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one

INT-971 478.3 INT- 970 CIS-8-Dimethylamino-8-(4- methoxyphenyl)-3-[(4- methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one

SC_2017 424.3 INT- 972 CIS-8-Dimethylamino-8-(3- methoxyphenyl)-3-[(4- methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one

SC_2017 424.3 INT- 973 CIS-8-Dimethylamino-8-(4- fluorophenyl)-3-[(4- methoxyphenyl)-methyl]-1,3- diazaspiro[4.5]decan-2-one

INT-974 412.2 INT- 979 CIS-8-Dimethylamino-1-(3- methoxy-propy)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-984 346.2 INT- 980 CIS-8-Dimethylamino-1-(2- methoxy-ethyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-984 332.2 INT- 981 CIS-8-Dimethylamino-8-phenyl- 1-propyl-1,3-diazaspiro[4.5] decan-2-one

INT-984 316.2 INT- 983 CIS-1-(Cyclopropyl-methyl)-8- dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-984 328.2 INT- 985 CIS-1-(Cyclobutyl-methyl)-8- (methyl-propyl-amino)-8- phenyl-1,3-diazaspiro[4.5] decan-2-one

INT-986 370.3 INT- 993 4-benzyl-4-(dimethylamino) cyclohexanone

INT-965 232.3 INT- 994 CIS-8-benzyl-8-(dimethylamino)- 1,3-diazaspiro[4.5]decan-2-one

INT-976 288.2 INT- 995 TRANS-8-benyl-8- (dimethylamino)-1,3-diazaspiro [4.5]decan-2-one

INT-976 288.2 INT- 997 CIS-8-(dimethylamino)-8- (thiophen-2-yl)-1,3- diazaspiro[4.5]decan-2-one

INT-976 280.1 INT- 998 TRANS-8-(dimethylamino)-8- (thiophen-2-yl)-1,3-diazaspiro [4.5]decan-2-one

INT-976 280.1 INT- 999 4-(dimethylamino)-4-(1-methyl- 1H-benzo[d]imidazol-2-yl) cyclohexanone

INT-965 272.2 INT- 1000 CIS-8-(dimethylamino)-8-(1- methyl-1H-benzo[d]imidazol- 2-yl)-1,3-diazaspiro[4.5]decan- 2-one

INT-976 328.2 INT- 1001 TRANS-8-(dimethylamino)-8-(1- methyl-1H-benzo[d]imidazol-2- yl)-1,3-diazaspiro[4.5]decan- 2-one

INT-976 328.2 INT- 1009 TRANS-8-ethylamino-8- phenyl-1,3-diaza-spiro[4.5] decan-2-one

INT-1008 274.2 INT- 1024 CIS-8-(dimethylamino)-8-(3- fluorophenyl)-1,3-diazaspiro [4.5]decan-2-one

INT-977 (step 2) 292.2 INT- 1025 CIS-8-(dimethylamino)-8-(4- fluorophenyl)-1,3-diazaspiro[4.5] decan-2-one

INT-974, INT-977 (step 2) 292.2 INT- 1039 CIS-8-(dimethylamino)-8-(3- trifluoromethoxy)phenyl)-1,3- diazaspiro[4.5]decan-2-one

INT-1038 358.2 INT- 1040 (CIS)-8-(dimethylamino)-8-(3- (trifluoromethyl)phenyl)-1,3- diazaspiro[4.5]decan-2-one

INT-1038 342.2 INT- 1041 (CIS)-8-(dimethylamino)-8-(3- methoxyphenyl)-1,3-diazaspiro [4.5]decan-2-one

INT-1038 304.2 INT- 1042 (CIS)-8-(5-chlorothiophen-2-yl)- 8-(dimethylamino)-1,3- diazaspiro[4.5]decan-2-one

INT-1038 314.1 INT- 1043 (CIS)-8-(dimethylamino)-8-(3- fluoro-5-methylphenyl)-1,3- diazaspiro[4.5]decan-2-one

INT-1038 306.2 INT- 1044 (CIS)-8-(3-chlorophenyl)-8- (dimethylamino)-1,3- diazaspiro[4.5]decan-2-one

INT-1038 308.2 INT- 1047 (CIS)-8-(methyl(oxetan-3- ylmethyl)amino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-1026 330.5 INT- 1050 (CIS)-8-(dimethylamino)-8- phenyl-3-(piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one

SC_4054 357.3 INT- 1051 (CIS)-8-(dimethylamino)-8- phenyl-3-(piperidin-4-ylmethyl)- 1,3-diazaspiro[4.5]decan-2-one

SC_4058 371.5 INT- 1053 (CIS)-3-(2-amino-2- methylpropyl)-8-(dimethylamino)- 1-((1-hydroxycyclobutyl) methyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-1052 429.3 INT- 1061 TRANS-1-(cyclopropyl-methyl)- 8-dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-984 328.2 INT- 1063 CIS-1-(cyclopropylmethyl)-8- (dimethylamino)-8-(3- fluorophenyl)-1,3-diazaspiro [4.5]decan-2-one

INT-1031 346.2 INT- 1066 TRANS-1-(cyclobutylmethyl)-8- (dimethylamino)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one

INT-987 342.3 INT- 1070 CIS-8-(dimethylamino)-8-phenyl- 1-(3,3,3-trifluoropropyl)-1,3- diazaspiro[4.5]decan-2-one

INT-1068 360.2 INT- 1072 CIS-8-(dimethylamino)-1-((1- hydroxycyclobutyl)methyl)-8- phenyl-3-(piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one

SC_4054 441.3 INT- 1073 CIS-8-(dimethhylamino)-1-((1- hydroxycyclobutyl)methyl)-8- phenyl-3-(piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one

SC_4054 429.3 INT- 1074 CIS-8-(dimethylamino)-8-(3- fluorophenyl)-1-((1- hydroxycyclobutyl)methyl)-1,3- diazaspiro[4.5]decan-2-one

INT-1031 376.2

Synthesis of Exemplary Compounds Synthesis of SC_4001: CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyramide

CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile (SC_4012) (201 mg, 0.5 mmol) was dissolved in DMSO (7 mL) and K₂CO₃ (136 mg, 1 mmol) and hydrogen peroxide (30% in water, 0.7 mL) were added. The resulting mixture was stirred at RT for 18 h, then quenched with 2N aq. NaOH (5 mL) and extracted with ethyl acetate (3×5 mL). The combined organic layers were dried over Na₂SO₄, concentrated in vacuo and purified by flash chromatography to yield CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyramide SC_4001 (58 mg) as a white solid. [M+H]⁺ 427.3

Synthesis of SC_4003: CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In an oven dried flask, sodium hydroxide powder (28 mg, 0.7 mmol) was added to DMSO (0.25 mL) at RT. The mixture was stirred for 5 min, then CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987) (60 mg, 0.18 mmol) was added and the reaction mixture was stirred for 10 min at RT. 1-[2-(2-Bromo-ethoxy)ethoxy]-2-methoxy-ethane (120 mg, 0.53 Mmol) was added and the resulting mixture was stirred for 30 min at RT and for 2 h at 60° C. Water was added and the aqueous layer was extracted with DCM (3×10 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography to yield CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4003) (38 mg) as a white solid. [M+H]⁺ 488.3

Synthesis of SC_4010: CIS-1-(Cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

N-Iodosuccinimide (30 mg, 0.14 mmol) was added to a suspension of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4009) (40 mg, 0.09 mmol) in a mixture of acetonitrile and THF (1:1 v/v, 20 mL) at RT and the resultant mixture was stirred at RT for 16 h. The reaction mixture was basified with 2N aq. NaOH to pH-10 and the organic product was extracted with DCM (3×10 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was stirred vigorously with a mixture of 10 wt % aq. citric acid (5 mL) and DCM (10 mL) at RT for 10 min. The reaction mixture was basified with 5N aq. NaOH to pH-10 and extracted with DCM (3×10 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography and prep. HPLC to give 16 mg of CIS-1-(cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4010). [M+H]⁺ 434.2

Synthesis of SC_4012: CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile

Potassium cyanide (131 mg, 2 mmol) and sodium iodide (202 mg, 1.4 mmol) were added to a solution of CIS-3-(3-chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4027) (57 mg, 1.4 mmol) in DMSO (5 mL) at RT and the resulting mixture was stirred at 90° C. for 18 h. The reaction mixture was quenched with water (5 mL) and extracted with ethyl acetate (5×25 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography to yield CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile (SC_4012) (38 mg) as a white solid. [M+H]⁺ 409.3

Synthesis of SC_4013: CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-butyramide

CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester (SC_(—) 4028) (59 mg, 0.13 mmol) was treated with 2M methylamine in methanol (1.5 mL) and heated for 100 min at 100° C. in a closed vessel. Volatiles were removed under a stream of nitrogen, the residue was taken up in 2M methylamine in methanol (1.5 mL) and heated for 50 min at 120° C. in a closed vessel. All volatiles were removed under a stream of nitrogen to afford the crude product, which was purified by column chromatography to yield 49 mg of CIS-4-[1-(cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methyl-butyramide (SC_4013) as a white solid. [M+H]⁺ 441.3

Synthesis of SC_4025: CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one

KOtBu (1M in THF) (0.5 mL, 0.504 mmol) was added to a suspension of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-799) (0.15 g, 0.42 mmol) in THF (4 mL) at 0° C. The reaction mixture was stirred for 10 min and a solution of 4-(bromomethyl)tetrahydro-2H-pyran (90 mg, 0.504 mmol) in THF (2 mL) was added. The reaction mixture was stirred at 70° C. for 16 h, then quenched with sat. aq. NH₄Cl (5 mL) and extracted with ethyl acetate (2×20 mL). The combined organic extracts were washed with water, brine, dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The residue was purified by preparative TLC to afford 0.044 g of CIS-8-dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one (SC_4025) as an off-white solid (TLC system: 10% MeOH in DCM Rf: 0.52.). [M+H]⁺ 456.3

Synthesis of SC_4027: CIS-3-(3-Chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Sodium hydride (60% suspension in mineral oil, 23 mg, 0.6 mmol) was added to a solution of CIS-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987) (100 mg, 0.3 mmol) in THF (3 mL) at 0° C. and the resulting mixture was stirred for 30 min at 50° C. A solution of 1-bromo-3-chloro-propane (0.14 mL, 1.5 mmol) in THF (0.7 mL) was added at 50° C. and stirring was continued at 80° C. for 18 h. The reaction mixture was quenched with cold water (10 mL) and extracted with ethyl acetate (3×10 mL). The combined organic layers were dried over Na₂SO₄ and concentrated in vacuo. The residue was purified by flash chromatography to yield CIS-3-(3-chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4027) (50 mg) as a white powder. [M+H]⁺ 418.3

Synthesis of SC_4028: CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric Acid Methyl Ester

CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile SC_4012 (345 mg, 0.85 mmol) was dissolved in 5 mL conc. HCl and stirred for 6 h at 100° C. Volatiles were removed under reduced pressure to afford the crude product as hydrochloride salt. This salt was dissolved in MeOH/toluene and concentrated under reduced pressure. The latter dissolution/evaporation cycle was repeated, yielding 380 mg of CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester SC_4028. [M+H]⁺ 442.

Synthesis of SC_4031: CIS-3-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To the mixture of CIS-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-976) (3.5 g, 12.83 mmol, 1.0 eq.) and K₂CO₃ (3.54 g, 25.66 mmol, 2.0 eq.) in THF (200 ml) at 0° C. was added acetyl chloride (1.4 ml, 19.23 mmol, 1.5 eq.). The reaction mixture was stirred at RT for 3 h, diluted with DCM (300 ml) and filtered through Celite. The filtrate was washed with sat. aq. NaHCO₃ (100 ml), water (100 ml) and brine (100 ml). The organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The resulting residue was purified by column chromatography (silica gel neutralized with ammonia, 5% MeOH/DCM) to yield CIS-3-acetyl-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC-4031) as an off white solid. Note: This reaction was done in two parallel batches of 3.5 g scale and yield given for two combined batches. Yield: 63% (5.1 g, 16.19 mmol). ¹HNMR (DMSO-d6, 400 MHz), δ (ppm)=8.05 (bs, 1H), 7.36-7.25 (m, 5H), 3.44 (s, 2H), 2.31 (s, 5H, CH₃+CH₂), 1.92 (s, 6H), 1.83-1.76 (m, 4H), 1.39 (bs, 2H). Mass: m/z 316.1 [M+H]⁺

Synthesis of SC_4032: CIS-8-(dimethylamino)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

KOtBu (1M in THF) (1.1 mL, 0.11 mmol) was added to the suspension of CIS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-976) (0.3 g, 0.11 mmol) in THF (10 mL) at 0° C. The reaction mixture was stirred for 10 min and 1-bromo-2-(methylsulfonyl)ethane (0.16 g, 0.09 mmol) was added. The reaction mixture was stirred at 0° C. for 4 h, then quenched with sat. aq. NH₄Cl (15 mL) and the organic product was extracted with DCM (3×20 mL). The combined organic extracts were washed with brine, dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. Purification of the residue by reverse phase preparative HPLC afforded 180 mg (43%) of CIS-8-(dimethylamino)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4032) as an off white solid (TLC system: 10% MeOH in DCM Rf: 0.3.). ¹H NMR (DMSO-d6): δ 7.37-7.23 (m, 5H), 6.90 (br s, 1H), 3.43 (t, 2H), 3.26 (t, 2H), 3.10 (s, 2H), 2.95 (s, 3H), 2.32 (br m, 2H), 1.93 (s, 6H), 1.79-1.76 (m, 4H), 1.38-1.36 (m, 2H). Mass: m/z 380.2 [M+H]⁺

Synthesis of SC_4033: CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-1-acetyl-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To a solution of CIS-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (INT-975) (19.5 g, 49.6 mmol, 1.0 eq.) in THF (180 ml) was added 2.5M solution of n-BuLi in hexane (39.7 ml, 99.23 mmol, 2.0 eq.) at 0° C. and the resulting mixture was stirred for 111. A solution of acetyl chloride (7.7 g, 99.23 mmol, 2.0 eq.) in THF (20 ml) was added dropwise at 0° C. The cooling bath was removed, the reaction mixture was stirred at RT for 16 h, then cooled down to 0° C. again, quenched with water and extracted with ethyl acetate (2×200 ml). The combined organic extracts were washed with brine (250 ml), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; 30% EtOAc/Hexane) to yield CIS-1-acetyl-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (6.1 g, 14.02 mmol, 28%) as a light yellow sticky solid. Mass: m/z 436.3 [M+H]⁺

Step 2: CIS-1-acetyl-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4033)

To a solution of CIS-1-acetyl-8-dimethylamino-3-(4-methoxy-benzyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (5.0 g, 11.5 mmol, 1.0 eq.) in acetonitrile (60 ml) was added a solution cerium(IV) ammonium nitrate (18.98 g, 34.5 mmol, 3.0 eq.) in water (60 ml) at 0° C. and the reaction mixture was stirred at RT for 2 h. The reaction mixture was quenched with aq. NaHCO₃ solution (50 ml) and extracted with ethyl acetate (2×100 ml). The combined organic layer was washed with brine (2×100 ml), dried over Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel neutralized with TEA; 2/3 v/v EtOAc/Hexane) to yield CIS-1-acetyl-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_4033) as an off white solid. Yield: 61% (4.9 g, 15.55 mmol). ¹HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.57 (s, 1H), 7.33-7.23 (m, 5H), 3.21 (s, 2H), 3.03 (t, 2H, J=12.78 Hz), 2.60 (d, 2H, J=13.32 Hz), 2.32 (s, 3H), 1.89 (s, 6H), 1.37-1.32 (m, 4H). Mass: m/z 316.2 [M+H]⁺

Synthesis of SC_4034: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To a solution of CIS-8-dimethylamino-3-(2-methanesulfonyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_4032) (150 mg, 0.395 mmol, 1.0 eq.) in dry DMF (5 ml) was added 60% NaH (47 mg, 1.18 mmol, 3.0 eq.) at RT and the reaction mixture was stirred for 20 min. Bromomethylcyclopropane (160 mg, 1.18 mmol, 3.0 eq.) was added and the reaction mixture was stirred for 16 h. The reaction mixture was quenched with ice-water (20 ml) and extracted with EtOAc (2×20 ml). The combined organic layers were washed with water (20 ml) and brine (20 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel; 3% MeOH/DCM) to yield CIS-1-cyclopropylmethyl-8-dimethylamino-3-(2-methanesulfonyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (80 mg, 0.18 mmol, 47%) (SC_4034) as a white solid. ¹HNMR (CDCl3, 400 MHz), δ (ppm)=7.36-7.24 (m, 5H, merged with CDCl3), 3.65 (t, 2H, J=6.46 Hz), 3.27 (t, 2H, J=6.46 Hz), 3.23 (s, 2H), 3.04 (d, 2H, J=6.7 Hz), 2.94 (s, 3H), 2.65-2.62 (m, 2H), 2.30-2.23 (m, 2H), 2.02 (s, 6H), 1.46-1.40 (m, 4H), 1.02-0.98 (m, 1H), 0.53-0.49 (m, 2H), 0.33-0.29 (2H), Mass: m/z 434.0 (M+H)⁺ (MW calc.=433.61).

Synthesis of SC_4037: CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one

CIS-8-(dimethylamino)-3-[(4-methoxyphenyl)methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-975) (500 mg, 1.271 mmol) was dissolved in THF (8 mL) under nitrogen atmosphere and the solution was cooled down to −78° C. [Bis(trimethylsilyl)amino]lithium (1M in THF, 1.5 equiv., 1.906 mmol, 1.9 mL) was added dropwise and the reaction mixture was stirred at −78° C. for 30 min, then at 0° C. for 30 min. The reaction mixture was cooled down to −78° C. again and the solution of p-toluenesulfonyl chloride (1.5 equiv., 1.906 mmol) in THF (5 mL) was added. The reaction mixture was stirred further 2.5 h at −78° C. and then the temperature was allowed to increase to RT overnight. The reaction mixture was quenched by the addition of sat. aq. NaHCO₃ (20 mL). The aqueous phase was extracted with EtOAc (3×40 mL). The combined organic extracts were washed with brine (30 mL), dried over MgSO₄ and concentrated under reduced pressure. Purification of the residue by flash chromatography on silica gel (elution with gradient DCM/EtOH 100/0 to 97/3) yielded 281 mg (40%) of CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one. ¹H NMR (600 MHz, DMSO) δ 7.90-7.84 (m, 2H), 7.47-7.40 (m, 2H), 7.42-7.27 (m, 4H), 7.27-7.22 (m, 1H), 7.15-7.06 (m, 2H), 6.92-6.83 (m, 2H), 4.16 (s, 2H), 3.72 (s, 3H), 3.24 (s, 2H), 2.99 (ddd, 2H), 2.70-2.62 (m, 2H), 2.42 (s, 3H), 2.01 (s, 6H), 1.56-1.49 (m, 2H), 1.31 (td, 2H). Mass: m/z 548.3 (M+H)⁺.

Step 2: CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (SC_4037)

In analogy to the method described for INT-982 (step 2) CIS-8-(dimethylamino)-3-(4-methoxybenzyl)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one was reacted with trifluoroacetic acid to be converted into CIS-8-(dimethylamino)-8-phenyl-1-tosyl-1,3-diazaspiro[4.5]decan-2-one (SC_4037). ¹HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.82 (d, 2H, J=8.0 Hz), 7.48 (s, 1H), 7.40 (d, 2H, J=7.88 Hz), 7.35-7.24 (m, 5H), 3.27 (s, 2H), 2.97 (t, 2H, J=11.88 Hz), 2.66 (d, 2H, J=12.76 Hz), 2.39 (s, 3H), 2.0 (s, 6H), 1.60 (d, 2H, J=11.04 Hz), 1.38 (t, 2H, J=13.56 Hz). Mass: m/z 427.9 (M+H)⁺.

Synthesis of SC_4038: CIS-8-(dimethylamino)-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-3-((tetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one

NaH (60% in mineral oil) (84.03 mg, 2.101 mmol) was added to an ice cold solution of CIS-8-(methyl amino)-8-phenyl-3-(2-(trifluoromethyl)pyrimidin-5-yl)-1,3-diazaspiro[4.5]decan-2-one (INT-799) (500 mg, 1.401 mmol) in DMF (5 mL) under argon atmosphere and the resulting mixture was stirred for 2 min. The reaction mixture was allowed to warm up to RT and a solution of (tetrahydro-2H-thiopyran-4-yl)methyl 4-methylbenzenesulfonate (481.5 mg, 1.681 mmol) in DMF (4.8 mL) was added. The reaction mixture was stirred at RT for 16 h. The reaction progress was monitored by LCMS. The reaction mixture was diluted with water (50 mL) and the organic product was extracted with EtOAc (3×40 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to give 550 mg of crude product. The crude product was purified by prep-HPLC (column LUNA-PHENYL HEXYL-C₁₈ (150*30 mm) 5 μm, detection at 215 nm, eluent 10 mM ammonium bicarbonate in water/Acetonitrile gradient 45/55 to 2/98, flow rate: 25 ml/min) to afford 235 mg (35%) of CIS-8-(dimethylamino)-1-((l-hydroxycyclobutyl)methyl)-8-phenyl-3-((tetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one as an off white solid (TLC system: 5% MeOH in DCM Rf: 0.63.). Mass: m/z 472.3 (M+H)⁺.

Step 2: CIS-8-(dimethylamino)-3-((1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4038)

A solution of oxone (599.53 mg, 0.975 mmol) in water (6 mL) was added to a solution of CIS-8-(dimethylamino)-1-(O-hydroxycyclobutyl)methyl)-8-phenyl-3-((tetrahydro-2H-thiopyran-4-yl)methyl)-1,3-diazaspiro[4.5]decan-2-one (230 mg, 0.488 mmol) in MeOH (8 mL) at RT under argon atmosphere. The reaction mixture was stirred for 16 h. The reaction progress was monitored by LCMS. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give 330 mg of crude product, which was purified by prep. HPLC (column LUNA-PHENYL HEXYL-C₁₈ (150*30 mm) 5 μm, detection at 215 nm, eluent 10 mM ammonium bicarbonate in water/Acetonitrile gradient 45/55 to 2/98, flow rate: 25 ml/min) to get 128 mg (52%) of CIS-8-(dimethylamino)-3-(4-(bromomethyl)-1-λ6-thiane-1,1-dione)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4038) as an off white solid (TLC system: 10% MeOH in DCM Rf: 0.53). ¹H NMR (DMSO-d6): δ 7.37-7.25 (m, 5H), 6.01 (s, 1H), 3.26 (s, 2H), 3.09-2.99 (m, 8H), 2.69-2.65 (m, 2H), 2.09-1.82 (m, 15H), 1.66-1.51 (m, 3H), 1.41-1.33 (m, 5H). Mass: m/z 504.2 (M+H)⁺.

Synthesis of SC_4044: CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

NaH (0.14 g, 3.501 mmol, 60% dispersion in mineral oil) was added to a solution of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-799) (0.25 g, 0.700 mmol) in THF (40 mL) at 0° C. under argon atmosphere. The solution of 1,6-dioxaspiro[2.5]octane (0.479 g, 4.200 mmol) in THF (2 mL) was added dropwise and the reaction mixture was stirred at 85° C. for 16 h. The reaction mixture was cooled to 0° C. and quenched with water (50 mL). The organic product was extracted with ethyl acetate (2×50 mL).

Combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (silica gel 230-400 mesh size, 0-60% EtOAc in pet ether as eluent) followed by reverse phase prep HPLC to get 0.180 g of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one formiate. The product formiate salt was taken in water (20 mL), basified with solid NaHCO₃ and extracted with ethyl acetate (2×20 mL). The combined organic layer was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to afford 0.130 g (39%) of CIS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-((4-hydroxytetrahydro-2H-pyran-4-yl)methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4044) as an off white solid. (TLC system: 5% MeOH in DCM; Rf: 0.3). ¹H NMR (DMSO-d6): S 7.37-7.34 (m, 4H), 7.27-7.26 (m, 1H), 6.04 (s, 1H), 4.51 (s, 1H), 3.61-3.56 (m, 4H), 3.43 (s, 2H), 3.09-3.05 (m, 4H), 2.70-2.67 (m, 2H), 2.07-1.82 (m, 12H), 1.63-1.61 (m, 1H), 1.51-1.30 (m, 9H). Mass: m/z 472.3 (M+H′7.

Synthesis of SC_4049: CIS-(5s,8s)-3-(1-benzoylpiperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Triethylamine (0.51 mL, 3.65 mmol) was added to a stirred solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (0.3 g, 0.73 mmol) in DCM (10 mL) at 0° C. under argon atmosphere. After 10 min, acetyl chloride (86 mg, 1.09 mmol) was added dropwise at 0° C. and the reaction mixture was stirred at RT for 16 h. The reaction mixture was quenched with sat. aq. NaHCO₃. The organic product was extracted with DCM (2×50 mL), the combined organic layer was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reverse phase prep. HPLC to afford 0.133 g (40%) of CIS-34 l-acetylpiperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4049) as a white solid. (TLC system: 10% MeOH in DCM; Rf: 0.55). NMR (DMSO-d6): δ 7.36-7.33 (m, 2H), 7.28-7.25 (m, 3H), 4.70-4.67 (m, 1H), 3.98-3.81 (m, 2H), 3.12-3.04 (m, 5H), 2.65-2.57 (m, 3H), 2.26 (t, 2H), 2.06-2.04 (m, 9H), 1.79-1.70 (m, 2H), 1.50-1.39 (m, 6H), 1.02 (m, 1H), 0.53-0.50 (m, 2H), 0.34-0.31 (m, 2H). Mass: m/z 453.3 (M+H)⁺.

Synthesis of SC_4052: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(1-hydroxycyclohexyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-3-(2-(1-(benzyloxy)cyclohexyl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

In analogy to the method described for SC_4034 CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-787) was reacted with 2-(4-(benzyloxy)tetrahydro-2H-pyran-4-yl)ethyl 4-methylbenzenesulfonate to be converted into CIS-3-(2-(1-(benzyloxy)cyclohexyl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one. Mass: m/z 558.4 (M+H)^(÷).

Step 2: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(1-hydroxycyclohexyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4052)

Trifluoroacetic acid (20 mL) was added to CIS-3-(2-(1-(benzyloxy)cyclohexyl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.4 g, 0.71 mmol) at RT. The reaction mixture was stirred at RT for 16 h and then concentrated under reduced pressure. To the residue sat. aq. NaHCO₃ was added and the organic product was extracted with dichloromethane (3×150 mL). The combined organic extract was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by column chromatography (230-400 mesh silica gel; 4-8% MeOH in DCM as eluent) and further by reverse phase prep HPLC to afford 0.112 g (40%) of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(1-hydroxycyclohexyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4052) as a white solid. (TLC system: 10% MeOH in DCM; Rf: 0.45). ¹H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.23 (m, 1H), 4.25 (s, 1H), 3.62-3.49 (m, 4H), 3.17-3.13 (m, 2H), 3.09 (s, 2H), 3.01 (d, 2H), 2.66-2.63 (m, 2H), 2.05-2.02 (m, 1H), 1.97-1.91 (m, 9H), 1.80-1.65 (m, 4H), 1.53-1.43 (m, 5H), 1.38-1.35 (m, 6H). Mass: m/z 470.4 (M+H)⁺.

Synthesis of SC_4054: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-tert-butyl 4-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)piperidine-1-carboxylate

In analogy to the method described for SC_4044 CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-983) was reacted with tert-butyl 4-(tosyloxy)piperidine-1-carboxylate to be converted into CIS-tert-butyl 4-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)piperidine-1-carboxylate. Mass: m/z 511.4 (M+H)⁺.

Step 2: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4054)

4N HCl in dioxane (20 mL) was added to a solution of CIS-tert-butyl 4-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)piperidine-1-carboxylate (1.9 g, 3.7 mmol) in DCM (30 mL) at 0° C. under argon atmosphere. The reaction was stirred at 0° C. for 2 h and then concentrated under reduced pressure to get CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride as gummy, which was triturated with diethyl ether to get CIS-1-(cyclopropyl methyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (SC_4054) as an off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.15). NMR (DMSO-d6): δ 7.37-7.32 (m, 1H), 7.28-7.23 (m, 1H), 3.58-3.50 (m, 2H), 3.10 (s, 2H), 2.94-2.89 (m, 4H), 2.66-2.62 (m, 2H), 2.46-2.41 (m, 2H), 2.13 (t, 2H), 1.97 (s, 6H), 1.49-1.41 (m, 6H), 1.32-1.29 (m, 2H), 0.93-0.88 (m, 1H), 0.46-0.42 (m, 2H), 0.25-0.24 (m, 2H). Mass: m/z 411.3 (M+H)⁺.

Synthesis of SC_4055: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-hydroxy-2-methylpropyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: tert-butyl 2-(CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate

In analogy to the method described for SC_4027 CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-983) was reacted with tert-butyl bromoacetate to be converted into tert-butyl 2-(CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate. Mass: m/z 442.3 (M+H)⁺.

Step 2: methyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate

4M HCl in dioxane (8 mL) was added to tert-butyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate (800 mg, 1.81 mmol) in DCM (6 mL) at 0° C. The reaction mixture was stirred at RT for 16 h and then concentrated under reduced pressure. The residue was suspended in DCM and the resulting mixture was concentrated under reduced pressure again. The residue was washed with diethyl ether (5 mL) to give CIS-2-(8-(dimethylamino)-3-oxo-8-phenyl-2-azaspiro[4,5]decan-2-yl)acetic acid hydrochloride which was dissolved in methanol (10 mL) and refluxed for 2 h. The reaction mixture was cooled down to RT and concentrated under reduced pressure. The residue was partitioned between EtOAc and sat. aq. NaHCO₃. The organic layer was separated and washed with water, brine, dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. Purification of the residue by column chromatography (silica gel 100-200 mesh, 0-3% MeOH in DCM) yielded 500 mg (56%) of methyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate as a solid. (TLC system: 10% MeOH in DCM Rf: 0.20). Mass: m/z 400.3 (M+H)⁺.

Step 3: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-hydroxy-2-methylpropyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4055)

Methylmagnesium bromide (3M in Et₂O, 2.1 mL, 6.25 mmol) was added to a solution of methyl CIS-2-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)acetate (500 mg, 1.25 mmol) in THF (10 mL) at 0° C. The reaction mixture was warmed to RT and stirred for 2 h. The reaction mixture was quenched with sat. aq. NH₄Cl and the organic product was extracted with DCM (3×25 mL). The combined organic extracts were washed with water, brine, dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. Purification of the resulting residue by column chromatography (silica gel 100-200 mesh, 0-3% MeOH in DCM) followed by preparative HPLC yielded 80 mg (16%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-hydroxy-2-methylpropyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4055) as a solid. (TLC system: 10% MeOH in DCM Rf: 0.20). ¹H NMR (DMSO d6): δ 7.36-7.33 (m, 4H), 7.26-7.24 (m, 1H), 4.39 (s, 114), 3.30 (m, 2H), 2.95-2.91 (m, 4H), 2.69-2.66 (m, 2H), 2.18-2.13 (m, 2H), 1.97 (s, 6H), 1.37-1.31 (m, 4H), 1.03 (s, 6H), 0.92-0.91 (m, III), 0.46-0.43 (m, 2H), 0.26-0.23 (in, 2H). Mass: m/z 400.3 (M+H)⁺.

Synthesis of SC_4056: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyrimidin-5-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one

CsCO₃ (1.27 g, 3.90 mmol) was added to a solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (SC_4054) (0.4 g, 0.97 mmol), XanthPhos (85 mg, 0.146 mmol), Pd₂(dba)₃ (89 mg, 0.097 mmol) and 5-bromopyrimidine (0.31 g, 1.95 mmol) in 1,4-dioxane (20 mL). The mixture was purged with argon for 5 min and then stirred for 16 h at 120° C. The reaction mixture was cooled to RT and concentrated under reduced pressure. The residue was diluted with DCM (20 mL), filtered through a pad of celite and concentrated under reduced pressure. The crude product was purified by flash chromatography (silica gel 230-400 mesh size, 5-10% methanol in DCM as eluent) to afford 0.4 g of the desired product, which was further purified by reverse phase prep HPLC to afford 172 mg (36%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyrimidin-5-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4056) as off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.35). ¹H NMR (CDCl3): δ 8.64 (s, 1H), 8.34 (s, 2H), 7.36-7.33 (m, 2H), 7.29-7.27 (m, 2H), 7.24 (m, 1H), 4.00-3.96 (m, 1H), 3.78-3.76 (m, 2H), 3.09-3.06 (m, 4H), 2.96-2.90 (m, 2H), 2.66-2.63 (m, 2H), 2.30-2.24 (m, 2H), 2.04 (s, 6H), 1.83-1.81 (m, 2H), 1.73-1.61 (m, 2H), 1.45-1.40 (m, 4H), 1.04-1.01 (m, 1H), 0.54-0.50 (m, 2H), 0.35-0.32 (m, 2H). Mass: m/z 489.3 (M+H)⁺.

Synthesis of SC_4057: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyrimidin-5-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one

Triethylamine (0.23 mL, 1.70 mmol) was added to a solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one hydrochloride (SC_4054) (0.35 g, 0.85 mmol) and phenylboronic acid (0.21 g, 1.70 mmol) in acetonitrile (15 mL). Copper(II) acetate (155 mg, 0.85 mmol) was added and the reaction mixture was stirred at 100° C. for 24 h. The reaction mixture was cooled to RT, filtered through a pad of celite and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (3% MeOH/DCM) to give 100 mg of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one, which was further purified by reverse phase prep HPLC to afford 38 mg (9%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4057) as an off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.65). ¹H NMR (DMSO-d6): δ 7.36-7.33 (m, 2H), 7.29-7.27 (m, 2H), 7.24-7.21 (m, 3H), 6.91 (d, 2H), 6.81 (t, 1H), 3.95-3.91 (m, 1H), 3.72-3.69 (m, 2H), 3.11-3.06 (m, 4H), 2.84-2.79 (m, 2H), 2.65-2.62 (m, 2H), 2.26 (t, 2H), 2.04 (s, 6H), 1.79-1.70 (m, 4H), 1.45-1.40 (m, 4H), 1.05-1.01 (m, 1H), 0.53-0.51 (m, 2H), 0.34-0.32 (m, 2H). Mass: m/z 487.4 (M+H)⁺.

Synthesis of SC_4064: CIS-3-((1-aminocyclopropyl)methyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To a solution titanium isopropoxide (0.89 mL, 3.0 mmol, 2 eq.) in dry THF (15 mL) was added EtMgBr (3 M in Et₂O) (2 mL, 6.0 mmol, 4 eq.) at −78° C. and the resulting mixture was stirred for 1.5 h at −78° C. A solution of CIS-(1-cyclopropylmethyl-8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-acetonitrile (INT-1071) (550 mg, 1.50 mmol, 1.0 eq.) in THF (5 mL) was added dropwise at −78° C. The reaction mixture was stirred at same temperature for 10 min, then warmed to RT and stirred for 1.5 h. The reaction mixture was cooled again to -78° C., BF₃.Et₂O (0.37 mL, 3.0 mmol, 2 eq.) was added and the resulting mixture was stirred at -78° C. for 10 min and at RT for 1.5 h. The reaction mixture was basified (pH˜9-10) with 10 wt % aq. NaOH, stirred for 30 min and extracted with EtOAc (2×250 mL). The combined organic layer was washed with water (2×150 mL), brine (200 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude product which was purified by column chromatography (neutral alumina; 2.5% MeOH/DCM) to yield CIS-3-(1-amino-cyclopropylmethyl)-1-cyclopropylmethyl-8-dimethylamino-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_4064) as off white solid. This step was done in two batches of 550 mg scale and yield is given for combined batches. Yield: 16% (200 g, 0.25 mmol). LC-MS: m/z [M+H]⁺=397.1 (MW calc.=3960.57). ¹HNMR (DMSO-d₆, 400 MHz), δ (ppm)=7.35-7.25 (5H), 3.24 (s, 2H), 3.00 (s, 2H), 2.92 (d, 2H, J=6.48 Hz), 2.68-2.65 (m, 2H), 2.19-2.07 (m, 2H), 1.97 (s, 6H), 1.75 (bs, 2H), 1.43-1.36 (m, 4H), 0.93 (bs, 1H), 0.46-0.36 (m, 6H), 0.25-0.23 (m, 2H).

Synthesis of SC 4071: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(3-hydroxyoxetan-3-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: 2-(3-(benzyloxy)oxetan-3-yl)acetaldehyde

To a stirred solution of 3-allyl-3-(benzyloxy)oxetane (10.0 g, 49.01 mmol, prepared from 3-allyl-3-hydroxyoxetane and benzyl bromide) in acetone (300 mL) and water (200 mL) was added potassium osmate(VI) dihydrate (0.61 g, 1.66 mmol). The reaction mixture was cooled to 0° C. and sodium periodate (41.93 g, 916.07 mmol) was added portionwise over a period of 15 min. The reaction mixture was allowed to stir for 1 h at 0° C. The reaction mixture was filtered and the filter cake was washed with acetone (300 mL). The combined filtrate was concentrated under reduced pressure and the aqueous layer was extracted with dichloromethane (2×300 mL). The combined organic layer was washed with water (2×200 mL), brine (300 mL), dried was over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 230-400 mesh size 30-40% EtOAc in Pet. ether as eluent) to afford 2-(3-(benzyloxy)oxetan-3-yl)acetaldehyde (4.5 g, 43%) as a liquid. (TLC system: 40% EtOAc in Pet. ether; Rf: 0.4).

Step 2: 2-(3-(benzyloxy)oxetan-3-yl)ethanol

To a cold stirred solution of 2-(3-(benzyloxy)oxetan-3-yl)ethanol (4.50 g, 21.84 mmol) in methanol (50 mL) was added portionwise NaBH₄ (1.24 g, 32.76 mmol). The reaction mixture was stirred at 0° C. for 1 h. The reaction mixture was quenched with water (30 mL), concentrated under reduced pressure and the residue was taken in DCM (150 mL). The organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure to get 5.0 g of crude 2-(3-(benzyloxy)oxetan-3-yl)ethanol which was used in the next step without further purification.

Step 3: 2-(3-(benzyloxy)oxetan-3-yl)ethyl 4-methylbenzenesulfonate

To a stirred solution of 2-(3-(benzyloxy)oxetan-3-yl)ethanol (5.0 g, 24.03 mmol) in DCM (15 mL) were added triethylamine (13.4 mL, 96.15 mmol) and DMAP (0.29 g, 2.40 mmol). The reaction mixture was cooled to 0° C. and tosyl chloride (9.13 g, 48.07 mmol) was added to the reaction mixture portionwise. The reaction mixture was stirred at RT for 16 h, then diluted with sat. aq. NaHCO₃ and the organic product was extracted with DCM (200 mL). The organic layer was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (230-400 mesh silica gel; 20-40% EtOAc in Pet. ether as eluent) to afford 2-(3-(benzyloxy)oxetan-3-yl)ethyl 4-methylbenzenesulfonate (4.0 g, 50% over 2 steps) as an off-white solid.

Step 4: CIS-3-(2-(3-(benzyloxy)oxetan-3-yl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

NaH (0.29 g, 7.33 mmol, 60% dispersion in mineral oil) was added to a solution of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-987) (0.50 g, 1.46 mmol) in DMF (15 mL) at RT under argon atmosphere and the resulting mixture was stirred for 10 min. 2-(3-(Benzyloxy)oxetan-3-yl)ethyl 4-methylbenzenesulfonate (1.58 g, 4.39 mmol) was added and the reaction mixture was stirred at 120° C. for 16 h. The reaction progress was monitored by LCMS. The reaction mixture was cooled to 0° C. and quenched with sat. aq. NaHCO₃ (50 mL). The organic product was extracted with DCM (2×100 mL), the combined organic phase was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by flash chromatography (silica gel 230-400 mesh size 2-5% methanol in DCM as eluent) to afford 0.40 g (51%) of CIS-3-(2-(3-(benzyloxy)oxetan-3-yl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one as a brown oil. (TLC system: 10% MeOH in DCM; Rf: 0.6).

Step 5: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(3-hydroxyoxetan-3-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4071)

CIS-3-(2-(3-(benzyloxy)oxetan-3-yl)ethyl)-1-(cyclobutylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.38 g, 0.71 mmol) in THF (4 mL) was added to sodium metal (0.32 g, 14.31 mmol) in liquid ammonia (5 mL) at −78° C. The reaction mixture was stirred for 20 min at −78° C., then quenched with saturated NH₄Cl solution and the organic product was extracted with EtOAc (2×20 mL). The combined organic layer was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by flash chromatography (silica gel 230-400 mesh 2-5% methanol in DCM as eluent) to afford 0.155 g (49%) of CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-(3-hydroxyoxetan-3-yl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4071) as an off-white solid. (TLC system: 5% MeOH in DCM; Rf: 0.4). NMR (DMSO-d6): δ 7.36-7.32 (m, 4H), 7.26-7.23 (m, 1H), 5.62 (s, 1H), 4.38-4.31 (m, 4H), 3.14-3.10 (m, 4H), 3.01 (d, 2H), 2.64-2.63 (m, 2H), 2.49 (m, 1H), 2.02-1.96 (m, 10H), 1.87-1.77 (m, 6H), 1.39 (t, 2H), 1.28 (d, 2H). Mass: m/z 442.3 (M+H)⁺.

Synthesis of SC_4072: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-methyl-2-(2-oxopyrrolidin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-4-chloro-N-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)butanamide

In analogy to the method described for SC_4049 CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (INT-1052) was reacted with 4-chlorobutanoyl chloride to be converted into CIS-4-chloro-N-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)butanamide. Mass: m/z 503.3 (M+H)⁺.

Step 2: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-methyl-2-(2-oxopyrrolidin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4072)

NaH (60% in mineral oil) (95.62 mg, 2.390 mmol) was added to a solution of CIS-4-chloro-N-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)butanamide (0.3 g, 0.598 mmol) in THF (30 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred at 70° C. for 4 h, then cooled to 0° C. and quenched with water (15 mL). The organic product was extracted with EtOAc (2×30 mL). The combined organic extracts were dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 230-400 mesh, 0-10% MeOH in DCM) and reverse phase HPLC to yield 80 mg (28%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-3-(2-methyl-2-(2-oxopyrrolidin-1-yl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4072) as a white solid (TLC system: 5% MeOH in DCM; Rf: 0.30). ¹H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.24 (m, 1H), 3.34-3.27 (m, 4H), 3.16-3.13 (m, 4H), 2.93 (d, 2H), 2.67-2.64 (m, 2H), 2.16-2.05 (m, 4H), 1.97 (s, 6H), 1.40-1.36 (m, 4H), 1.29 (s, 6H), 0.93-0.92 (m, 11-), 0.46-0.44 (m, 2H), 0.26-0.24 (m, 21-1). Mass: m/z 503.3 (M+H)⁺.

Synthesis of SC_4080: CIS-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one

KOtBu (94.26 mg, 0.840 mmol) was added to a solution of CIS-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (INT-1050) (0.25 g, 0.70 mmol), bromobenzene (109.9 mg, 0.70 mmol), BINAP (65.38 mg, 0.105 mmol) and Pd₂(dba)₃ (96.15 mg, 0.105 mmol) in toluene (40 mL). The mixture was purged with argon for 5 min and stirred for 16 h at 90° C. The reaction mixture was cooled to RT and diluted with DCM (20 mL), filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The resulting crude product was purified by flash chromatography (silica gel 230-400 mesh, 5-10% methanol in DCM as eluent) followed by reverse phase prep. HPLC to afford 57 mg (18%) of CIS-8-(dimethylamino)-8-phenyl-3-(1-phenylpiperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4080) as an off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.40). Reverse prep HPLC condition: mobile phase: 10 mM ammonium bicarbonate in H₂O/acetonitrile; column: INERTSIL-ODS (250*19 mm) 5 μm; gradient (% B): 0/65, 8/80, 8.1/98, 12/98, 12.1/65, 15/65; flow rate: 18 ml/min; diluent: ACN+THF+MeOH+H₂O. ¹H NMR (DMSO-d6): δ 7.36-7.30 (m, 4H), 7.23 (t, 1H), 7.18-7.14 (m, 2H), 6.90 (d, 2H), 6.72 (t, 2H), 3.72-3.69 (m, 2H), 3.65-3.60 (m, 1H), 3.01 (s, 2H), 2.70-2.65 (m, 2H), 2.28 (br s, 2H), 1.93 (s, 6H), 1.78 (br m, 4H), 1.68-1.60 (m, 2H), 1.57-1.55 (m, 2H), 1.34-1.31 (m, 2H). Mass: m/z 433.3 (M+H)⁺.

Synthesis of SC_4084: CIS-1-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)pyrrolidine-2,5-dione

Step 1: CIS-4-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-ylamino)-4-oxobutanoic acid

Succinic anhydride (233.3 mg, 2.330 mmol) was added to a stirred solution of CIS-3-(2-amino-2-methylpropyl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (0.58 g, 1.457 mmol) in DCM (15 mL) at RT under argon atmosphere. The reaction mixture was stirred at RT for 4 h and then concentrated under reduced pressure to yield 440 mg of crude CIS-4-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-ylamino)-4-oxobutanoic acid as an off-white solid (TLC system: 5% MeOH in DCM; Rf: 0.35).

Step 2: CIS-1-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)pyrrolidine-2,5-dione (SC_4084)

Acetyl chloride (2.2 mL) was added to a solution of CIS-4-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-ylamino)-4-oxobutanoic acid (0.44 g, 0.883 mmol) in EtOAc (30 mL) at 0° C. under argon atmosphere. The reaction mixture was stirred at 80° C. for 16 h. The reaction mixture was cool to RT, concentrated under reduced pressure, quenched with sat. aq. NaHCO₃ and the organic product was extracted with EtOAc (2×30 mL). The combined organic extracts were dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (silica gel 230-400 mesh, 0-8% MeOH in DCM) followed by reverse phase prep HPLC to get 50 mg (9%) of CIS-1-(1-(1-(cyclopropylmethyl)-8-(dimethylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2-methylpropan-2-yl)pyrrolidine-2,5-dione (SC_4084) as a white solid (TLC system: 5% MeOH in DCM; Rf: 0.30). Reverse prep HPLC condition: mobile phase: 10 mM ammonium bicarbonate in H₂O/acetonitrile; column: INERTSIL-ODS (250*19 mm) 5 μm; gradient (% B): 0/80, 9/90, 9.1/80, 12/80; flow rate: 18 ml/min; diluent: ACN+THF+H₂O. ¹H NMR (DMSO-d6): δ 7.35-7.34 (m, 4H), 7.27-7.24 (m, 1H), 3.34 (s, 2H), 3.19 (s, 2H), 2.87 (d, 2H), 2.66-2.64 (m, 2H), 2.43 (s, 4H), 2.13-2.08 (m, 2H), 1.97 (s, 6H), 1.51 (s, 6H), 1.37-1.32 (m, 4H), 0.89-0.87 (m, 1H), 0.45-0.42 (m, 2H), 0.27-0.24 (m, 2H). Mass: m/z 481.3 (M+H)⁺.

Synthesis of SC_4096: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyridazin-4-yl)piperidin-4-3/1)-1,3-diazaspiro[4.5]decan-2-one

Step 1: CIS-3-(1-(6-chloropyridazin-4-yl)piperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

DIPEA (0.566 g, 4.3 mmol) was added to a solution of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4054) (0.6 g, 1.4 mmol) and 3,5-dichloropyridazine (310 mg, 2.10 mmol) in N-methyl-2-pyrrolidone (30 mL). The reaction mixture was purged with argon for 10 min and stirred for 16 h at 80° C. The reaction mixture was quenched with water and extracted with EtOAc (3×20 mL). The combined organic layer was concentrated under reduced pressure and the crude product was purified by flash chromatography (silica gel 230-400 mesh size, 5-10% methanol in dichloromethane as eluent) to afford 250 mg of CIS-3-(1-(6-chloropyridazin-4-yl)piperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one) as a light brown solid. (TLC system: 10% MeOH in DCM; Rf: 0.35).

Step 2: CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyridazin-4-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4096)

10% Pd-C (125 mg) was added to a solution of CIS-3-(1-(6-chloropyridazin-4-yl)piperidin-4-yl)-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-1,3-di azaspiro[4.5]decan-2-one) (0.25 g, 0.47 mmol) and triethylamine (96 mg, 0.95 mmol) in ethanol. The resultant mixture was hydrogenated under balloon pressure for 4 h. The reaction mixture was diluted with EtOH (10 mL); filtered through a pad of celite and the filtrate was concentrated under reduced pressure. The crude product was purified by flash chromatography (silica gel 230-400 mesh, 5-10% methanol in DCM as eluent) and further purified by reverse phase prep HPLC to afford 85 mg (17%) of CIS-1-(cyclopropylmethyl)-8-(dimethylamino)-8-phenyl-3-(1-(pyridazin-4-yl)piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one (SC_4096) as an off-white solid. (TLC system: 10% MeOH in DCM; Rf: 0.35). Reverse prep HPLC condition: column X-BRIDGE C18 (4.6×150 mm) 3.5 μm; mobile phase: 10 mM ammonium acetate in water (A)/acetonitrile (B); gradient time (min)/% B: 0/5, 1.2/5, 3/55, 5/70, 7/95, 10/95, 12/100, 14/5, 16/5; flow rate: 1 ml/min; diluent: (acetonitrile/water). NMR (DMSO): δ 8.92 (m, 1H), 8.55-8.54 (m, 1H), 7.34-7.30 (m, 4H), 7.24-7.21 (m, 1H), 6.91-6.89 (m, 1H), 4.09-4.07 (d, 2H), 3.84 (m, 1H), 3.09 (s, 2H), 2.95-2.90 (m, 4H), 2.62-2.59 (d, 2H), 2.12-2.09 (t, 2H), 1.96 (s, 6H), 1.60-1.56 (m, 4H), 1.42-1.39 (m, 2H), 1.31-1.28 (m, 2H), 0.91 (m, 1H), 0.46-0.43 (m, 2H), 0.26-0.23 (m, 2H). Mass: m/z 489.4 (M+H)⁺.

Synthesis of SC_4091: CIS-1-(cyclobutylmethyl)-8-(dimethylamino)-3-(2-methyl-2-(methylsulfonyl)propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To a solution of 1-cyclobutylmethyl-8-dimethylamino-3-(2-methyl-2-methylsulfanyl-propyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (45 mg, 0.1 mmol, 1.0 eq) in THF/H₂O (6 ml, 5:1) was added oxone (119 mg, 0.19 mmol, 1.9 eq.) at 0° C. The reaction mixture was stirred at RT for 16 h, then quenched with sat. aq. NaHSO₃, diluted with EtOAc (50 mL) and washed with sat. aq. NaHCO₃ (25 ml). Organic layer was dried over Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (neutral alumina; 1.5% MeOH in DCM) to yield 1-cyclobutylmethyl-8-dimethylamino-3-(2-methanesulfonyl-2-methyl-propyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (SC_4091) (100 mg, 0.17 mmol, 94%) as an off-white solid. ¹HNMR at 100° C. (DMSO-d6, 400 MHz), 3 (ppm)=7.33-7.24 (m, 3H), 3.41 (s, 2H), 3.29 (s, 2H), 3.10 (d, 2H, J=7.04 Hz), 2.87 (s, 3H), 2.63-2.56 (m, 3H), 2.12-2.01 (m, 10H), 1.83-1.81 (m, 4H), 1.47-1.27 (m, 10H). Mass: m/z 576.0 (M+H)⁺.

Synthesis of SC_4098: TRANS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

Step 1: TRANS-8-(dimethylamino)-3-(2-(methylthio)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione

In analogy to the method described for SC_4034 TRANS-8-(dimethylamino)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione (step 1 of INT-1059) was reacted with 1-bromo-2-methylsulfanyl-ethane to be converted into TRANS-8-(dimethylamino)-3-(2-(methylthio)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decane-2,4-dione. Mass: m/z 362.2 (M+H)⁺.

Step 2: TRANS-8-(dimethylamino)-3-(2-(methylthio)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one

To a slurry of LiAlH₄ (315 mg, 8.31 mmol, 6.0 eq.) in THF (10 mL) was added a solution of TRANS-8-dimethylamino-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decane-2,4-dione (500 mg, 1.38 mmol, 1.0 eq.) in THF (10 mL) at 0° C. under argon atmosphere and the reaction mixture was stirred at reflux for 16 h. The reaction mixture was cooled to 0° C. and quenched with sat. aq. Na₂SO₄ (10 mL). The resulting suspension was stirred at RT for 30 min. The reaction mixture was filtered through celite and filter cake was washed with 10% MeOH in DCM (30 mL). The combined filtrate was dried over anhydr. Na₂SO₄ and concentrated under reduced pressure and residue was dissolved in HCOOH (15 mL) and NaBH₄ (314 mg, 8.31 mmol, 6.0 eq.) was added portionwise at 0° C. The reaction mixture was stirred at RT for 3 h, then basified with sat. aq. NaHCO₃ up to pH-8 and extracted with EtOAc (2×50 mL). Combined organic layer was washed with brine (30 mL), dried over Na₂SO₄ and concentrated under reduced pressure to get crude TRANS-8-dimethylamino-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (400 mg, 1.29 mmol, 83%) as a brown solid which was used in the next step without further purification. LC-MS: m/z [M+1]⁺=348.4 (MW calc. 347.52).

Step 3: TRANS-8-dimethylamino-1-(1-hydroxy-cyclobutylmethyl)-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one

To a solution of TRANS-8-dimethylamino-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (450 mg, 1.29 mmol, 1.0 eq.) in DMSO (10 mL) was added NaOH (363 mg, 9.07 mmol, 7.0 eq.) at RT. The reaction mixture was heated to 60° C. for 30 min, then cooled to RT and 1-oxa-spiro[2.3]hexane (435 mg, 5.18 mmol, 4.0 eq.) was added. The reaction mixture was stirred at 60° C. for 48 h, then quenched with ice water (25 mL), extracted with EtOAc (2×50 mL). Combined organic layer was washed with brine (25 ml), dried over Na₂SO₄, filtered and concentrated under reduced pressure to get the crude product which was purified by column chromatography (neutral alumina; 4% MeOH/DCM) to yield TRANS-8-dimethylamino-1-(1-hydroxy-cyclobutylmethyl)-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one (120 mg, 0.27 mmol, 21%) as a brown liquid. LC-MS: m/z [M+1]⁺=432.0 (MW calc. 431.64. Step 4: TRANS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4098)

In analogy to the method described for step 2 of SC_4038 TRANS-8-dimethylamino-1-(1-hydroxy-cyclobutylmethyl)-3-(2-methylsulfanyl-ethyl)-8-phenyl-1,3-diaza-spiro[4.5]decan-2-one was reacted with oxone to be converted into TRANS-8-(dimethylamino)-1-((1-hydroxycyclobutyl)methyl)-3-(2-(methylsulfonyl)ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (SC_4098). Mass: m/z 464.3 (M+H)⁺. ¹HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.39-7.28 (m, 5H), 5.35 (s, 1H), 3.59-3.56 (m, 2H), 3.42-3.34 (m, 4H), 2.97-2.95 (m, 3H), 2.66 (s, 2H), 2.67 (bs, 2H), 2.59-2.56 (m, 2H), 2.00 (s, 6H), 1.77-1.63 (m, 6H), 1.50-1.27 (m, 5H), 1.05-0.98 (m, 1H).

Synthesis of SC_5063: CIS-2,2-dimethyl-3-(8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)propanenitrile

Step 1: CIS-3-(8-(dimethylamino)-1-(methoxymethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile

To a solution of CIS-3-(8-dimethylamino-2-oxo-8-phenyl-1,3-diaza-spiro[4.5]dec-3-yl)-2,2-dimethyl-propionitrile (SC_5062) (1.8 g, 5.08 mmol, 1.0 eq.) in THF (20 ml) was added NaH (95%, 366 mg, 15.25 mmol, 3.0 eq.) at 0° C. and the reaction mixture was stirred for 20 min at RT. A solution of methoxymethyl chloride (0.57 ml, 7.62 mmol, 1.5 eq.) in THF (5 ml) was added at 0° C. and the resulting mixture was stirred at RT for 16 h. The reaction mixture was diluted with water (20 ml) and extracted with EtOAc (2×50 ml). The combined organic layers were washed with water (50 ml) and brine (50 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure. The resulting crude product was purified by column chromatography (neutral alumina; 0.2% MeOH/DCM) to yield CIS-3-(8-(dimethylamino)-1-(methoxymethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (700 mg, 1.75 mmol, 34%) as an off-white sticky solid. LC-MS: m/z [M+H]⁺=399.3 (MW calc.=398.54).

Step 2: CIS-3-(1-(methoxymethyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile

To a solution of CIS-3-(8-(dimethylamino)-1-(methoxymethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (700 mg, 1.75 mmol, 1.0 eq.) in acetonitrile (20 ml) and THF (10 ml) was added N-iodosuccinimide (590 mg, 2.63 mmol, 1.5 eq.) at 0° C. and the mixture was stirred at RT for 3 h. The reaction mixture was diluted with water (20 ml) and 1N aq. NaOH (5 ml) and extracted with DCM (2×30 ml). The combined organic layers were washed with brine (40 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure to give CIS-3-(1-(methoxymethyl)-8-(methylamino)-2-oxo-8-phenyl -1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (350 mg, 0.911 mmol, 52%) which was used directly for next step without further purification. LC-MS: m/z [M+H]+=385.2 (MW calc.=384.52).

Step 3: CIS-2,2-dimethyl-3-(8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)propanenitrile (SC_5063)

To a solution of CIS-3-(1-(methoxymethyl)-8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)-2,2-dimethylpropanenitrile (400 mg, 1.04 mmol, 1.0 eq.) in MeOH (10 ml) was added 2M aq. HCl (30 ml) at 0° C. and the mixture was stirred at RT for 16 h. The reaction mixture was basified with 2M aq. NaOH and extracted with DCM (2×25 ml). The combined organic layers were washed with brine (30 ml), dried over anhydr. Na₂SO₄ and concentrated under reduced pressure to give CIS-2,2-dimethyl-3-(8-(methylamino)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl)propanenitrile (SC_5063) (300 mg, 0.882 mmol, 84%) which was 95.72% pure according to HPLC. LC-MS: m/z [M+H]+=341.27 (MW calc.=340.46). ¹HNMR (DMSO-d6, 400 MHz), δ (ppm)=7.42-7.19 (m, 5H), 6.78 (bs, 1H), 3.36 (s, 2H), 3.18 (s, 2H), 1.96-1.85 (m, 7H), 1.66 (bs, 2H), 1.46-1.43 (m, 2H), 1.25 (s, 6H).

For further exemplary compounds the last synthesis step in analogy to previously described methods is given in the following table. The syntheses of the building blocks and intermediates have either been described previously within this application or can be performed in analogy to the herein described methods or by methods known to the person, skilled in the art. Such a person will also know which building blocks and intermediates need to be chosen for synthesis of each exemplary compound.

in analogy m/z Example Chemical Name Reactant I Reactant II to method [M + H]⁺ SC_4002 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-(2- INT-987 19-bromo-2,5,8,11,14,17- SC_4003 620.4 methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl- hexaoxanonadecane 1,3-diazaspiro[4.5]decan-2-one SC_4004 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-(2- INT-987 22-bromo-2,5,8,11,14,17,20- SC_4003 664.4 methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8- heptaoxadocosane phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4005 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2- INT-987 16-bromo-2,5,8,11,14- SC_4003 576.4 methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3- pentaoxahexadecane diazaspiro[4.5]decan-2-one SC_4006 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(2-methoxy- INT-987 1-bromo-2-(2- SC_4003 444.3 ethoxy)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one methoxyethoxy)ethane SC_4007 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-ethyl)-8- INT-987 1-bromo-2-methoxyethane SC_4003 400.3 phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4008 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-(2-methoxy- INT-987 13-bromo-2,5,8,11- SC_4003 532.4 ethoxy)-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2- tetraoxatridecane one SC_4009 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl- INT-987 1-bromo-2- SC_4025 448.3 ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (methylsulfonyl)ethane SC_4011 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2- INT-799 1-bromo-2- SC_4025 464.3 methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one (methylsulfonyl)ethane SC_4014 CIS-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3- INT-799 3-bromo-2,2- SC_4025 423.3 diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile dimethylpropanenitrile SC_4017 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-[2- INT-987 25-bromo-2,5,8,11,14,17,20,23- SC_4003 708.5 (2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]- octaoxapentacosane ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4018 CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-methyl-8-phenyl-1,3- INT-987 Methyliodide SC_4025 356.3 diazaspiro[4.5]decan-2-one SC_4021 CIS-1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2- SC_4011 — SC_4010 450.2 methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4022 CIS-3-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8- SC_4029 — SC_4010 397.3 phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile SC_4024 CIS-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8- SC_4030 — SC_4010 383.2 phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile SC_4026 CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2- INT-799 4-(2-bromoethyl)morpholine SC_4025 471.3 morpholin-4-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4029 CIS-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo- INT-799 3-bromopropanenitrile SC_4025 411.3 8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile SC_4030 CIS-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo- INT-799 2-bromoacetonitrile SC_4025 397.3 8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile

in analogy Example Chemical name Reactant I Reactant II to method SC_4035 CIS-8-Dimethylamino-3-(2- SC_4032 toluene-4-sulfonic acid SC_4034 methylsulfonyl-ethyl)-1-(oxetan-3-yl- oxetan-3-ylmethyl ester methyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4036 CIS-8-Dimethylamino-1-(3-methoxy- SC_4032 1-bromo-3-methoxy-propane SC_4034 propyl)-3-(2-methylsulfonyl-ethyl)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4039 CIS-1-(Cyclobutyl-methyl)-8- INT-987 l,6-dioxaspiro[2.5]octane SC_4027 dimethylamino-3-[(4-hydroxy- tetrahydro-pyran-4-yl)-methyl]-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4040 CIS-1-(Cyclopropyl-methyl)-8- INT-983 tetrahydro-2H-pyran-4-yl 4- SC_4027 dimethylamino-8-phenyl-3-tetrahydro- methylbenzenesulfonate pyran-4-yl-1,3-diazaspiro[4.5]decan-2- one SC_4041 CIS-1-(Cyclobutyl-methyl)-8- INT-987 1-oxa-6-thiaspiro[2.5]octane SC_4027 dimethylamino-3-[(4-hydroxy-1,1- (step 1) (for step 1), dioxo-thian-4-yl)-methyl]-8-phenyl-1,3- SC_4038 diazaspiro[4.5]decan-2-one (for step 2) SC_4042 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-799 tetrahydro-2H-pyran-4-yl 4- SC_4027 cyclobutyl)-methyl]-8-phenyl-3- methylbenzenesulfonate tetrahydro-pyran-4-yl-1,3- diazaspiro[4.5]decan-2-one SC_4043 CIS-1-[[8-Dimethylamino-3-(2- SC_4032 toluene-4-sulfonic acid 1- SC_4034 methylsulfonyl-ethyl)-2-oxo-8-phenyl- cyano-cyclobutylmethyl 1,3-diazaspiro[4.5]decan-1-yl]-methyl]- ester cyclobutane-1-carbonitrile SC_4045 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-799 1-oxa-6-thiaspiro[2.5]octane SC_4044 cyclobutyl)-methyl]-3-[(4-hydroxy-1,1- (step 1) (for step 1), dioxo-thian-4-yl)-methyl]-8-phenyl-1,3- step 2 of diazaspiro[4.5]decan-2-one SC_4038 (for step 2) SC_4046 CIS-1-(Cyclopropyl-methyl)-8- INT-983 tetrahydro-2H-thiopyran-4- SC_4044 dimethylamino-3-(1,1-dioxo-thian-4- yl 4-methylbenzenesulfonate (for step 1), yl)-8-phenyl-1,3-diazaspiro[4.5]decan- (step 1) step 2 of 2-one SC_4038 (for step 2) SC_4047 CIS-8-Dimethylamino-3-(1,1-dioxo- INT-799 tetrahydro-2H-thiopyran-4- SC_4044 thian-4-yl)-1-[(1-hydroxy-cyclobutyl)- yl 4-methylbenzenesulfonate (for step 1), methyl]-8-phenyl-1,3- (step 1) step 2 of diazaspiro[4.5]decan-2-one SC_4038 (for step 2) SC_4049 CIS-3-(1-Benzoyl-piperidin-4-yl)-1- SC_4054 benzoyl chloride SC_4048 (cyclopropyl-methyl)-8-dimethylamino- 8-phenyl-1,3-diazaspiro[4.5]decan-2- one SC_4050 CIS-1-(Cyclopropyl-methyl)-8- SC_4054 isonicotinoyl chloride SC_4048 dimethylamino-8-phenyl-3-[1-(pyridine- hydrochloride 4-carbonyl)-piperidin-4-yl]-1,3- diazaspiro[4.5]decan-2-one SC_4051 CIS-1-(Cyclopropyl-methyl)-8- INT-983 1,6-dioxaspiro[2.5]octane SC_4044 dimethylamino-3-[(4-hydroxy- tetrahydro-pyran-4-yl)-methyl]-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4053 CIS-3-[(1-Acetyl-piperidin-4-yl)- SC_4058 acetyl chloride SC_4048 methyl]-1-(cyclopropyl-methyl)-8- dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4058 CIS-1-(Cyclopropyl-methyl)-8- INT-983 tert-butyl 4- SC_4034 dimethylamino-8-phenyl-3-(piperidin-4- ((tosyloxy)methyl)piperidine- (for step 1), yl-methyl)-1,3-diazaspiro[4.5]decan-2- 1-carboxylate (step 1) step 2 of one SC_4054 (for step 2) SC_4059 CIS-3-(1-Benzoyl-piperidin-4-yl)-8- INT-976 tert-butyl 4- SC_4054 dimethylamino-8-phenyl-1,3- (tosyloxy)piperidine-1- (for steps diazaspiro[4.5]decan-2-one carboxylate (step 1), benzoyl 1, 2), chloride (step 3) SC_4048 (for step 3) SC_4060 CIS-8-Dimethylamino-8-phenyl-3-[1- INT-976 isonicotinoyl chloride SC_4054 (pyridine-4-carbonyl)-piperidin-4-yl]- hydrochloride (for steps 1,3-diazaspiro[4.5]decan-2-one 1, 2), SC_4048 (for step 3) SC_4061 CIS-3-(1-Acetyl-piperidin-4-yl)-8- INT-976 acetyl chloride SC_4054 dimethylamino-8-phenyl-1,3- (for steps diazaspiro[4.5]decan-2-one 1, 2), SC_4048 (for step 3) SC_4062 CIS-1-(Cyclopropyl-methyl)-8- INT-983 1-oxa-6-thiaspiro[2.5]octane SC_4044 dimethylamino-3-[(4-hydroxy-1,1- (step 1) (for step 1), dioxo-thian-4-yl)-methyl]-8-phenyl-1,3- step 2 of diazaspiro[4.5]decan-2-one SC_4038 (for step 2) SC_4063 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-799 tert-butyl bromoacetate (step SC_4055 cyclobutyl)-methyl]-3-(2-hydroxy-2- 1), methylmagnesium methyl-propyl)-8-phenyl-1,3- bromide (step 3) diazaspiro[4.5]decan-2-one SC_4066 CIS-8-Dimethylamino-1,3-bis(2- INT-976 1-bromo-2-methylsulfonyl- SC_4003 methylsulfonyl-ethyl)-8-phenyl-1,3- ethane diazaspiro[4.5]decan-2-one SC_4067 CIS-N-[1-[[1-(Cyclopropyl-methyl)-8- SC_4064 acetyl chloride SC_4048 dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-methyl]- cyclopropyl]-acetamide SC_4068 CIS-1-(Cyclopropyl-methyl)-8- SC_4058 5-bromo-2- SC_4056 dimethylamino-8-phenyl-3-[(1- (trifluoromethyl)pyrimidine pyrimidin-5-yl-piperidin-4-yl)-methyl]- 1,3-diazaspiro[4.5]decan-2-one SC_4069 CIS-8-Dimethylamino-8-phenyl-3-[(1- INT-1051 5-bromopyrimidine SC_4056 pyrimidin-5-yl-piperidin-4-yl)-methyl]- 1,3-diazaspiro[4.5]decan-2-one SC_4070 CIS-8-Dimethylamino-8-phenyl-3-(1- INT-1050 5-bromopyrimidine SC_4056 pyrimidin-5-yl-piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4072 CIS-1-(Cyclopropyl-methyl)-8- INT-1052 4-chlorobutanoyl chloride SC_4048 dimethylamino-3-[2-methyl-2-(2-oxo- (step 1) (step 1), pyrrolidin-1-yl)-propyl]-8-phenyl-1,3- procedure diazaspiro[4.5]decan-2-one described (step 2) SC_4073 CIS-1-(Cyclopropyl-methyl)-8- INT-1052 3-chloropropane-1-sulfonyl SC_4072 dimethylamino-3-[2-(1,1-dioxo- chloride (step 1) [1,2]thiazolidin-2-yl)-2-methyl-propyl]- 8-phenyl-1,3-diazaspiro[4.5]decan-2- one SC_4074 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-799 2-(4-(benzyloxy)tetrahydro- SC_4052 cyclobutyl)-methyl]-3-[2-(4-hydroxy- 2H-pyran-4-yl)ethyl 4- tetrahydro-pyran-4-yl)-ethyl]-8-phenyl- methylbenzenesulfonate 1,3-diazaspiro[4.5]decan-2-one SC_4075 CIS-1-(Cyclobutyl-methyl)-8- INT-987 4-allyl-4- SC_4071 dimethylamino-3-[2-(4-hydroxy-1,1- (benzyloxy)tetrahydro-2H- dioxo-thian-4-yl)-ethyl]-8-phenyl-1,3- thiopyran diazaspiro[4.5]decan-2-one SC_4076 CIS-3-[(1-Acetyl-piperidin-4-yl)- INT-1051 acetyl chloride SC_4048 methyl]-8-dimethylamino-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4077 CIS-8-Dimethylamino-3-(2- SC_4032 2-chloro-1-pyrrolidin-1-yl- SC_4003 methylsulfonyl-ethyl)-1-(2-oxo-2- ethanone pyrrolidin-1-yl-ethyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4078 TRANS-8-Dimethylamino-3-(2- INT-1059 1-bromo-2-methylsulfonyl- SC_4003 methylsulfonyl-ethyl)-8-phenyl-1,3- ethane diazaspiro[4.5]decan-2-one SC_4079 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-799 4-allyl-4- SC_4071 cyclobutyl)-methyl]-3-[2-(4-hydroxy- (benzyloxy)tetrahydro-2H- 1,1-dioxo-thian-4-yl)-ethyl]-8-phenyl- thiopyran 1,3-diazaspiro[4.5]decan-2-one SC_4081 CIS-N-[2-[1-(Cyclopropyl-methyl)-8- INT-1052 acetyl chloride SC_4048 dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-1,1- dimethyl-ethyl]-acetamide SC_4082 CIS-N-[2-[1-(Cyclopropyl-methyl)-8- INT-1052 methanesulfonyl chloride SC_4048 dimethylamino-2-oxo-8-phenyl-1,3- diazaspiro[4.5]decan-3-yl]-1,1- dimethyl-ethyl]-methanesulfonic acid amide SC_4083 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-799 3-(benzyloxy)-3- SC_4071 cyclobutyl)-methyl]-3-[2-(3-hydroxy- vinyloxetane oxetan-3-yl)-ethyl]-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4085 CIS-N-[2-[8-Dimethylamino-1-[(1- INT-1053 acetyl chloride SC_4048 hydroxy-cyclobutyl)-methyl]-2-oxo-8- phenyl-1,3-diazaspiro[4.5]decan-3-yl]- 1,1-dimethyl-ethyl]-acetamide SC_4086 CIS-N-[2-[8-Dimethylamino-1-[(1- INT-1053 methanesulfonyl chloride SC_4048 hydroxy-cyclobutyl)-methyl]-2-oxo-8- phenyl-1,3-diazaspiro[4.5]decan-3-yl]- 1,1-dimethyl-ethyl]-methanesulfonic acid amide SC_4087 CIS-1-(Cyclopropyl-methyl)-8- SC_4054 3-bromopyridine SC_4056 dimethylamino-8-phenyl-3-(1-pyridin- 3-yl-piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4088 CIS-1-(Cyclopropyl-methyl)-8- INT-1063 1-bromo-2-methylsulfonyl- SC_4032 dimethylamino-8-(3-fluorophenyl)-3-(2- ethane methylsulfonyl-ethyl)-1,3- diazaspiro[4.5]decan-2-one SC_4089 CIS-1-(Cyclopropyl-methyl)-8- SC_4054 4-bromopyridine SC_4056 dimethylamino-8-phenyl-3-(1-pyridin- 4-yl-piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4090 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-1053 4-chlorobutanoyl chloride SC_4072 cyclobutyl)-methyl]-3-[2-methyl-2-(2- (step 1) oxo-pyrrolidin-1-yl)-propyl]-8-phenyl- 1,3-diazaspiro[4.5]decan-2-one SC_4092 TRANS-1-(Cyclobutyl-methyl)-8- INT-1056 — SC_4091 dimethylamino-3-(2-methyl-2- methylsulfonyl-propyl)-8-phenyl-1,3- diazaspiro[4.5]decan-2-one SC_4093 CIS-8-Dimethylamino-3-[2-(1,1-dioxo- INT-799 3-chloropropane-1-sulfonyl SC_4072 [1,2]thiazolidin-2-yl)-2-methyl-propyl]- chloride (step 1) 1-[(1-hydroxy-cyclobutyl)-methyl]-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4094 CIS-1-(Cyclopropyl-methyl)-8- INT-1063 1,6-dioxaspiro[2.5]octane SC_4044 dimethylamino-8-(3-fluorophenyl)-3- [(4-hydroxy-tetrahydro-pyran-4-yl)- methyl]-1,3-diazaspiro[4.5]decan-2-one SC_4095 CIS-8-Dimethylamino-1-[(1-hydroxy- INT-1072 5-bromopyrimidine SC_4056 cyclobutyl)-methyl]-8-phenyl-3-(1- pyrimidin-5-yl-piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4097 CIS-2-[8-Dimethylamino-3-(2- SC_4032 2-chloro-N,N-dimethyl- SC_4003 methylsulfonyl-ethyl)-2-oxo-8-phenyl- acetamide 1,3-diazaspiro[4.5]decan-1-yl]-N,N- dimethyl-acetamide SC_4099 CIS-1-(Cyclopropyl-methyl)-8- INT-1073 5-bromopyrimidine SC_4056 dimethylamino-8-(3-fluorophenyl)-3-(1- pyrimidin-5-yl-piperidin-4-yl)-1,3- diazaspiro[4.5]decan-2-one SC_4100 CIS-1-(cyclopropylmethyl)-8-(3- SC_4088 SC_4010 fluorophenyl)-8-(methylamino)-3-(2- (methylsulfonyl)ethyl)-1,3- diazaspiro[4.5]decan-2-one SC_4101 CIS-1-(cyclopropylmethyl)-8- INT-983 1-oxaspiro[2.3]hexane SC_4044 (dimethylamino)-3-((1- hydroxycyclobutyl)methyl)-8-phenyl- 1,3-diazaspiro[4.5]decan-2-one SC_4102 CIS-8-(dimethylamino)-8-(3- INT-1074 1-oxa-6-thiaspiro[2.5]octane SC_4044 fluorophenyl)-3-((4-hydroxy-1,1- (step 1) (for step 1), dioxidotetrahydro-2H-thiopyran-4- step 2 of yl)methyl)-1-((1- SC_4038 hydroxycyclobutyl)methyl)-1,3- (for step 2) diazaspiro[4.5]decan-2-one SC_4103 CIS-8-(dimethylamino)-8-(3- INT-1074 1,6-dioxaspiro[2.5]octane SC_4044 fluorophenyl)-1-((1- hydroxycyclobutyl)methyl)-3-((4- hydroxytetrahydro-2H-pyran-4- yl)methyl)-1,3-diazaspiro[4.5]decan-2- one SC_4104 CIS-1-(cyclopropylmethyl)-8- INT-1063 1-oxa-6-thiaspiro[2.5]octane SC_4044 (dimethylamino)-8-(3-fluorophenyl)-3- (step 1) (for step 1), ((4-hydroxy-1,1-dioxidotetrahydro-2H- step 2 of thiopyran-4-yl)methyl)-1,3- SC_4038 diazaspiro[4.5]decan-2-one (for step 2) SC_4105 CIS-1-(cyclopropylmethyl)-8- INT-983 3-(bromomethyl)oxetane SC_4032 (dimethylamino)-3-(oxetan-3-ylmethyl)- 8-phenyl-1,3-diazaspiro[4.5]decan-2- one SC_4106 CIS-8-(dimethylamino)-8-phenyl-3- INT-976 (R)-1-(thiophen-3- SC_4032 ((S)-1-(thiophen-3-yl)propan-2-yl)-1,3- yl)propan-2-yl diazaspiro[4.5]decan-2-one methanesulfonate SC_4107 CIS-8-(dimethylamino)-8-phenyl-1,3- INT-976 (1-(trifluoromethyl)cyclo- SC_4032 bis((1- propyl)methyl (trifluoromethyl)cyclopropyl)methyl)- 4-methylbenzenesulfonate 1,3-diazaspiro[4.5]decan-2-one SC_4108 CIS-8-(dimethylamino)-1,3-bis((1- INT-976 (1-fluorocyclopropyl)methyl SC_4032 fluorocyclopropyl)methyl)-8-phenyl- 4-methylbenzenesulfonate 1,3-diazaspiro[4.5]decan-2-one SC_4109 CIS-1-(cyclopropylmethyl)-8- INT-983 (3-(bromomethyl)oxetan-3- SC_4032 (dimethylamino)-3-((3- yl)methanol (hydroxymethyl)oxetan-3-yl)methyl)-8- phenyl-1,3-diazaspiro[4.5]decan-2-one SC_4110 CIS-3-((3-aminooxetan-3-yl)methyl)-1- INT-983 tert-butyl (3- SC_4034 (cyclopropylmethyl)-8- (bromomethyl)oxetan-3- (for step 1), (dimethylamino)-8-pnenyl-1,3- yl)carbamate step 2 of diazaspiro[4.5]decan-2-one SC_4054 (for step 2) SC_4111 CIS-3-(8-(dimethylamino)-1-((1- INT-983 (1-cyanocyclobutyl)methyl SC_4032 fluorocyclopropyl)methyl)-2-oxo-8- 4-methylbenzenesulfonate phenyl-1,3-diazaspiro[4.5]decan-3-yl)- 2,2-dimethylpropanenitrile SC_4112 CIS-3-(8-(dimethylamino)-1-((1- INT-976 2-cyano-2-methylpropyl 4- SC_4032 fluorocyclopropyl)methyl)-2-oxo-8- methylbenzenesulfonate (step 1), phenyl-1,3-diazaspiro[4.5]decan- (step 1), (1- SC_4034 3-yl)-2,2-dimethylpropanenitrile fluorocyclopropyl)methyl 4- (step 2) methylbenzenesulfonate (step 2) SC_5061 CIS-3-[8-(Ethyl-methyl-amino)-2-oxo- INT-797 3-bromo-2,2-dimethyl- step 1 of 8-phenyl-1,3-diazaspiro[4.5]decan-3- propionitrile INT-897 yl]-2,2-dimethyl-propionitrile SC_5062 CIS-3-(8-Dimethylamino-2-oxo-8- INT-976 3-bromo-2,2-dimethyl- step 1 of phenyl-1,3-diazaspiro[4.5]decan-3-yl)- propionitrile INT-897 2,2-dimethyl-propionitrile SC_5065 CIS-3-[8-(Ethyl-methyl-amino)-1- SC_5061 methyl iodide step 1 of methyl-2-oxo-8-phenyl-1,3- INT-953 diazaspiro[4.5]decan-3-yl]-2,2- dimethyl-propionitrile SC_5068 CIS-3-(8-Ethylamino-2-oxo-8-phenyl- INT-1008 3-bromo-2,2-dimethyl- step 1 of 1,3-diazaspiro[4.5]decan-3-yl)-2,2- propionitrile INT-897 dimethyl-propionitrile SC_5080 TRANS-3-[1-(Cyclopropyl-methyl)-8- INT-1059 3-bromo-2,2-dimethyl- step 1 of dimethylamino-2-oxo-8-phenyl-1,3- propionitrile (step 1), INT-897 diazaspiro[4.5]decan-3-yl]-2,2- cyclopropylmethylbromide (for step 1), dimethyl-propionitrile (step 2) step 1 of INT-953 (for step 2) m/z Example ¹H NMR data (M + H)⁺ SC_4035 ¹HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.34-7.25 450.1 (m, 5H), 4.59 (t, 2H, 6.64 Hz) 4.35 (bs, 2H), 3.48 (bs, 2H), 3.21 (s, 2H), 3.13 (bs, 1H), 2.95 (s, 3H), 2.67-2.65 (m, 2H), 1.97 (s, 8H), 1.41-1.30 (m, 4H). SC_4036 ¹HNMR (CDCl3, 400 MHz), δ (ppm) = 7.35-7.25 (m, 452.3 5H, merged with CDCl3), 3.64 (t, 2H, J = 6.32 Hz), 3.44 (t, 2H, J = 6.08 Hz), 3.34 (s, 3H), 3.28-3.19 m, 6H), 2.95 (s, 3H), 2.64-2.61 (m, 2H), 2.22-2.16 (m, 2H), 2.01 (s, 6H), 1.89-1.86 (m, 2H), 1.29-1.27 (m, 4H). SC_4039 ¹H NMR (DMSO-d6): δ 7.37-7.31 (m, 4H), 7.26-7.23 456.3 (m, 1H), 4.52 (s, 1H), 3.60-3.56 (m, 4H), 3.28 (s, 2H), 3.03-3.01 (m, 4H), 2.68-2.65 (m, 2H), 2.49-2.46 (m, 1H), 2.06-1.92 (m, 10H), 1.82-1.65 (m, 4H), 1.49-1.44 (m, 2H), 1.34-1.31 (m, 6H). SC_4040 ¹H NMR (DMSO-d6): δ 7.34-7.25 (m, 5H), 3.86-3.84 412.3 (m, 2H), 3.76-3.70 (m, 1H), 3.35 (m, 2H), 3.13 (s, 2H), 2.91 (d, 2H), 2.66-2.62 (m, 2H), 2.14 (t, 2H), 1.97 (s, 6H), 1.66-1.58 (m, 2H), 1.46-1.23 (m, 6H), 0.91 (m, 1H), 0.44 (m, 2H), 0.24 (m, 2H). SC_4041 ¹H NMR (DMSO-d6): δ 7.37-7.23 (m, 5H), 5.02 (s, 504.3 1H), 3.27 (s, 2H), 3.17-3.03 (m, 6H), 2.97-2.94 (m, 2H), 2.68-2.65 (m, 2H), 2.54-2.46 (m, 1H), 2.07-1.92 (m, 10H), 1.87-1.84 (m, 4H), 1.80-1.66 (m, 4H), 1.34-1.31 (m, 4H). SC_4042 ¹H NMR (DMSO-d6): δ 7.37-7.23 (m, 5H), 6.05 (s, 442.3 1H), 3.87-3.84 (m, 2H), 3.74-3.73 (m, 1H), 3.36-3.35 (m, 2H), 3.24 (s, 2H), 3.07 (s, 2H), 2.66-2.63 (m, 2H), 2.06-1.83 (m, 12H), 1.65-1.58 (m, 3H), 1.48-1.32 (m, 7H). SC_4043 ¹HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.33-7.32 473.2 (m, 2H), 7.25 (s, 3 H), 3.69-3.66 (t, 2H, J = 5), 3.41 (s, 2H), 3.30-3.25 (m, 4H), 2.95 (s, 3H), 2.67-2.64 (d, 2H, J = 13.4), 2.45 (bs, 4H), 2.19-2.08 (m, 4H), 2.02 (s, 6H), 1.46-1.39 (m, 2H). SC_4045 ¹H NMR (DMSO-d6): δ 7.37-7.25 (m, 5H), 5.93 (s, 520.3 1H), 5.01 (s, 1H), 3.41 (s, 2H), 3.16-3.09 (m, 6H), 2.98- 2.95 (m, 2H), 2.70-2.66 (m, 2H), 2.06-2.03 (m, 4H), 1.97 (s, 6H), 1.89-1.87 (m, 6H), 1.64-1.61 (m, 1H), 1.45-1.31 (m, 5H). SC_4046 ¹H NMR (DMSO-d6): δ 7.37-7.26 (m, 5H), 4.08-4.02 460.3 (m, 1H), 3.17-3.03 (m, 8H), 2.67-2.63 (m, 2H), 2.32- 2.04 (m, 12H), 1.46-1.39 (m, 4H), 1.02-0.99 (m, 1H), 0.54-0.50 (m, 2H), 0.34-0.30 (m, 2H). SC_4047 ¹H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.23 490.3 (m, 1H), 5.94 (s, 1H), 3.97-3.91 (m, 1H), 3.33-3.31 (m, 2H), 3.27 (s, 2H), 3.07 (s, 2H), 3.02-2.99 (m, 2H), 2.64- 2.61 (m, 2H), 2.12-2.02 (m, 6H), 1.97 (s, 6H), 1.88-1.85 (m, 4H), 1.66-1.61 (m, 1H), 1.50-1.29 (m, 5H). SC_4049 ¹H NMR (CDCl3): δ 7.40-7.34 (m, 7H), 7.30-7.27 (m, 515.4 3H), 4.79 (m, 1H), 4.06-4.00 (m, 1H), 3.78 (br m, 1H), 3.90-3.05 (m, 5H), 2.80-2.77 (br m, 1H), 2.65 (d, 2H), 2.27 (t, 2H), 2.05 (s, 6H), 1.82-1.62 (m, 3H), 1.46-1.41 (m, 5H), 1.04-0.99 (m, 1H), 0.53-0.50 (m, 2H), 0.33- 0.30 (m, 2H). SC_4050 ¹H NMR (CDCl3): δ 8.67-8.66 (m, 2H), 7.36-7.35 (m, 516.3 2H), 7.30-7.27 (m, 3H), 7.25-7.24 (m, 2H), 4.80-4.77 (m, 1H), 4.06-4.01 (m, 1H), 3.65-3.62 (m, 1H), 3.14- 3.05 (m, 5H), 2.82 (t, 1H), 2.67-2.65 (m, 2H), 2.28 (m, 2H), 2.05 (s, 6H), 1.86-1.84 (m, 1H), 1.71-1.62 (m, 2H), 1.46-1.39 (m, 5H), 1.03-0.99 (m, 1H), 0.53-0.50 (m, 2H), 0.34-0.33 (m, 2H). SC_4051 ¹H NMR (DMSO-d6): δ 7.37-7.33 (m, 4H), 7.27-7.23 442.3 (m, 1H), 4.54 (s, 1H), 3.60-3.53 (m, 4H), 3.32 (m, 2H), 3.03 (s, 2H), 2.91 (d, 2H), 2.67 (d, 2H), 2.15 (t, 2H), 1.97 (s, 6H), 1.49-1.44 (m, 2H), 1.40-1.31 (m, 6H), 0.95-0.90 (m, 1H), 0.46-0.43 (m, 2H), 0.30-0.21 (m, 2H). SC_4053 ¹H NMR (DMSO d6): δ 7.35-7.34 (m, 4H), 7.25 (m, 467.3 1H), 4.31-4.28 (m, 1H), 3.77-3.74 (m, 1H), 3.15 (s, 2H), 2.97-2.90 (m, 5H), 2.68-2.64 (m, 2H), 2.19-2.13 (m, 2H), 1.97-1.95 (m, 9H), 1.76 (m, 1H), 1.59-1.52 (m, 2H), 1.43-1.31 (m, 4H), 1.03-0.87 (m, 3H), 0.45-0.44 (m, 2H), 0.25-0.24 (m, 2H). SC_4058 ¹H NMR (DMSO d6): δ 7.37-7.34 (m, 4H), 7.27-7.23 425.3 (m, 1H), 3.13 (s, 2H), 2.91-2.87 (m, 6H), 2.67-2.64 (m, 2H), 2.39-2.33 (m, 2H), 2.18-2.12 (m, 2H), 1.97 (s, 6H), 1.58-1.54 (m, 1H), 1.47-1.30 (m, 6H), 0.98-0.88 (m, 3H), 0.46-0.42 (m, 2H), 0.26-0.22 (m, 2H). SC_4059 ¹H NMR (DMSO d6): δ 7.42-7.23 (m, 10H), 6.67 (br s, 461.3 1H), 4.51 (m, 1H), 3.75 (m, 1H), 3.54 (m, 1H), 3.05 (s, 3H), 2.75 (m, 1H), 2.34 (m, 2H), 1.93 (s, 6H), 1.77 (m, 4H), 1.55-1.35 (m, 6H). SC_4060 ¹H NMR (DMSO d6): δ 8.64-8.62 (m, 2H), 7.37-7.32 462.3 (m, 6H), 7.26-7.23 (m, 1H), 6.67 (br s, 1H), 4.50 (d, 1H), 3.80-3.73 (m, 1H), 3.40-3.37 (m, 1H), 3.11-3.05 (m, 3H), 2.78 (t, 1H), 2.36-2.33 (m, 2H), 1.93 (s, 6H), 1.80-1.65 (m, 4H), 1.61-1.52 (m, 3H), 1.49-1.35 (m, 3H). SC_4061 ¹H NMR (DMSO-d6): δ 7.36-7.23 (m, 5H), 6.68 (br, s, 399.3 1H), 4.40 (d, 1H), 3.80 (d, 1H), 3.69 (m, 1H), 3.05-2.99 (m, 3H), 2.32 (m, 3H), 1.95-1.92 (m, 9H), 1.78-1.76 (m, 4H), 1.50-1.46 (m, 3H), 1.33-1.30 (m, 3H). SC_4062 ¹H NMR (DMSO-d6): δ 7.37-7.33 (m, 4H), 7.27-7.24 490.3 (m, 1H), 5.04 (s, 1H), 3.30 (m, 2H), 3.15-3.07 (m, 4H), 2.97-2.92 (m, 4H), 2.69-2.66 (m, 2H), 2.18-2.13 (m, 2H), 1.97 (s, 6H), 1.87-1.84 (m, 4H), 1.38-1.31 (m, 4H), 0.94-0.91 (m. 1H), 0.47-0.43 (m, 2H), 0.26-0.24 (m, 2H). SC_4063 ¹H NMR (DMSO d6): δ 7.37-7.33 (m, 4H), 7.26-7.23 430.3 (m, 1H), 6.11 (s, 1H), 4.41 (s, 1H), 3.42 (s, 2H), 3.09 (s, 2H), 2.98 (s, 2H), 2.70-2.67 (m, 2H), 2.07-2.02 (m, 4H), 1.97 (s, 6H), 1.91-1.83 (m, 3H), 1.63-1.61 (m, 1H), 1.45-1.42 (m, 2H), 1.36-1.32 (m, 3H), 1.04 (s, 6H). SC_4066 1H NMR (600 MHz, DMSO) δ 7.40-7.32 (m, 4H), 380.2 7.30-7.23 (m, 1H), 3.52 (t, 2H), 3.46-3.31 (m, 1H), 3.27 (s, 2H), 3.05 (s, 3H), 2.97 (s, 3H), 2.72-2.63 (m, 2H), 2.11-2.01 (m, 2H), 1.99 (s, 6H), 1.45-1.36 (m, 4H). SC_4067 [0375] 1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.98 439.1 (s, 1H), 7.36-7.25 (m, 5H), 3.25 (s, 2H), 3.12 (s, 2H), 2.89 (d, 2H, J = 6.48 Hz), 2.67-2.64 (m, 2H), 2.16-2.07 (m, 2H), 1.97 (s, 6H), 1.67 (s, 3H), 1.44-1.36 (m, 4H), 0.91 (bs, 1H), 0.62-0.42 (m, 6H), 0.25-0.23 (m, 2H). SC_4068 1H NMR (DMSO d6): δ 8.52 (s, 1H), 8.45 (s, 2H), 503.4 7.37-7.33 (m, 4H), 7.27-7.23 (m, 1H), 3.83-3.80 (m, 2H), 3.17 (s, 2H), 2.96-2.75 (m, 4H), 2.73-2.65 (m, 4H), 2.16 (m, 2H), 1.98 (s, 6H), 1.65 (m, 1H), 1.65-1.63 (m, 2H), 1.40-1.32 (m, 4H), 1.20-1.17 (m, 2H), 0.94 (m, 1H), 0.46-0.44 (m, 2H), 0.26-0.24 (m, 2H). SC_4069 1H NMR (DMSO d6): δ 8.52 (s, 1H), 8.45 (s, 2H), 449.3 7.37-7.33 (m, 4H), 7.26-7.23 (m, 1H), 6.72 (broad s, 1H), 3.82-3.79 (m, 2H), 3.18 (s, 2H), 2.90-2.89 (m, 2H), 2.72-2.69 (m, 2H), 2.30 (m, 2H), 1.92 (s, 6H), 1.79-1.69 (m, 5H), 1.64-1.61 (m, 2H), 1.35 (m, 2H), 1.20-1.12 (m, 2H). SC_4070 1H NMR (DMSO-d6): δ 8.52 (s, 1H), 8.46 (s, 2H), 435.3 7.36-7.30 (m, 4H), 7.24-7.22 (m, 1H), 6.71 (br s, 1H), 3.90-3.88 (m, 2H), 3.71-3.67 (m, 1H), 3.00 (s, 2H), 2.84-2.79 (m, 2H), 2.28 (br s, 2H), 1.92 (s, 6H), 1.78 (br m, 4H), 1.66-1.55 (m, 4H), 1.34-1.33 (m, 2H). SC_4072 1H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.24 467.3 (m, 1H), 3.40-3.36 (m, 4H), 3.16 (s, 2H), 2.92 (d, 2H), 2.69-2.66 (m, 2H), 2.19-2.07 (m, 4H), 1.97 (s, 6H), 1.79-1.75 (m, 2H), 1.37-1.29 (m, 4H), 1.26 (s, 6H), 0.93-0.92 (m, 1H), 0.47-0.42 (m, 2H), 0.27-0.24 (m, 2H). SC_4073 1H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.24 503.3 (m, 1H), 3.34-3.27 (m, 4H), 3.16-3.13 (m, 4H), 2.93 (d, 2H), 2.67-2.64 (m, 2H), 2.16-2.05 (m, 4H), 1.97 (s, 6H), 1.40-1.36 (m, 4H), 1.29 (s, 6H), 0.93-0.92 (m, 1H), 0.46-0.44 (m, 2H), 0.26-0.24 (m, 2H). SC_4074 1H NMR (DMSO-d6): δ 7.37-7.34 (m, 4H), 7.27-7.24 486.4 (m, 1H), 6.17 (s, 1H), 4.28 (br s, 1H), 3.61-3.51 (m, 4H), 3.25 (s, 2H), 3.22-3.18 (m, 2H), 3.07 (s, 2H), 2.68- 2.65 (m, 2H), 2.06-2.03 (m, 4H), 1.97 (s, 6H), 1.91-1.83 (m, 2H), 1.64-1.61 (m, 1H), 1.57-1.50 (m, 2H), 1.47- 1.29 (m, 9H). SC_4075 1H NMR (DMSO-d6): δ 7.37-7.23 (m, 5H), 4.76 (s, 518.3 1H), 3.16-3.10 (m, 6H), 3.01 (d, 2H), 2.91-2.88 (m, 2H), 2.67-2.63 (m, 2H), 2.02-1.82 (m, 14H), 1.80-1.65 (m, 5H), 1.58 (m, 2H), 1.42-1.35 (m, 2H), 1.28-1.26 (m, 2H). SC_4076 1H NMR (DMSO d6): δ 7.37-7.23 (m, 5H), 6.72 (b s, 413.3 1H), 4.30-4.27 (m, 1H), 3.76-3.73 (m, 1H), 3.03 (s, 2H), 2.96-2.91 (m, 1H), 2.86-2.81 (m, 2H), 2.44 (m, 1H), 2.32 (m, 2H), 1.95-1.92 (m, 9H), 1.79-1.68 (m, 5H), 1.58-1.50 (m, 2H), 1.36-1.34 (m, 2H), 1.05-1.01 (m, 1H), 0.98-0.92 (m, 1H). SC_4077 1H NMR (600 MHz, DMSO) δ 7.38-7.30 (m, 4H), 491.3 7.29-7.22 (m, 1H), 3.79 (s, 2H), 3.53-3.48 (m, 5H), 3.35-3.27 (m, 5H), 2.96 (s, 3H), 2.67-2.59 (m, 2H), 1.98-1.87 (m, 10H), 1.77 (p, 2H), 1.44-1.34 (m, 4H). SC_4078 1HNMR (DMSO-d6, 400 MHz at 100 0 C.), δ (ppm) = 380.2 7.35-7.24 (m, 5H), 6.43 (s, 1H), 3.50 (t, 2H, J = 6.46 Hz), 3.31-3.22 (m, 4H), 2.95 (3H, merged with DMSO- water), 2.17 (bs, 2H), 1.99 (bs, 8H), 1.72 (bs, 2H), 1.45- 1.39 (m, 2H). SC_4079 1H NMR (DMSO-d6): δ 7.37-7.33 (m, 4H), 7.27-7.24 534.3 (m, 1H), 6.13 (br s, 1H), 3.26 (s, 2H), 3.20-3.11 (m, 4H), 3.07 (s, 2H), 2.92-2.89 (m, 2H), 2.68-2.65 (m, 2H), 2.05-2.01 (m, 4H), 1.97(s, 6H), 1.89-1.85 (m, 8H), 1.64- 1.60 (m, 3H), 1.43-1.32 (m, 4H). SC_4081 1HNMR (CDCl3, 400 MHz), δ (ppm) = 7.53 (s, 1H), 441.3 7.36-7.28 (m, 5H), 3.28 (s, 2H), 3.08-3.04 (m, 4H), 2.66-2.63 (m, 2H), 2.31-2.25 (m, 2H), 2.03 (s, 6H), 1.87 (s, 3H), 1.51-1.41 (m, 4H), 1.35 (s, 6H), 1.02 (bs, 1H), 0.53-0.51 (m, 2H), 0.33-0.32 (m, 2H). SC_4082 1HNMR (CDCl3, 400 MHz), δ (ppm) = 7.34-7.25 (m, 477.2 5H), 6.16 (s, 1H), 3.31 (s, 2H), 3.10-3.05 (m, 4H), 2.97 (s, 3H), 2.67-2.63 (m, 2H), 2.32-2.25 (m, 2H), 2.03 (s, 6H), 1.51-1.43 (m, 4H), 1.37 (s, 6H), 1.01-0.99 (m, 1H), 0.52-0.50 (m, 2H), 0.32 (m, 2H). SC_4083 1H NMR (DMSO-d6): δ 7.36-7.33 (m, 4H), 7.26-7.25 458.3 (m, 1H), 6.12 (s, 1H), 5.65 (s, 1H), 4.39 (d, 2H), 4.33 (d, 2H), 3.29 (s, 2H), 3.17-3.14 (m, 2H), 3.08 (s, 2H), 2.68-2.65 (m, 2H), 2.07-2.02 (m, 4H), 1.97 (s, 6H), 1.91-1.86 (m, 4H), 1.69-1.59 (m, 1H), 1.43-1.40 (m, 4H), 1.38-1.31 (m, 1H). SC_4085 1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.48 (s, 471.3 1H), 7.32 (m, 5H), 5.95 (s, 1H), 3.29-3.26 (m, 4H), 3.06 (s, 2H), 2.65-2.62 (m, 2H), 2.05-1.99 (m, 4H), 1.93 (s, 6H), 1.85-1.82 (m, 2H), 1.67 (s, 3H), 1.60-1.59 (m, 1H), 1.43-1.26 (m, 5H), 1.13 (m, 6H). SC_4086 1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.35-7.25 507.1 (m, 5H), 6.90 (s, 1H), 5.95 (s, 1H), 3.44 (s, 2H), 3.14 (s, 2H), 3.10 (s, 2H), 2.92 (s, 3H), 2.68-2.66 (m, 3H), 2.08-2.03 (m, 4H), 1.97 (s, 6H), 1.88-1.85 (m, 2H), 1.47-1.31 (m, 7H), 1.21 (s, 6H). SC_4087 1H NMR (DMSO d6): δ 8.26 (d, 1H), 7.93 (m, 1H), 488.4 7.35-7.27 (m, 4H), 7.25-7.23 (m, 2H), 7.17-7.15 (m, 1H), 3.80 (d, 2H), 3.77-3.68 (m, 1H), 3.29-3.27 (m, 1H), 3.13 (s, 2H), 2.91 (d, 2H), 2.77 (t, 2H), 2.64-2.62 (m, 1H), 2.14 (t, 2H), 1.97 (s, 6H), 1.72-1.68 (m, 2H), 1.61-1.59 (m, 2H), 1.44 (t, 2H), 1.32 (d, 2H), 0.94-0.90 (m, 1H), 0.47-0.44 (m, 2H), 0.28-0.25 (m, 2H). SC_4088 1H NMR (600 MHz, DMSO) δ 7.44-7.36 (m, 1H), 452.2 7.18 (d, 1H), 7.15 (dt, 1H), 7.10 (td, 1H), 3.51 (t, 2H), 3.32 (t, 2H), 3.23 (s, 2H), 2.96 (s, 3H), 2.93 (d, 2H), 2.68-2.60 (m, 2H), 2.18-2.10 (m, 2H), 2.00 (s, 6H), 1.45-1.33 (m, 4H), 0.93 (tdd, 1H), 0.50-0.41 (m, 2H), 0.31-0.22 (m, 2H). SC_4089 1H NMR (DMSO d6): δ 8.09-8.08 (d, 2H), 7.33-7.30 488.4 (m, 4H), 7.24-7.23 (m, 1H), 6.77-76 (d, 2H), 3.98-3.96 (d, 2H), 3.80 (m, 1H), 3.09 (s, 2H), 2.91-2.84 (m, 4H), 2.62-2.59 (m, 2H), 2.15-2.10 (m, 2H), 1.94 (m, 6H), 1.59-1.56 (m, 4H), 1.42-1.37 (m, 2H), 1.33-1.29 (m, 2H), 0.91-0.90 (m, 1H), 0.46-0.43 (m, 2H), 0.26 (m, 2H). SC_4090 1H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.25 497.4 (m, 1H), 6.03 (s, 1H), 3.43 (s, 2H), 3.39 (t, 2H), 3.27 (s, 2H), 2.09 (s, 2H), 2.69-2.66 (m, 2H), 2.12 (t, 2H), 2.07- 2.03 (m, 4H), 1.96 (s, 6H), 1.90-1.86 (m, 2H), 1.84-1.76 (m, 2H), 1.63-1.61 (m, 1H), 1.45-1.43 (m, 2H), 1.41 (m, 3H), 1.35-1.31 (m, 6H). SC_4092 1HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.44-7.29 476.3 (m, 5H), 3.38 (s, 2H), 3.34 (s, 2H), 2.94 (s, 3H), 2.87 (s, 3H), 2.64 (d, 2H, J = 12.24 Hz), 2.60 (d, 2H, J = 7.24 Hz), 2.10-2.06 (m, 1H), 1.90 (s, 6H), 1.73-1.49 (m, 6H), 1.42-1.33 (m, 6H), 1.27 (s, 6H). SC_4093 1H NMR (DMSO-d6): δ 7.37-7.32 (m, 4H), 7.27-7.23 533.3 (m, 1H), 6.01 (s, 1H), 3.42 (s, 2H), 3.36-3.31 (m, 2H), 3.18-3.13 (m, 4H), 3.10 (s, 2H), 2.68-2.64 (m, 2H), 2.10-2.03 (m, 6H), 1.96 (s, 6H), 1.90-1.84 (m, 2H), 1.70-1.60 (m, 1H), 1.47-1.44 (m, 2H), 1.41-1.35 (m, 3H), 1.32 (s, 6H). SC_4094 1H NMR (DMSO-d6): δ 7.34-7.29 (m, 1H), 7.06-7.04 460.3 (m, 1H), 6.99-6.95 (m, 2H), 4.43 (s, 1H), 3.82-3.78 (m, 2H), 3.74-3.71 (m, 2H), 3.28 (s, 2H), 3.14 (s, 2H), 3.06 (d, 2H), 2.59 (d, 2H).2.26 (t, 2H), 2.05 (s, 6H).1.58-1.49 (m, 4H), 1,47-1.42 (m, 4H), 1.02 (m, 1H), 0.54-0.51 (m, 2H), 0.33-031 (m, 2H) SC_4095 519.3 SC_4097 1H NMR (600 MHz, DMSO) δ 7.35 (d, 4H), 7.29- 465.3 7.22 (m, 1H), 3.86 (s, 2H), 3.51 (t, 2H), 3.32 (t, 2H), 3.29 (s, 2H), 3.03 (s, 3H), 2.97 (s, 3H), 2.84 (s, 3H), 2.64 (d, 2H), 2.02-1.86 (m, 8H), 1.44-1.35 (m, 4H). SC_4099 507.3 SC_4100 438.2 SC_4101 SC_4102 SC_4103 SC_4104 SC_4105 SC_4106 398.2 SC_4107 SC_4108 SC_4109 SC_4110 SC_4111 SC_4112 SC_5061 ¹HNMR (DMSO-d6, 400 MHz, at 100 0 C.), δ (ppm) = 369.2 7.34-7.21 (m, 5H), 6.70 (bs, 1H), 3.28 (s, 2H), 3.19 (s, 2H), 2.32-2.24 (m, 4H), 2.06 (s, 3H), 1.87-1.82 (m, 4H), 1.45-1.37 (bs, 2H), 1.27 (s, 6H), 0.93 (t, 3H, 6.8 Hz). SC_5062 ¹HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.35-7.24 355.2 (m, 5H), 7.03 (bs, 1H), 3.25 (s, 2H), 3.15 (s, 2H), 2.32 (bs, 2H), 1.92 (s, 6H), 1.82 (bs, 4H), 1.38 (bs, 2H), 1.24 (s, 6H). SC_5065 ¹HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.34-722 383.2 (m, 5H), 3.38 (s, 2H), 3.21 (s, 2H), 2.71-2.64 (m, 5H), 2.19-2.16 (m, 4H), 1.96 (s, 3H), 1.37-1.30 (m, 4H), 1.25 (s, 6H), 0.98 (t, 3H, J = 6.48 Hz). SC_5068 ¹HNMR (DMSO-d6, 400 MHz), δ (ppm) = 7.42 (d, 355.1 12H, J = 7.32 Hz), 7.30 (t, 2H, J = 7.20 Hz), 7.17 (t, 1H, J = 7.12 Hz), 6.78 (s, 1H), 3.35 (s, 2H), 3.17 (s, 2H), 2.05 (m, 7H), 1.67-1.43 (m, 4H), 1.25 (s, 6H), 0.91 (t, 3H, J = 6.78 Hz). SC_5080 1HNMR at 20° C. (DMSO-d6, 400 MHz), δ (ppm) = 409.2 7.44-7.28 (m, 5H), 3.46 (s, 2H), 3.23 (s, 2H), 2.72-2.66 (m, 2H), 2.57-2.55 (m, 2H), 1.91 (s, 6H), 1.55-1.45 (m, 6H), 1.27 (s, 6H), 0.51 (bs, 1H), 0.19-0.14 (m, 2H), (−0.22)-(−0.26) (m, 2H).

Chemical Structure of all Examples

Pharmacological Investigations

Functional investigation on the human mu-opioid receptor (hMOP), human kappa-opioid receptor (hKOP), human delta-opioid receptor (hDOP), and human nociceptin/orphanin FQ peptide receptor (hNOP)

Human Mu-Opioid Peptide (hMOP) Receptor Binding Assay

The hMOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.052 mg/ml bovine serum albumin (Sigma-Aldrich Co. St. Louis. Mo.). The final assay volume (250 μl/well) included 1 nM of [N-allyl-2.3-³H]naloxone as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA), and either test compound in dilution series or 25 μM unlabelled naloxone for determination of unspecific binding. The test compound was diluted with 25% DMSO in H₂O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). After incubation for 90 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux ß-counter (PerkinElmer Life Sciences/Wallac. Turku. Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [³H]naloxone-specific receptor binding were calculated by nonlinear regression analysis and Ki values were calculated by using the Cheng-Prusoff equation. (Cheng and Prusoff. 1973).

Human Kappa-Opioid Peptide (hKOP) Receptor Binding Assay

The hKOP receptor binding assay is run as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl (pH 7.4) supplemented with 0.076 mg BSA/ml. The final assay volume of 250 μl per well includes 2 nM of [³H]U69,593 as ligand, and either test compound in dilution series or 100 μM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H₂O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 μl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hKOP receptor membranes (14.8 μg/250 μl final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 90 minutes at room temperature. After this incubation, the microtiter plates are sealed with a topseal and centrifuged for 20 minutes at 500 rpm. The signal rate is measured after a short delay of 5 minutes by means of a 1450 Microbeta Trilux ß-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [³H]U69.593-specific receptor binding are calculated by nonlinear regression analysis and K_(i) values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).

Human Delta-Opioid Peptide (hDOP) Receptor Binding Assay

The hDOP receptor binding assay is performed as homogeneous SPA-assay using the assay buffer 50 mM TRIS-HCl, 5 mM MgCl₂ (pH 7.4). The final assay volume (250 μl/well) includes 1 nM of [Tyrosyl-3,5-³H]2-D-Ala-deltorphin II as ligand, and either test compound in dilution series or 10 μM unlabelled naloxone for determination of unspecific binding. The test compound is diluted with 25% DMSO in H₂O to yield a final 0.5% DMSO concentration which serves as respective vehicle control, as well. The assays are started by the addition of wheat germ agglutinin coated SPA beads (1 mg SPA beads/250 μl final assay volume per well) which has been preloaded for 15 minutes at room temperature with hDOP receptor membranes (15.2 μg/250 μl final assay volume per well). After short mixing on a mini-shaker, the microtiter plates are covered with a lid and the assay plates are incubated for 120 minutes at room temperature and centrifuged for 20 minutes at 500 rpm. The signal rate is measured by means of a 1450 Microbeta Trilux ß-counter (PerkinElmer Life Sciences/Wallac, Turku, Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [Tyrosyl-3,5-³H]2-D-Ala-deltorphin II-specific receptor binding are calculated by nonlinear regression analysis and K_(i) values are calculated by using the Cheng-Prusoff equation, (Cheng and Prusoff, 1973).

Human Nociceptin/Orphanin FQ Peptide (hNOP) Receptor Binding Assay

The hNOP receptor binding assay was performed as homogeneous SPA-assay (scintillation proximity assay) using the assay buffer 50 mM TRIS-HCl. 10 mM MgCl₂. 1 mM EDTA (pH 7.4). The final assay volume (250 μl/well) included 0.5 nM of [leucyl-³H]nociceptin as ligand (PerkinElmer Life Sciences. Inc. Boston. Mass. USA). and either test compound in dilution series or 1 μM unlabelled nociceptin for determination of unspecific binding. The test compound was diluted with 25% DMSO in H₂O to yield a final 0.5% DMSO concentration. which also served as a respective vehicle control. The assay was started by adding wheat germ agglutinin coated SPA beads (GE Healthcare UK Ltd. Buckinghamshire. UK) which had been preloaded with hMOP receptor membranes (PerkinElmer Life Sciences. Inc. Boston. Mass. USA).

After incubation for 60 minutes at RT and centrifugation for 20 minutes at 500 rpm the signal rate was measured by means of a 1450 Microbeta Trilux ß-counter (PerkinElmer Life Sciences/Wallac. Turku. Finland). Half-maximal inhibitory concentration (IC50) values reflecting 50% displacement of [³H]nociceptin-specific receptor binding were calculated by nonlinear regression analysis and Ki values were calculated by using the Cheng-Prusoff equation. (Cheng and Prusoff. 1973).

hNOP Ki hMOP Ki [nM] or % Example [nM] μinhibition at 1M SC_4001 2.3 80.5 SC_4002 28 755 SC_4003 7.7 39.5 SC_4004 44 305 SC_4005 19 64.5 SC_4006 3.6 16 SC_4007 2.6 58 SC_4008 7.3 69.8 SC_4009 1.1 37.4 SC_4010 9.5 87 SC_4011 13 210 SC_4012 1.6 99.7 SC_4013 5.8 40.5 SC_4014 2.1 84 SC_4017 45 375 SC_4018 1.3 19.7 SC_4021 83 636.7 SC_4022 140 555 SC_4024 155 285 SC_4025 26 206 SC_4026 57 643 SC_4031 119 1430 SC_4032 345 8530 SC_4033 — 15% @ 1 μM  SC_4034 11 245 SC_4035 69 1580 SC_4036 8 210 SC_4037 815 185 SC_4038 69 1290 SC_4039 3 165 SC_4040 19 270 SC_4041 4 125 SC_4042 11 290 SC_4043 4 124 SC_4044 19 1065 SC_4045 17 415 SC_4046 15 655 SC_4047 8 265 SC_4048 46 805 SC_4049 11 220 SC_4050 19 255 SC_4051 21 770 SC_4052 3 175 SC_4053 34 1350 SC_4054 26 1305 SC_4055 54 1865 SC_4056 10 1755 SC_4057 3 1050 SC_4058 15 540 SC_4059 710 9% @ 1 μM SC_4060 1170 5% @ 1 μM SC_4061 710 9% @ 1 μM SC_4062 27 1810 SC_4063 15 2910 SC_4064 5 495 SC_4066 40 3045 SC_4067 12 615 SC_4068 13 985 SC_4069 140 6900 SC_4070 140  8% SC_4071 1 63 SC_4072 10 255 SC_4073 6 300 SC_4074 12 460 SC_4075 1 39 SC_4076 235 17% SC_4077 75 3230 SC_4078 125 74 SC_4079 6 415 SC_4080 145 4145 SC_4081 10 765 SC_4082 10 270 SC_4083 10 235 SC_4084 118 2465 SC_4085 3 495 SC_4086 6 570 SC_4087 12 535 SC_4088 6 935 SC_4089 64 275 SC_4090 6 520 SC_4091 0.4 76 SC_4092 16 17 SC_4093 17 1000 SC_4094 23 1980 SC_4095 8 630 SC_4096 36 330 SC_4097 114 4355 SC_4098 395 96 SC_5061 705 6% @ 1 μM SC_5062 84 2925 SC_5063 690 4% @ 1 μM SC_5065 0% @ 1 μM 13% @ 1 μM  (DOP 40%) SC_5068 0% @ 1 μM 8% @ 1 μM (KOP 40%) SC_5075 10 305 SC_5080 24 230

Protocol for [³⁵S]GTPγS Functional NOP/MOP/KOP/DOP Assays

Cell membrane preparations of CHO-K1 cells transfected with the human MOP receptor (Art.-No. RBHOMM) or the human DOP receptor (Art.-No.RBHODM), and HEK293 cells transfected with the human NOP receptor (Art.-No.RBHORLM) or the human KOP receptor (Art.-No. 6110558) are available from PerkinElmer (Waltham, Mass.). Membranes from CHO-K1 cells transfected with the human nociceptin/orphanin FQ peptide (hNOP) receptor (Art.-No. 93-0264C2, DiscoveRx Corporation, Freemont, Calif.) are also used. [³⁵S]GTPγS (Art.-No. NEG030H; Lot-No. #0112, #0913, #1113 calibrated to 46.25 TBq/mmol) is available from PerkinElmer (Waltham, Mass.).

The [³⁵S]GTPγS assays are carried out essentially as described by Gillen et al (2000). They are run as homogeneous scintillation proximity (SPA) assays in microtiter luminescence plates, where each well contains 1.5 mg of WGA-coated SPA-beads. To test the agonistic activity of test compounds on recombinant hNOP, hMOP, hDOP, and hKOP receptor expressing cell membranes from CHO-K1 or HEK293 cells, 10 or 5 μg membrane protein per assay are incubated with 0.4 nM [³⁵S]GTPγS and serial concentrations of receptor-specific agonists in buffer containing 20 mM HEPES pH 7.4, 100 mM NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 1.28 mM NaN₃, and 10 μM GDP for 45 min at room temperature. The microtiter plates are then centrifuged for 10 min at 830 to sediment the SPA beads. The microtiter plates are sealed and the bound radioactivity [cpm] is determined after a delay of 15 min by means of a 1450 Microbeta Trilux (PerkinElmer, Waltham, Mass.).

The unstimulated basal binding activity (UBS_(obs) [cpm]) is determined from 12 unstimulated incubates and is set as 100% basal binding. For determination of the potency and the efficacy, the arithmetic mean of the observed total [³⁵S]GTPγS binding (TB_(obs) [cpm]) of all incubates (duplicates) stimulated by the receptor-specific agonists (i.e. N/OFQ, SNC80, DAMGO, or U69,593) are transformed in percent total binding (TB_(obs) [%]) relative to the basal binding activity (i.e. 100% binding). The potency (EC₅₀) of the respective agonist and its maximal achievable total [³⁵S]GTPγS binding (TB_(calc) [%]) above its calculated basal binding (UBS_(calc) [%]) are determined from its transformed data (TB_(obs) [%]) by means of nonlinear regression analysis with XLfit for each individual concentration series. Then the difference between the calculated unstimulated [³⁵S]GTPγS binding (UBS_(calc) [%]) and the maximal achievable total [³⁵S]GTPγS binding (TB_(calc) [%]) by each tested agonist is determined (i.e. B1_(calc) [%]). This difference (B1_(calc) [%]) as a measure of the maximal achievable enhancement of [³⁵S]GTPγS binding by a given agonist is used to calculate the relative efficacy of test compounds versus the maximal achievable enhancement by a receptor-specific full agonist, e.g. N/OFQ (B1_(calc-N/OFQ) [%]) which is set as 100% relative efficacy for the hNOP receptor. Likewise, the percentage efficacies of test compounds at the hDOP, hMOP, or hKOP receptor are determined versus the calculated maximal enhancement of [³⁵S]GTPγS binding by the full agonists SNC80 (B1_(calc-SNC80 [%]), DAMGO (B)1 talc-DAMGO [%]) and U69,593 (B1_(calc-U69,593) [%]) which are set as 100% relative efficacy at each receptor, respectively.

The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the described embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed broadly to include all variations within the scope of the appended claims and equivalents thereof. 

1. A compound according to general formula (I)

wherein R¹ and R² independently of one another mean —H; —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH₃, —CN and —CO₂CH₃; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH₃, —CN and —CO₂CH₃; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —OH, —OCH₃, —CN and —CO₂CH₃; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃₋₆—; —(CH₂)₂—O—(CH₂)₂—; or —(CH₂)₂—NR^(A)—(CH₂)₂—, wherein R^(A) means —H or —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I; R³ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; R⁴ means —H; —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said —C₁-C₆-alkyl is optionally connected through —C(═O)—, —C(═O)O—, or —S(═O)₂—; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂—; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂—; a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 6-14-membered aryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂—; or a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or wherein said 5-14-membered heteroaryl moiety is optionally connected through —C(═O)—, —C(═O)O—, —C(═O)O—CH₂—, or —S(═O)₂—; R⁵ means —H; —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or a moiety according to general formula (X);

R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ independently of one another mean —H, —F, —Cl, —Br, —I, —OH, or —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein “mono- or polysubstituted” means that one or more hydrogen atoms are replaced by a substituent independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —R²¹, —C(═O)R²¹, —C(═O)OR²¹, —C(═O)NR²¹R²², —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, ═O, —OR²¹, —OC(═O)R²¹, —OC(═O)OR²¹, —OC(═O)NR²¹R²², —NO₂, —NR²¹R²², —NR²¹—(CH₂)₁₋₆—C(═O)R²², —NR²¹—(CH₂)₁₋₆—C(═O)OR²², —NR²³—(CH₂)₁₋₆—C(═O)NR²¹R²², —NR²¹C(═O)R²², —NR²¹C(═O)—OR²², —NR²³C(═O)NR²¹R²², —NR²¹S(═O)₂R²², —SR²¹, —S(═O)R²¹, —S(═O)₂R²¹, —S(═O)₂OR²¹, and —S(═O)₂NR²¹R²²; wherein R₂₁, R²² and R²³ independently of one another mean —H; —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, and —O—C₁-C₆-alkyl; a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —NH₂, —C₁-C₆-alkyl and —O—C₁-C₆-alkyl; or R²¹ and R²² within —C(═O)NR²¹R²², —OC(═O)NR²¹R²², —NR²¹R²², —NR²³—(CH₂)₁₋₆—C(═O)NR²¹R²², —NR²³C(═O)NR²¹R²², or —S(═O)₂NR²¹R²² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃₋₆—; —(CH₂)₂—O—(CH₂)₂—; or —(CH₂)₂—NR^(B)—(CH₂)₂—, wherein R^(B) means —H or —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br and —I; or a physiologically acceptable salt thereof.
 2. The compound according to claim 1, wherein R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ independently of one another mean —H, —F, —OH, or —C₁-C₆-alkyl.
 3. The compound according to claim 1, wherein R¹ means —H; and R² means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 4. The compound according to claim 1, wherein R¹ means —CH₃; and R² means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 5. The compound according to claim 1, wherein R¹ means —H or —CH₃; and wherein R² means —CH₂-cycloalkyl, —CH₂-cyclobutyl, —CH₂-cyclopentyl, —CH₂-oxetanyl or —CH₂-tetrahydrofuranyl.
 6. The compound according to claim 1, wherein R¹ and R² together with the nitrogen atom to which they are attached form a ring and mean —(CH₂)₃₋₆—.
 7. The compound according to claim 1, wherein R³ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 8. The compound according to claim 1, wherein R³ means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted.
 9. The compound according to claim 1, wherein R³ means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted.
 10. The compound according to claim 1, wherein R⁴ means —H.
 11. The compound according to claim 1, wherein R⁴ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 12. The compound according to claim 1, wherein R⁴ means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein the 3-12-membered cycloalkyl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 13. The compound according to claim 1, wherein R⁴ means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted, mono- or polysubstituted; wherein said 3-12-membered heterocycloalkyl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 14. The compound according to claim 1, wherein R⁴ means a 6-14-membered aryl moiety, unsubstituted, mono- or polysubstituted; wherein said 6-14-membered aryl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 15. The compound according to claim 1, wherein R⁴ means a 5-14-membered heteroaryl moiety, unsubstituted, mono- or polysubstituted; wherein said 5-14-membered heteroaryl moiety is connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted, mono- or polysubstituted.
 16. The compound according to claim 1, wherein R⁵ means —H.
 17. The compound according to claim 1, wherein R⁵ means —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl.
 18. The compound according to claim 1, wherein R⁵ means a 3-12-membered cycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —C₁-C₄-alkyl-OH, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —NH₂, —NHC₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NC₁-C₄-alkylC(═O)C₁-C₄-alkyl, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted.
 19. The compound according to claim 1, wherein R⁵ means a 3-12-membered heterocycloalkyl moiety, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, —C₁-C₄-alkyl, —C₁-C₄-alkyl-OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —NH₂, —NHC₁-C₄-alkyl, N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —C₄-alkylC(═O)C₁-C₄-alkyl, —S(═O)C₁-C₄-alkyl and —S(═O)₂C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted.
 20. The compound according to claim 1, which has a structure according to any of general formulas (II-A) to (VIII-C):

wherein in each case R¹, R², R³, R⁴, and R⁵ are defined as in claim 1, R^(C) means —H, —OH, —F, —CN or —C₁-C₄-alkyl; R^(D) means —H or —F; or a physiologically acceptable salt thereof.
 21. The compound according to claim 1, wherein R⁵ is selected from the group consisting of:


22. The compound according to claim 1, wherein R¹ means —H or —CH₃; R² means —C₁-C₆-alkyl, linear or branched, saturated, unsubstituted; R³ means -phenyl, -thienyl or -pyridinyl, in each case unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —CN, —CH₃, —CH₂CH₃, —CH₂F, —CHF₂, —CF₃, —OCF₃, —OH, —OCH₃, —C(═O)NH₂, C(═O)NHCH₃, —C(═O)N(CH₃)₂, —NH₂, —NHCH₃, —N(CH₃)₂, —NHC(═O)CH₃, —CH₂OH, SOCH₃ and SO₂CH₃; or R⁴ means —H; —C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, ═O, —S(═O)₂—C₁-C₄-alkyl and —O—C₁-C₄-alkyl; 3-6-membered cycloalkyl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl, wherein said 3-6-membered cycloalkyl is connected through —C₁-C₆-alkylene; 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl; wherein said 3-12-membered heterocycloalkyl is optionally connected through —C₁-C₆-alkylene-, unsubstituted or substituted with ═O; 6-14-membered aryl, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, —OH, and —O—C₁-C₄-alkyl; wherein said 6-14-membered aryl is optionally connected through —C₁-C₆-alkylene- or —S(═O)₂—; R⁵ means —H; —C₁-C₆-alkyl, linear or branched, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)C₁-C₄-alkyl, —C(═O)OC₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, —NH₂, —NH—C₁-C₄-alkyl, —N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NH—S(═O)₂C₁-C₄-alkyl; or 3-12-membered cycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —C₁-C₄-alkyl, —C₁-C₄-alkyl-OH, —NH₂, —NH—C₁-C₄-alkyl, —N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NHS(═O)₂—C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —O—(CH₂CH₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)C₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, -phenyl, —C(═O)-phenyl, —C(═O)-pyridyl, -pyridyl, -thiazolyl, —N-methyldiazolyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered cycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; or 3-12-membered heterocycloalkyl, saturated or unsaturated, unsubstituted or substituted with one, two, three or four substituents independently of one another selected from the group consisting of —F, —Cl, —Br, —I, —CN, ═O, —OH, —C₁-C₄-alkyl, —NH₂, —NH—C₁-C₄-alkyl, —N(C₁-C₄-alkyl)₂, —NHC(═O)—C₁-C₄-alkyl, —NHS(═O)₂—C₁-C₄-alkyl, —O—C₁-C₄-alkyl, —O—(CH₂CF₁₂—O)₁₋₃₀—H, —O—(CH₂CH₂—O)₁₋₃₀—CH₃, —C(═O)OH, —C(═O)OC₁-C₄-alkyl, —C(═O)C₁-C₄-alkyl, —C(═O)NH₂, —C(═O)NHC₁-C₄-alkyl, —C(═O)N(C₁-C₄-alkyl)₂, —S(═O)C₁-C₄-alkyl, —S(═O)₂C₁-C₄-alkyl, -phenyl, —C(═O)-phenyl, —C(═O)-pyridyl, -pyridyl, -thiazolyl, —N-methyldiazolyl, -pyrimidinyl, and -pyridazinyl; wherein said 3-12-membered heterocycloalkyl moiety is optionally connected through —C₁-C₆-alkylene-, linear or branched, saturated or unsaturated, unsubstituted; and R¹¹, R¹², R¹³, R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, and R²⁰ mean —H.
 23. The compound according to claim 1, which has a structure according to general formula (I′)

wherein R¹ to R⁵, R¹⁰ to R²⁰ are defined as in claim 1, or a physiologically acceptable salt thereof.
 24. The compound according to claim 1, which has a structure according to general formula (IX)

wherein R^(C) means —H or —OH; R³ means -phenyl or -3-fluorophenyl; R⁵ means C₁-C₆-alkyl, linear or branched, saturated, unsubstituted or monosubstituted with —OH, —CN, —NH₂, —NHC(═O)C₁-C₄-alkyl, —NHS(═O)₂—C₁-C₄-alkyl, or —S(═O)₂—C₁-C₄-alkyl; or 3-6-membered heterocycloalkyl, saturated, unsubstituted or substituted with —OH; wherein said 3-6-membered heterocycloalkyl is optionally connected through —CH₂— or —(CH₂)₂—; or a physiologically acceptable salt thereof.
 25. The compound according to claim 24, wherein the 3-6-membered heterocycloalkyl is selected from the group consisting of oxetanly, tetrahydrofuranyl and tetrahydropyranyl.
 26. The compound according to claim 1, which is selected from the group consisting of CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyramide; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(2-methoxy-ethoxy)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methoxy-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyronitrile; CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-N-methy 1-butyl amide; CIS-3-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-2,2-dimethyl-propionitrile; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-[2-[2-[2-[2-[2-[2-(2-methoxy-ethoxy)-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethoxy]-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-methyl-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS -1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-3-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile; CIS-2-[1-[(1-Hydroxy-cyclobutyl)-methyl]-8-methylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile; CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-(tetrahydro-pyran-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-morpholin-4-yl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-3-(3-Chloro-propyl)-1-(cyclobutyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-4-[1-(Cyclobutyl-methyl)-8-dimethylamino-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-butyric acid methyl ester; CIS-3-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-propionitrile; CIS-2-[8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-3-yl]-acetonitrile; CIS-3-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Di methylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one CIS-1-Acetyl-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethyl amino-3-(2-methylsulfonyl-ethyl)-1-(oxetan-3-yl-methyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-1-(3-methoxy-propyl)-3-(2-methylsulfonyl-ethyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-8-phenyl-1-(p-tolylsulfonyl)-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-3-[(1,1-dioxo-thian-4-yl)-methyl]-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Di methylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-3-tetrahydro-pyran-4-yl-1,3-di azaspiro[4.5]decan-2-one; CIS-1-[[8-Dimethylamino-3-(2-methylsulfonyl-ethyl)-2-oxo-8-phenyl-1,3-diazaspiro[4.5]decan-1-yl]-methyl]-cyclobutane-1-carbonitrile; CIS-8-Dimethyl amino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-[(4-hydroxy-1, 1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(1,1-dioxo-thian-4-yl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-3-(1,1-dioxo-thian-4-yl)-1-[(1-hydroxy-cyclobutyl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-3-(1-Acetyl-piperidin-4-yl)-1-(cyclopropyl -methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-3-(1-Benzoyl-piperidin-4-yl)-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-tetrahydro-pyran-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclobutyl-methyl)-8-dimethylamino-3-[2-(4-hydroxy-tetrahydro-pyran-4-yl)-ethyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-3-[(1-Acetyl-piperidin-4-yl)-methyl]-1-(cyclopropyl-methyl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-piperidin-4-yl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-(2-hydroxy-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-pyrimidin-5-yl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(1-phenyl-piperidin-4-yl)-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-8-phenyl-3-(piperidin-4-yl-methyl)-1,3-diazaspiro[4.5]decan-2-one; CIS-3-(1-Benzoyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one CIS-8-Dimethylamino-8-phenyl-3-[1-(pyridine-4-carbonyl)-piperidin-4-yl]-1,3-diazaspiro[4.5]decan-2-one; CIS-3-(1-Acetyl-piperidin-4-yl)-8-dimethylamino-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-1-(Cyclopropyl-methyl)-8-dimethylamino-3-[(4-hydroxy-1,1-dioxo-thian-4-yl)-methyl]-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; CIS-8-Dimethylamino-1-[(1-hydroxy-cyclobutyl)-methyl]-3-(2-hydroxy-2-methyl-propyl)-8-phenyl-1,3-diazaspiro[4.5]decan-2-one; and the physiologically acceptable salts thereof.
 27. The compound according to claim 1 for use in the treatment of pain.
 28. A medicament comprising a compound according to claim
 1. 29. A compound according to general formula (IIIa) or (IIIb),

wherein R¹, R² and R³ are defined as in claim 1; and PG is a protecting group; or a physiologically acceptable salt thereof.
 30. A method of treating pain in a patient in need thereof, said method comprising administering to said patient an effective amount therefor of at least one compound according to claim
 1. 